

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 August 2003 (21.08.2003)

PCT

(10) International Publication Number  
**WO 03/068944 A2**

- (51) International Patent Classification<sup>7</sup>: **C12N**
- (21) International Application Number: **PCT/US03/04792**
- (22) International Filing Date: 13 February 2003 (13.02.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/357,069 13 February 2002 (13.02.2002) US
- (71) Applicant (for all designated States except US):  
**DANA-FARBER CANCER INSTITUTE, INC.**  
[US/US]; 44 Binney Street, Boston, MA 02115 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SPIEGELMAN, Bruce, M.** [US/US]; 271 Waban Avenue, Waban, MA 02168 (US). **LIN, Jiandie** [CN/US]; 79 Chestnut Street, Apt.#1, Brookline, MA 02445 (US).
- (74) Agents: **SMITH, DeAnn, F.**; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 et al. (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 03/068944 A2**

(54) Title: METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1 $\alpha$ -

(57) Abstract: The invention provides novel methods and compositions for modulating type I muscle formation through modulation of PGC-1 $\alpha$  activity or expression. Also provided are methods for identifying compounds that modulate type I muscle formation through modulation of PGC-1 $\alpha$  activity or expression. Further provided are methods for treating disorders associated with type I and/or type II muscle formation, as well as transgenic animals expressing PGC-1 $\alpha$  in muscle.

## METHODS AND COMPOSITIONS FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1 $\alpha$

### Government Support

5           Work described herein was supported under grant DK54477 awarded by the National Institutes of Health. The U.S. government may have certain rights in this invention.

### Related Applications

10           This application claims priority to U.S. provisional Application No. 60/357,069, filed on February 13, 2002, incorporated herein in it's entirety by this reference.

### Background of the Invention

15           The metabolic properties of muscle are profoundly influenced by exercise and disease. Long-term endurance exercise training or low frequency motor nerve stimulation promote the transition toward an oxidative metabolism with enhanced mitochondrial biogenesis characteristic of slow (type) skeletal muscle fibers. Conversely, disuse atrophy, exercise intolerance associated with congestive heart failure, and mitochondrial myopathies result in loss of type I oxidative skeletal muscle fibers,  
20           chronic fatigue, and increased glycolytic fibers.

          Accordingly, there exists a need for additional therapeutic options which can modulate type I muscle formation to provide relief for symptoms of heart failure, disuse atrophy, mitochondrial myopathies, and systemic metabolic disorders.

### Summary of the Invention

25           The present invention is based, at least in part, on the discovery that PGC-1 $\alpha$  (also known as, and used interchangeably herein with, PGC-1), regulates type I (slow-twitch) muscle fiber differentiation and contributes to maintaining muscle cell determination. Accordingly, the present invention provides methods for modulating  
30           type I muscle formation comprising contacting a cell (*i.e.*, a muscle cell such as a type I muscle cell or a type II muscle cell) with an agent that modulates PGC-1 $\alpha$  expression or

activity, such that type I muscle formation is modulated. In a preferred embodiment, PGC-1 $\alpha$  expression or activity is increased, thereby increasing type I muscle formation.

In addition to PGC-1 $\alpha$ , several additional factors involved in the signaling cascades underlying muscle fiber type determination have been identified, such as the calcium/calmodulin-dependent protein kinase IV (CaMKIV) and calcineurin A (CnA). It has been found that the PGC-1 $\alpha$  promoter is regulated by both CaMKIV as well as CnA activity. CaMKIV activates PGC-1 $\alpha$  almost entirely through a binding site for cAMP response element binding protein (CREB), which is found in the PGC-1 $\alpha$  promoter. Moreover, a positive autoregulatory loop exists by which PGC-1 $\alpha$  controls its own transcription through binding to and coactivation of myocyte enhancer factor 2 (MEF2) transcription factors, *e.g.*, MEF2C and MEF2D, which are transcription factors that are targets of CaMKIV and CnA signaling and that bind directly to the PGC-1 $\alpha$  promoter.

In one embodiment, the agent that modulates PGC-1 $\alpha$  expression or activity is a PGC-1 $\alpha$  nucleic acid molecule (*i.e.*, a human PGC-1 $\alpha$  nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO:1). In another embodiment, the PGC-1 $\alpha$  nucleic acid molecule is contained within a vector. In yet another embodiment, the agent is a PGC-1 $\alpha$  polypeptide (*i.e.*, a human PGC-1 $\alpha$  polypeptide comprising the amino acid sequence of SEQ ID NO:2). In a further embodiment, the agent is a small molecule.

The invention also provides methods for identifying compounds capable of modulating type I muscle formation comprising contacting a cell (*i.e.*, a muscle cell such as a type I muscle cell or a type II muscle cell) with a compound, and determining whether PGC-1 $\alpha$  expression or activity is modulated. In one embodiment, PGC-1 $\alpha$  expression or activity is increased. In another embodiment, determining whether PGC-1 $\alpha$  expression or activity is modulated is by measuring PGC-1 $\alpha$  expression by Northern blotting. In another embodiment, determining whether PGC-1 $\alpha$  expression or activity is modulated comprises determining whether expression of at least one of myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, or cytochrome c is modulated. In still another embodiment, determining whether PGC-1 $\alpha$  expression or activity is modulated comprises determining whether an MEF2 transcription factor is activated.

In another embodiment, the invention provides methods for identifying compounds capable of treating a disorder characterized by aberrant type I muscle formation (*i.e.*, heart failure, disuse atrophy, mitochondrial myopathies, or systemic metabolic disorders) comprising identifying the ability of the compound to modulate the expression or activity of PGC-1 $\alpha$  to thereby identify a compound capable of treating a disorder characterized by aberrant type I muscle formation. In a preferred embodiment, PGC-1 $\alpha$  expression or activity is increased. In another embodiment, determining whether PGC-1 $\alpha$  expression or activity is modulated is by measuring PGC-1 $\alpha$  expression by Northern blotting. In yet another embodiment, determining whether PGC-1 $\alpha$  expression or activity is modulated comprises determining whether expression of at least one of myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, or cytochrome c is modulated. In another embodiment, the invention provides compounds identified by the methods of the invention. In still another embodiment, determining whether PGC-1 $\alpha$  expression or activity is modulated comprises determining whether an MEF2 transcription factor is activated.

The invention further provides methods for treating subjects having disorders characterized by aberrant type I muscle formation (*i.e.*, heart failure, disuse atrophy, mitochondrial myopathies, or systemic metabolic disorders), comprising administering to the subject an agent capable of modulating PGC-1 $\alpha$  expression or activity, such that the disorder is treated. In one embodiment, PGC-1 $\alpha$  expression or activity is increased. In another embodiment, type I muscle formation is increased. In yet another embodiment, the agent is a PGC-1 $\alpha$  nucleic acid molecule (*i.e.*, a human PGC-1 $\alpha$  nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO:1). In a further embodiment, the PGC-1 $\alpha$  nucleic acid molecule is contained within a vector. In yet a further embodiment, the agent is a small molecule.

The invention also provides transgenic non-human animals (*i.e.*, mice, rats, monkeys, horses, dogs, turkeys, fish, cows, pigs, sheep, goats, frogs, chickens, etc.) comprising an exogenous PGC-1 $\alpha$  nucleic acid molecule, wherein the exogenous PGC-1 $\alpha$  nucleic acid molecule is expressed in the skeletal muscle of the non-human transgenic animal. In one embodiment, the exogenous PGC-1 $\alpha$  nucleic acid molecule is operatively linked to a muscle-specific promoter (*e.g.*, the muscle creatine kinase

promoter, the dystrophin promoter, the myostatin promoter, the GDF-8 promoter, the UCP-3 promoter, the MyoD promoter, the MEF2 promoter, the myosin heavy chain promoter, the myosin light chain promoter, or a troponin promoter). In a preferred embodiment, the non-human animal is a mouse. In another preferred embodiment, the expression of at least one of myoglobin, troponin I slow, MCAD, COX II, COX IV, or cytochrome c is upregulated in the muscle cells of the non-human animal.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

#### 10 **Brief Description of the Drawings**

*Figure 1A-C* depicts the induction of PGC-1 $\alpha$  by CaMKIV via CREB. (A) CaMKIV-activation of PGC-1 $\alpha$  can be abolished by the dominant negative ACREB. (B) The sequence of the CRE in the mouse PGC-1 $\alpha$  promoter (SEQ ID NO:14) and the human promoter (SEQ ID NO:15). For a description of the CRE in the human PGC-1 $\alpha$  promoter, see Herzig, S. *et al.* (2001) *Nature* 413, 179-183. The PGC-1 $\alpha$  promoter with a mutation in the CRE site ( $\Delta$ CRE) is also depicted (SEQ ID NO:16). (C) Site-directed mutagenesis of the CRE inhibits CaMKIV-mediated activation of PGC-1 $\alpha$ .

*Figure 2A-B* illustrates the coactivation of MEF2s on the PGC-1 $\alpha$  promoter. (A) MEF2C and MEF2D activate the mouse PGC-1 $\alpha$  promoter. (B) MEF2 activity is increased by CnA.

*Figure 3A-B* depicts the activation of PGC-1 by MEF2C and MEF2D via a conserved binding site. (A) Identification of putative MEF2-binding sites in the human (SEQ ID NO:18) and mouse (SEQ ID NO:19) PGC-1 $\alpha$  promoter. Both promoters were compared to the TRANSFAC transcription factor binding sites database (Quandt, K. *et al.* (1995) *Nucleic Acids Res* 23, 4878-4884) and high-scoring hits to the matrix V\$AMEF2.01 depicted (SEQ ID NO:17). In the TRANSFAC matrix, basepairs marked bold are of high information content and underlined basepairs denote the core sequence. Putative MEF2 binding sites in the PGC-1 $\alpha$  promoters are bold and underlined. The PGC-1 $\alpha$  promoter with a mutation in the MEF2 binding site ( $\Delta$ MEF2) is also depicted

(SEQ ID NO:20). (B) MEF2C and MEF2D activate a conserved MEF-response element in the PGC-1 $\alpha$  promoter.

Figure 4A-D depicts a model for the autoregulatory loop regulating PGC-1 $\alpha$  in muscle fiber type determination. (B-D) Endogenous PGC-1 $\alpha$  expression is increased in transgenic mice expressing ectopic PGC-1 $\alpha$  in skeletal muscle.

### **Detailed Description of the Invention**

The present invention is based, at least in part, on the discovery that PGC-1 $\alpha$  can modulate type I (slow-twitch) muscle formation and mitochondrial biogenesis in muscle cells, as well as contribute to maintaining muscle cell determination. In particular, it has been found that PGC-1 $\alpha$  can regulate type I muscle fiber differentiation. The present invention is further based, at least in part, on the discovery that transgenic animals expressing PGC-1 $\alpha$  contain increased type I muscle fibers. Moreover, the muscles from these animals are more resistant to exercise-induced fatigue, a hallmark for slow-twitch muscle fibers and muscles following endurance training.

PGC-1 $\alpha$  is a recently described coactivator of nuclear receptors and has been shown to play a major role in cellular respiration, adaptive thermogenesis, and gluconeogenesis in tissues such as brown fat and skeletal muscle (Puigserver, P. *et al.* (1998) *Cell* 92:829-839; Wu, Z. *et al.* (1999) *Cell* 98:115-124; Yoon J.C. *et al.* (2001) *Nature* 413(6852):131-8. The discoveries of the instant invention implicate PGC-1 $\alpha$  as a major regulator of type I muscle formation.

More specifically, it has been found that expression of PGC-1 $\alpha$  in the muscles of transgenic mice induces dose-dependant expression of type I muscle specific genes (*i.e.*, myoglobin and troponin I slow), as well as mitochondrial specific genes indicative of type I muscle specific mitochondrial biogenesis (*i.e.*, MCAD, COX II, COX IV, and cytochrome c). PGC-1 $\alpha$  expression in the muscles of the transgenic mice also induces a dose-dependant down-regulation of the expression of a type II muscle marker, troponin I fast. Induction of the type I specific genes (also referred to herein as "type I markers"), by PGC-1 $\alpha$  in the muscles of the transgenic mice is seen in otherwise type II muscle fibers. Histological analysis indicates that the muscles of the transgenic mice have greater numbers of type I fibers than littermate controls, and the isolated muscle fibers

are more resistant to exercise-induced fatigue. The discoveries of the instant invention thus identify PGC-1 $\alpha$  as a major regulator of type I muscle differentiation.

In addition to PGC-1 $\alpha$ , several additional factors involved in the signaling cascades underlying muscle fiber type determination have been identified, including CaMKIV and CnA. It has been found that the PGC-1 $\alpha$  promoter is regulated by both CaMKIV as well as CnA activity. Exercise and subsequently elevated intracellular calcium levels result in an activation of both CaMKIV and CnA in skeletal muscle. CaMKIV activates PGC-1 $\alpha$  almost entirely through a binding site for CREB, which is found in the PGC-1 $\alpha$  promoter (see Herzig, S., *et al.* (2001) *Nature* 413, 179-183 for a description of the cAMP responsive element (CRE) in the human PGC-1 $\alpha$  promoter). Moreover, there is a positive autoregulatory loop by which PGC-1 $\alpha$  controls its own transcription through the binding to and coactivation of myocyte enhancer factor 2 (MEF2) transcription factors, *e.g.*, MEF2C and MEF2D, which are transcription factors that are targets of CaMKIV and CnA signaling and that bind directly to the PGC-1 $\alpha$  promoter. MEF2 transcription factors therefore can increase transcription of PGC-1 $\alpha$  and this induction response is enhanced by the presence of PGC-1 $\alpha$ . This positive autoregulatory loop helps to sustain high PGC-1 $\alpha$  levels and thus promotes a stable expression of muscle fiber type I specific genes. It has also been found that ectopic expression of PGC-1 $\alpha$  in the skeletal muscle of transgenic mice increased the levels of endogenous PGC-1 $\alpha$  transcript.

These findings indicate that muscle fiber type determination may therefore maintain a quasi-stable state through the establishment of a regulatory loop involving PGC-1 $\alpha$  and MEF2 proteins. In other words, once PGC-1 $\alpha$  expression is triggered by, for example, exercise, PGC-1 $\alpha$  expression levels are maintained without further muscle stimuli, thereby promoting a stable expression of muscle fiber type I specific genes. Knowledge of these mechanisms which control the regulation and maintenance of muscle fiber type determination allows for tissue-specific targeting of these and other factors in diseases with impaired muscle formation or general muscle wasting due to physical inactivity.

The instant invention therefore provides methods and compositions for modulating type I muscle formation using PGC-1 $\alpha$  and modulators thereof.

Accordingly, one aspect of the invention pertains to the use of PGC-1 $\alpha$  molecules, referred to herein as PGC-1 $\alpha$  nucleic acid and protein molecules, which comprise a family of molecules having certain conserved structural and functional features, and which play a role in or function in type I muscle formation associated activities. The term "family" when referring to the protein and nucleic acid molecules of the invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain and having sufficient amino acid or nucleotide sequence homology as defined herein. Such family members can be naturally occurring and can be from either the same or different species. For example, a family can contain a first protein of human origin, as well as other, distinct proteins of human origin or alternatively, can contain homologues of non-human origin. Members of a family may also have common functional characteristics.

Another aspect of the invention pertains to methods for treating a subject, having a disease or disorder characterized by (or associated with) aberrant or abnormal PGC-1 $\alpha$  nucleic acid expression and/or PGC-1 $\alpha$  protein activity. These methods include the step of administering a PGC-1 $\alpha$  modulator to the subject such that treatment occurs. The language "aberrant or abnormal PGC-1 $\alpha$  expression" refers to expression of a non-wild-type PGC-1 $\alpha$  protein or a non-wild-type level of expression of a PGC-1 $\alpha$  protein. Aberrant or abnormal PGC-1 $\alpha$  protein activity refers to a non-wild-type PGC-1 $\alpha$  protein activity or a non-wild-type level of PGC-1 $\alpha$  protein activity. As the PGC-1 $\alpha$  protein is involved in, for example, a pathway involving type I muscle formation, aberrant or abnormal PGC-1 $\alpha$  protein activity or nucleic acid expression interferes with the normal expression of type I muscle specific genes, and/or type I muscle differentiation.

Non-limiting examples of disorders or diseases characterized by or associated with abnormal or aberrant PGC-1 $\alpha$  protein activity or nucleic acid expression (also referred to herein as PGC-1 $\alpha$  associated disorders or as type I muscle associated disorders) include cardiovascular disorders (*i.e.*, heart failure), disuse atrophy, muscle wasting (*i.e.*, that caused by disorders such as cancer, AIDS, or other infectious diseases), mitochondrial myopathies, systemic metabolic disorders (*i.e.*, diabetes, insulin



resistance, hypoglycemia, obesity, body weight disorders, cachexia, or anorexia). See Braunwald, E. *et al.* eds. Harrison's Principles of Internal Medicine, Eleventh Edition (McGraw-Hill Book Company, New York, 1987) pp. 1778-1797; Robbins, S.L. *et al.* Pathologic Basis of Disease, 3rd Edition (W.B. Saunders Company, Philadelphia, 1984) 5 p. 972 for further descriptions of such disorders. The terms "treating" or "treatment," as used herein, refer to reduction or alleviation of at least one adverse effect or symptom of a disorder or disease, *i.e.*, a disorder or disease characterized by or associated with abnormal or aberrant PGC-1 $\alpha$  protein activity or PGC-1 $\alpha$  nucleic acid expression.

The terms "treating" or "treatment," as used herein, further refers to increasing 10 type I muscle formation in subjects without a type I muscle associated disorder, *i.e.*, in subjects wherein increased type I muscle formation is desirable. For example, athletes, competitive racing animals, and other subjects wherein increased type I muscle formation would be desirable, may benefit from the methods of the present invention.

As used herein, a PGC-1 $\alpha$  modulator is a molecule which can modulate PGC-1 $\alpha$  15 nucleic acid expression and/or PGC-1 $\alpha$  protein activity. For example, a PGC-1 $\alpha$  modulator can modulate, *i.e.*, upregulate (activate) or downregulate (suppress), PGC-1 $\alpha$  nucleic acid expression. In another example, a PGC-1 $\alpha$  modulator can modulate (*i.e.*, stimulate or inhibit) PGC-1 $\alpha$  protein activity. If it is desirable to treat a disorder or disease characterized by (or associated with) aberrant or abnormal (non-wild-type) PGC- 20 1 $\alpha$  nucleic acid expression and/or PGC-1 $\alpha$  protein activity by inhibiting PGC-1 $\alpha$  nucleic acid expression, a PGC-1 $\alpha$  modulator can be an antisense molecule, *i.e.*, a ribozyme, as described herein. Examples of antisense molecules which can be used to inhibit PGC-1 $\alpha$  nucleic acid expression include antisense molecules which are complementary to a portion of the 5' untranslated region of SEQ ID NO:1 or SEQ ID NO:4 which also 25 includes the start codon and antisense molecules which are complementary to a portion of the 3' untranslated region of SEQ ID NO:1 or SEQ ID NO:4.

A PGC-1 $\alpha$  modulator which inhibits PGC-1 $\alpha$  nucleic acid expression can also be a small molecule or other drug, *i.e.*, a small molecule or drug identified using the screening assays described herein, which inhibits PGC-1 $\alpha$  nucleic acid expression. A 30 PGC-1 $\alpha$  molecule of the invention can thus also be used as a target to screen molecules, *i.e.*, which can modulate PGC-1 $\alpha$  activity.

If it is desirable to treat a subject, by stimulating PGC-1 $\alpha$  nucleic acid expression, PGC-1 $\alpha$  modulator can be used, for example, a nucleic acid molecule encoding PGC-1 $\alpha$  (*i.e.*, a nucleic acid molecule comprising a nucleotide sequence homologous to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4), an active  
5 PGC-1 $\alpha$  protein or portion thereof (*i.e.*, a PGC-1 $\alpha$  protein or portion thereof having an amino acid sequence which is homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 or a portion thereof), or a small molecule or other drug, *i.e.*, a small molecule (peptide) or drug identified using the screening assays described herein, which stimulates PGC-1 $\alpha$  nucleic acid expression and/or PGC-1 $\alpha$  protein activity.

10 Alternatively, if it is desirable to treat a disease or disorder characterized by (or associated with) aberrant or abnormal (non-wild-type) PGC-1 $\alpha$  nucleic acid expression and/or PGC-1 $\alpha$  protein activity by inhibiting PGC-1 $\alpha$  protein activity, a PGC-1 $\alpha$  modulator can be used, such as an anti- PGC-1 $\alpha$  antibody or a small molecule or other drug, *i.e.*, a small molecule or drug identified using the screening assays described  
15 herein, which inhibits PGC-1 $\alpha$  protein activity. In a preferred embodiment, a PGC-1 $\alpha$  modulator is a PGC-1 $\alpha$  dominant negative.

If it is desirable to treat a disease or disorder characterized by (or associated with) aberrant or abnormal (non-wild-type) PGC-1 $\alpha$  nucleic acid expression and/or PGC-1 $\alpha$  protein activity by stimulating PGC-1 $\alpha$  protein activity, a PGC-1 $\alpha$  modulator can be an  
20 active PGC-1 $\alpha$  protein or portion thereof (*i.e.*, a PGC-1 $\alpha$  protein or portion thereof having an amino acid sequence which is homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 or a portion thereof) or a small molecule or other drug, *i.e.*, a small molecule or drug identified using the screening assays described herein, which stimulates PGC-1 $\alpha$  protein activity.

25 In addition, a subject having a type I muscle associated disorder (*i.e.*, heart failure, disuse atrophy, a mitochondrial myopathy, or a systemic metabolic disorder), can be treated according to the present invention by administering to the subject a PGC-1 $\alpha$  protein or portion thereof or a nucleic acid encoding a PGC-1 $\alpha$  protein or portion thereof such that treatment occurs.

Other aspects of the invention pertain to methods for modulating a cell associated activity. These methods include contacting the cell with an agent (or a composition which includes an effective amount of an agent) which modulates PGC-1 $\alpha$  protein activity or PGC-1 $\alpha$  nucleic acid expression such that a cell associated activity is altered relative to a cell associated activity of the cell in the absence of the agent. As used herein, "a cell associated activity" refers to a normal or abnormal activity or function of a cell. Examples of cell associated activities include proliferation, migration, differentiation, production or secretion of molecules, such as proteins, cell survival, gluconeogenesis, and thermogenesis. In a preferred embodiment, the cell associated activity is type I muscle formation and the cell is a muscle cell. The term "altered" as used herein refers to a change, *i.e.*, an increase or decrease, of a cell associated activity. In one embodiment, the agent stimulates PGC-1 $\alpha$  protein activity or PGC-1 $\alpha$  nucleic acid expression. Examples of such stimulatory agents include an active PGC-1 $\alpha$  protein, a nucleic acid molecule encoding PGC-1 $\alpha$  that has been introduced into the cell, and a modulatory agent which stimulates PGC-1 $\alpha$  protein activity or PGC-1 $\alpha$  nucleic acid expression and which is identified using the drug screening assays described herein. In another embodiment, the agent inhibits PGC-1 $\alpha$  protein activity or PGC-1 $\alpha$  nucleic acid expression. Examples of such inhibitory agents include a nucleic acid molecule encoding a dominant negative PGC-1 $\alpha$  protein, a dominant negative PGC-1 $\alpha$  protein, an antisense PGC-1 $\alpha$  nucleic acid molecule, an anti- PGC-1 $\alpha$  antibody, and a modulatory agent which inhibits PGC-1 $\alpha$  protein activity or PGC-1 $\alpha$  nucleic acid expression and which is identified using the drug screening assays described herein. These modulatory methods can be performed *in vitro* (*i.e.*, by culturing the cell with the agent) or, alternatively, *in vivo* (*i.e.*, by administering the agent to a subject). In a preferred embodiment, the modulatory methods are performed *in vivo*, *i.e.*, the cell is present within a subject, *i.e.*, a mammal, *i.e.*, a human, and the subject has a disorder or disease characterized by or associated with abnormal or aberrant PGC-1 $\alpha$  protein activity or PGC-1 $\alpha$  nucleic acid expression.

The methods of the present invention may therefore: 1) modulate type I muscle formation; 2) modulate the conversion of type II muscle fibers into type I muscle fibers; 3) modulate the response of muscle fibers to exercise induced fatigue; 4) treat diseases or

disorders characterized by aberrant PGC-1 $\alpha$  expression or activity, *i.e.*, heart failure, disuse atrophy, mitochondrial myopathy, and/or systemic metabolic disease; 5) modulate the expression of myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, and/or cytochrome c; and/or 6) modulate coactivation of MEF2 transcription factors, *e.g.*, MEF2C and MEF2D.

A nucleic acid molecule, a protein, a PGC-1 $\alpha$  modulator, a compound etc. used in the methods of treatment can be incorporated into an appropriate pharmaceutical composition described herein and administered to the subject through a route which allows the molecule, protein, modulator, or compound etc. to perform its intended function. Examples of routes of administration are also described herein.

The nucleotide sequence of the human PGC-1 $\alpha$  cDNA and the predicted amino acid sequence of the human PGC-1 $\alpha$  protein are shown in SEQ ID NOs:1 and 2, respectively. The human PGC-1 $\alpha$  gene, which is approximately 3023 nucleotides in length, encodes a full length protein having a molecular weight of approximately 120 kD and which is approximately 798 amino acid residues in length. Further description of the human PGC-1 $\alpha$  nucleic acid and polypeptide sequences can be found in PCT International Publication No. WO 00/32215, incorporated herein by reference.

The nucleotide sequence of the mouse PGC-1 $\alpha$  cDNA and the predicted amino acid sequence of the mouse PGC-1 $\alpha$  protein are shown in SEQ ID NOs:4 and 5, respectively. The mouse PGC-1 $\alpha$  gene, which is approximately 3066 nucleotides in length, encodes a full length protein having a molecular weight of approximately 120 kD and which is approximately 797 amino acid residues in length. Further description of the mouse PGC-1 $\alpha$  nucleic acid and polypeptide sequences can be found in PCT International Publication Nos. WO 00/32215 and WO 98/54220, U.S. Patent No. 6,166,192, Puigserver, P. et al. (1998) *Cell* 92(6):829-39, all of which are incorporated herein by reference.

PGC-1 $\alpha$  family member proteins include several domains/motifs. These domains/motifs include: two putative tyrosine phosphorylation sites (amino acid residues 205-213 and 379-386 of SEQ ID NO:2, and amino acid residues 204-212 and 378-385 of SEQ ID NO:5), three putative cAMP phosphorylation sites (amino acid residues 239-242, 374-377, and 656-658 of SEQ ID NO:2, and 238-241, 373-376, and

655-658 of SEQ ID NO:5), a serine-arginine (SR) rich domain (amino acid residues 563-601 of SEQ ID NO:2, and 562-600 of SEQ ID NO:5), an RNA binding motif (amino acid residues 657-710 of SEQ ID NO:2, and 656-709 of SEQ ID NO:5), and an LXXLL motif (amino acid residues 144-148 of SEQ ID NO:2, and 142-146 of SEQ ID NO:5; SEQ ID NO:3) which mediates interaction with PPAR $\gamma$ , HNF-4 $\alpha$ , and other nuclear receptors. As used herein, a tyrosine phosphorylation site is an amino acid sequence which includes at least one tyrosine residue which can be phosphorylated by a tyrosine protein kinase. Typically, a tyrosine phosphorylation site is characterized by a lysine or an arginine about seven residues to the N-terminal side of the phosphorylated tyrosine.

10 An acidic residue (asparagine or glutamine) is often found at either three or four residues to the N-terminal side of the tyrosine (Patschinsky, T. *et al.* (1982) *Proc. Natl. Acad. Sci. USA* 79:973-977); Hunter, T. (1982) *J. Biol. Chem.* 257:4843-4848; Cooper, J.A. *et al.* (1984) *J. Biol. Chem.* 259:7835-7841). As used herein, a "cAMP phosphorylation site" is an amino acid sequence which includes a serine or threonine residue which can be

15 phosphorylated by a cAMP-dependent protein kinase. Typically, the cAMP phosphorylation site is characterized by at least two consecutive basic residues to the N-terminal side of the serine or threonine (Fremisco, J.R. *et al.* (1980) *J. Biol. Chem.* 255:4240-4245; Glass, D. B. and Smith, S.B. (1983) *J. Biol. Chem.* 258:14797-14803; Glass, D.B. *et al.* (1986) *J. Biol. Chem.* 261:2987-2993). As used herein, a "serine-arginine rich domain" or an "SR rich domain" is an amino acid sequence which is rich in

20 serine and arginine residues. Typically, SR rich domains are domains which interact with the CTD domain of RNA polymerase II or are involved in splicing functions. As used herein, an "RNA binding motif" is an amino acid sequence which can bind an RNA molecule or a single stranded DNA molecule. RNA binding motifs are described in

25 Lodish, H., Darnell, J., and Baltimore, D. *Molecular Cell Biology*, 3rd ed. (W.H. Freeman and Company, New York, New York, 1995). As used herein, an "LXXLL motif" (SEQ ID NO:3) refers to a motif wherein L represents leucine and X can be any amino acid, and which mediates an interaction between a nuclear receptor and a coactivator (Heery *et al.* (1997) *Nature* 397:733-736; Torchia *et al.* (1997) *Nature*

30 387:677-684).

Various aspects of the invention are described in further detail in the following subsections:

#### I. Isolated Nucleic Acid Molecules

5 One aspect of the invention pertains to methods utilizing isolated nucleic acid molecules that encode PGC-1 $\alpha$  or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify PGC-1 $\alpha$ -encoding nucleic acid (*i.e.*, PGC-1 $\alpha$  mRNA). As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*i.e.*, cDNA or genomic DNA) and RNA molecules  
10 (*i.e.*, mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the  
15 nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated PGC-1 $\alpha$  nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid  
20 is derived (*i.e.*, a brown adipocyte). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, *i.e.*, a nucleic acid molecule  
25 having the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:4 or a nucleotide sequence which is at least about 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the  
30 nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:4 or a portion thereof (*i.e.*, 400, 450, 500, or more nucleotides), can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, a human PGC-

1 $\alpha$  cDNA can be isolated from a human liver, heart, kidney, or brain cell line (from Stratagene, LaJolla, CA, or Clontech, Palo Alto, CA) using all or portion of SEQ ID NO:1 or SEQ ID NO:4 as a hybridization probe and standard hybridization techniques (*i.e.*, as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO:1 or SEQ ID NO:4 or a nucleotide sequence which is at least about 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4 can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon the sequence of SEQ ID NO:1 or SEQ ID NO:4 or the homologous nucleotide sequence. For example, mRNA can be isolated from liver cells, heart cells, kidney cells, brain cells, or brown adipocytes (*i.e.*, by the guanidinium-thiocyanate extraction procedure of Chirgwin *et al.* (1979) *Biochemistry* 18: 5294-5299) and cDNA can be prepared using reverse transcriptase (*i.e.*, Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Petersburg, FL). Synthetic oligonucleotide primers for PCR amplification can be designed based upon the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4 or to the homologous nucleotide sequence. A nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to a PGC-1 $\alpha$  nucleotide sequence can be prepared by standard synthetic techniques, *i.e.*, using an automated DNA synthesizer.

In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4 or a nucleotide sequence which is at least about 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more

preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4. The sequence of SEQ ID NO:4 corresponds to the mouse PGC-1 $\alpha$  cDNA. This cDNA comprises sequences encoding the PGC-1 $\alpha$  protein (*i.e.*, "the coding region", from nucleotides 92 to 2482), as well as 5' untranslated sequences (nucleotides 1 to 91) and 3' untranslated sequences (nucleotides 2483 to 3066). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO:4 (*i.e.*, nucleotides 92 to 2482) or the homologous nucleotide sequence. The sequence of SEQ ID NO:1 corresponds to the human PGC-1 $\alpha$  cDNA. This cDNA comprises sequences encoding the PGC-1 $\alpha$  protein (*i.e.*, "the coding region", from nucleotides 89 to 2482), as well as 5' untranslated sequences (nucleotides 1 to 88) and 3' untranslated sequences (nucleotides 2513 to 3023). Alternatively, the nucleic acid molecule can comprise only the coding region of SEQ ID NO:1 (*i.e.*, nucleotides 89 to 2482) or the homologous nucleotide sequence.

15 In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4 or a nucleotide sequence which is at least about 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4. A nucleic acid molecule which is complementary to the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4 or to a nucleotide sequence which is at least about 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4 is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4 or to the homologous sequence such that it can hybridize to the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4 or to the homologous sequence, thereby forming a stable duplex.

30



In still another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which is at least about 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or  
5 more homologous to the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4 or a portion of this nucleotide sequence. In an additional preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes, *i.e.*, hybridizes under stringent conditions, to the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4 or to a nucleotide sequence which is at least about  
10 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4.

Moreover, the nucleic acid molecule of the invention can comprise only a portion  
15 of the coding region of SEQ ID NO:1 or SEQ ID NO:4 or the coding region of a nucleotide sequence which is at least about 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4, for  
20 example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of PGC-1 $\alpha$ . The nucleotide sequence determined from the cloning of the PGC-1 $\alpha$  gene from a mouse or human allows for the generation of probes and primers designed for use in identifying and/or cloning other PGC-1 $\alpha$  family members, as well as PGC-1 $\alpha$  homologues in other cell types, *i.e.* from other tissues, as  
25 well as PGC-1 $\alpha$  homologues from other mammals such as rats or monkeys. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably at least about 25, more preferably about 40, 50 or 75 consecutive nucleotides of SEQ ID NO:1 or SEQ ID NO:4  
30 sense, an anti-sense sequence of SEQ ID NO:1 or SEQ ID NO:4, or naturally occurring

mutants thereof. Primers based on the nucleotide sequence in SEQ ID NO:1 or SEQ ID NO:4 can be used in PCR reactions to clone PGC-1 $\alpha$  homologues.

In an exemplary embodiment, a nucleic acid molecule of the present invention comprises a nucleotide sequence which is about 100, preferably 100-200, preferably  
5 200-300, more preferably 300-400, and even more preferably 400-487 nucleotides in length and hybridizes under stringent hybridization conditions to a nucleic acid molecule of SEQ ID NO:1 or SEQ ID NO:4.

Probes based on the PGC-1 $\alpha$  nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In  
10 preferred embodiments, the probe further comprises a label group attached thereto, *i.e.* the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a PGC-1 $\alpha$  protein, such as by measuring a level of a PGC-1 $\alpha$ -encoding nucleic acid in a sample of cells from a subject *i.e.*, detecting PGC-1 $\alpha$   
15 mRNA levels or determining whether a genomic PGC-1 $\alpha$  gene has been mutated or deleted.

In one embodiment, the nucleic acid molecule of the invention encodes a protein or portion thereof which includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 such that the  
20 protein or portion thereof maintains one or more of the following biological activities: 1) it can modulate the expression of myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, and/or cytochrome c; 2) it can modulate coactivation of MEF2 transcription factors; 3) it can modulate type I muscle formation; 4) it can modulate the conversion of type II muscle fibers into type I muscle fibers; 5) it can modulate the  
25 response of muscle fibers to exercise induced fatigue; and/or 6) it can treat diseases or disorders characterized by aberrant PGC-1 $\alpha$  expression or activity, *i.e.*, heart failure, disuse atrophy, mitochondrial myopathy, and/or systemic metabolic disease.

As used herein, the language "sufficiently homologous" refers to proteins or portions thereof which have amino acid sequences which include a minimum number of  
30 identical or equivalent (*i.e.*, an amino acid residue which has a similar side chain as an amino acid residue in SEQ ID NO:2 or SEQ ID NO:5) amino acid residues to an amino

acid sequence of SEQ ID NO:2 or SEQ ID NO:5 such that the protein or portion thereof maintains one or more of the following biological activities: 1) modulation of the expression of myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, and/or cytochrome c; 2) modulate coactivation of MEF2 transcription factors; 3) modulation of type I muscle formation; 4) modulation of the conversion of type II muscle fibers into type I muscle fibers; 5) modulation of the response of muscle fibers to exercise induced fatigue; and/or 6) treatment of diseases or disorders characterized by aberrant PGC-1 $\alpha$  expression or activity, *i.e.*, heart failure, disuse atrophy, mitochondrial myopathy, and/or systemic metabolic disease.

10 In another embodiment, the protein is at least about 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the entire amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5.

Portions of proteins encoded by the PGC-1 $\alpha$  nucleic acid molecule of the invention are preferably biologically active portions of the PGC-1 $\alpha$  protein. As used  
 15 herein, the term "biologically active portion of PGC-1 $\alpha$ " is intended to include a portion, *i.e.*, a domain/motif, of PGC-1 $\alpha$  that has one or more of the following activities: 1) modulation of the expression of myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, and/or cytochrome c; 2) modulate coactivation of MEF2 transcription  
 20 factors; 3) modulation of type I muscle formation; 4) modulation of the conversion of type II muscle fibers into type I muscle fibers; 5) modulation of the response of muscle fibers to exercise induced fatigue; and/or 6) treatment of diseases or disorders characterized by aberrant PGC-1 $\alpha$  expression or activity, *i.e.*, heart failure, disuse atrophy, mitochondrial myopathy, and/or systemic metabolic disease. Standard  
 25 binding assays, *i.e.*, immunoprecipitations and yeast two-hybrid assays, as described herein, can be performed to determine the ability of a PGC-1 $\alpha$  protein or a biologically active portion thereof to interact with (*i.e.*, bind to) HNF-4 $\alpha$ , FKHR, the PEPCK promoter, PPAR $\gamma$ , C/EBP $\alpha$ , NRF-1, or nuclear hormone receptors (*i.e.*, known molecules which interact with PGC-1 $\alpha$ ). If a PGC-1 $\alpha$  family member is found to  
 30 interact with HNF-4 $\alpha$ , FKHR, the PEPCK promoter, PPAR $\gamma$ , C/EBP $\alpha$ , NRF-1, or nuclear hormone receptors, then they are also likely to be modulators of the activity of

HNF-4 $\alpha$ , FKHR, the PEPCK promoter, PPAR $\gamma$ , C/EBP $\alpha$ , NRF-1, or nuclear hormone receptors.

To determine whether a PGC-1 $\alpha$  family member of the present invention modulates myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, and/or cytochrome c expression, *in vitro* transcriptional assays can be performed. To perform such an assay, the full length promoter/enhancer region of the gene of interest (*i.e.*, myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, and/or cytochrome c) can be linked to a reporter gene such as chloramphenicol acetyltransferase (CAT) or luciferase and introduced into host cells (*i.e.*, liver cells such as Fao hepatoma cells, or COS cells). The same host cells can then be transfected with a nucleic acid molecule encoding the PGC-1 $\alpha$  molecule. In some embodiments, nucleic acid molecules encoding HNF-4 $\alpha$ , FKHR, NRF-1, and/or PPAR $\gamma$ /RXR $\alpha$  can also be transfected. The effect of the PGC-1 $\alpha$  molecule can be measured by testing CAT or luciferase activity and comparing it to CAT or luciferase activity in cells which do not contain nucleic acid encoding the PGC-1 $\alpha$  molecule. An increase or decrease in CAT or luciferase activity indicates a modulation of expression of the gene of interest. Because myoglobin, troponin I slow, MCAD, COX II, COX IV, and cytochrome c are known to be markers of mitochondrial biogenesis and/or type I muscle formation, and troponin I fast is known to be a marker of type II muscle, this assay can also measure the ability of the PGC-1 $\alpha$  molecule to modulate type I muscle formation.

The above described assay for testing the ability of a PGC-1 $\alpha$  molecule to modulate myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, and cytochrome c expression can also be used to test the ability of the PGC-1 $\alpha$  molecule to modulate type I muscle formation. If a PGC-1 $\alpha$  molecule can modulate myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, and/or cytochrome c expression, it can most likely modulate type I muscle formation. Alternatively, the ability of a PGC-1 $\alpha$  molecule to modulate type I muscle formation can be measured by introducing a PGC-1 $\alpha$  molecule into cells, *i.e.*, a muscle cells, and measuring the amount of type I and type II muscle fibers that form.

In one embodiment, the biologically active portion of PGC-1 $\alpha$  comprises at least one domain or motif. Examples of such domains/motifs include a tyrosine phosphorylation site, a cAMP phosphorylation site, a serine-arginine (SR) rich domain, an RNA binding motif, and an LXXLL (SEQ ID NO:3) motif which mediates  
5 interaction with HNF-4 $\alpha$  and nuclear receptors. In one embodiment, the biologically active portion of the protein which includes the domain or motif can modulate differentiation of white adipocytes to brown adipocytes and/or thermogenesis in brown adipocytes or can modulate gluconeogenesis. In a preferred embodiment, the  
10 biologically active portion of the protein includes the domain or motif that can modulate mitochondrial biogenesis and/or type I muscle formation. These domains are described in detail herein. Additional nucleic acid fragments encoding biologically active portions of PGC-1 $\alpha$  can be prepared by isolating a portion of SEQ ID NO:1 or SEQ ID NO:4 or a homologous nucleotide sequence, expressing the encoded portion of PGC-1 $\alpha$  protein or peptide (*i.e.*, by recombinant expression *in vitro*) and assessing the activity of the  
15 encoded portion of PGC-1 $\alpha$  protein or peptide.

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4 (and portions thereof) due to degeneracy of the genetic code and thus encode the same PGC-1 $\alpha$  protein as that encoded by the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:4. In  
20 another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:5 or a protein having an amino acid sequence which is at least about 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least  
25 about 95% or more homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5.

In addition to the mouse and human PGC-1 $\alpha$  nucleotide sequences shown in SEQ ID NO:1 and SEQ ID NO:4, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of  
30 PGC-1 $\alpha$  may exist within a population (*i.e.*, a mammalian population, *i.e.*, a human population). Such genetic polymorphism in the PGC-1 $\alpha$  gene may exist among

individuals within a population due to natural allelic variation. As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding a PGC-1 $\alpha$  protein, preferably a mammalian, *i.e.*, human, PGC-1 $\alpha$  protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the PGC-1 $\alpha$  gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in PGC-1 $\alpha$  that are the result of natural allelic variation and that do not alter the functional activity of PGC-1 $\alpha$  are intended to be within the scope of the invention. Moreover, nucleic acid molecules encoding PGC-1 $\alpha$  proteins from other species, and thus which have a nucleotide sequence which differs from the human or mouse sequences of SEQ ID NO:1 and SEQ ID NO:4, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the mouse or human PGC-1 $\alpha$  cDNAs of the invention can be isolated based on their homology to the mouse or human PGC-1 $\alpha$  nucleic acid sequences disclosed herein using the mouse or human cDNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions (as described herein).

Moreover, nucleic acid molecules encoding other PGC-1 $\alpha$  family members and thus which have a nucleotide sequence which differs from the PGC-1 $\alpha$  sequences of SEQ ID NO:1 or SEQ ID NO:4 are intended to be within the scope of the invention. For example, the use of alternately-spliced isoforms of PGC-1 $\alpha$ , referred to herein as PGC-1b and PGC-1c, or a PGC-1 $\alpha$  homologue referred to herein as PGC-1 $\beta$  may be used in the methods of the invention. The nucleotide and amino acid sequences of mouse PGC-1b (SEQ ID NOs:6 and 7, respectively) are described in U.S. Provisional Patent Application No. 60/303,468, incorporated herein by reference. The nucleotide and amino acid sequences of mouse PGC-1c (SEQ ID NOs:8 and 9, respectively) are also described in U.S. Provisional Patent Application No. 60/303,468. The nucleotide and amino acid sequences of human (SEQ ID NOs:10 and 11, respectively) and mouse (SEQ ID NOs:12 and 13, respectively) PGC-1 $\beta$  are described in U.S. Provisional Application No. 60/338,126 and in Lin, J. et al. (2002) *J. Biol. Chem.* 277(3):1645-8, incorporated herein by reference. The nucleotide and amino acid sequences of mouse PGC-1 $\beta$  are also described in GenBank Accession Nos. AF453324 and AAL47054, respectively.

Additionally, other PGC-1 $\alpha$  family members, for example a PGC-3 cDNA, can be identified based on the nucleotide sequence of human PGC-1 $\alpha$  or mouse PGC-1 $\alpha$ . (It should be noted that a gene called PPAR $\gamma$  coactivator 2, or PGC-2, has already been described in the literature (Castillo, G. *et al.* (1999) *EMBO J.* 18(13):3676-87).

5 However, PGC-2 is both structurally and functionally unrelated to PGC-1 $\alpha$ .) Moreover, nucleic acid molecules encoding PGC-1 $\alpha$  proteins from different species, and thus which have a nucleotide sequence which differs from the PGC-1 $\alpha$  sequences of SEQ ID NO:1 or SEQ ID NO:4 are intended to be within the scope of the invention. For example, rat or monkey PGC-1 $\alpha$  cDNA can be identified based on the nucleotide sequence of a  
10 human PGC-1 $\alpha$ .

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4 or a nucleotide sequence which is about 60%, preferably at least about 70%,  
15 more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4. In other embodiments, the nucleic acid is at least 30, 50, 100, 250 or 500 nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under  
20 which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about 65%, more preferably at least about 70%, and even more preferably at least about 75% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current*  
25 *Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of  
30 SEQ ID NO:1 or SEQ ID NO:4 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an

RNA or DNA molecule having a nucleotide sequence that occurs in nature (*i.e.*, encodes a natural protein). In one embodiment, the nucleic acid encodes a natural human PGC-1 $\alpha$ .

In addition to naturally-occurring allelic variants of the PGC-1 $\alpha$  sequence that  
5 may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4, thereby leading to changes in the amino acid sequence of the encoded PGC-1 $\alpha$  protein, without altering the functional ability of the PGC-1 $\alpha$  protein. For example, nucleotide  
10 substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO:1 or SEQ ID NO:4. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of PGC-1 $\alpha$  (*i.e.*, the sequence of SEQ ID NO:2 or SEQ ID NO:5) without altering the activity of PGC-1 $\alpha$ , whereas an "essential" amino acid residue is required for PGC-1 $\alpha$  activity. For example, amino acid residues involved in the interaction of PGC-1 $\alpha$  to binding partners  
15 or target molecules (*i.e.*, those present in an LXXLL motif) are most likely essential residues of PGC-1 $\alpha$ . Other amino acid residues, however, (*i.e.*, those that are not conserved or only semi-conserved between mouse and human) may not be essential for activity and thus are likely to be amenable to alteration without altering PGC-1 $\alpha$  activity. Furthermore, amino acid residues that are essential for PGC-1 $\alpha$  functions related to  
20 thermogenesis, adipogenesis, or gluconeogenesis, but not essential for PGC-1 $\alpha$  functions related to type I muscle formation, are likely to be amenable to alteration.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding PGC-1 $\alpha$  proteins that contain changes in amino acid residues that are not essential for PGC-1 $\alpha$  activity. Such PGC-1 $\alpha$  proteins differ in amino acid sequence  
25 from SEQ ID NO:2 or SEQ ID NO:5 yet retain at least one of the PGC-1 $\alpha$  activities described herein. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 60% homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 and is capable of modulating type I muscle formation. Preferably, the  
30 protein encoded by the nucleic acid molecule is at least about 70% homologous, preferably at least about 80-85% homologous, still more preferably at least about 90%,



and most preferably at least about 95% homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5.

“Sequence identity or homology”, as used herein, refers to the sequence similarity between two polypeptide molecules or between two nucleic acid molecules.

- 5 When a position in both of the two compared sequences is occupied by the same base or amino acid monomer subunit, *i.e.*, if a position in each of two DNA molecules is occupied by adenine, then the molecules are homologous or sequence identical at that position. The percent of homology or sequence identity between two sequences is a function of the number of matching or homologous identical positions shared by the two
- 10 sequences divided by the number of positions compared x 100. For example, if 6 of 10, of the positions in two sequences are the same then the two sequences are 60% homologous or have 60% sequence identity. By way of example, the DNA sequences ATTGCC and TATGGC share 50% homology or sequence identity. Generally, a comparison is made when two sequences are aligned to give maximum homology.
- 15 Unless otherwise specified “loop out regions”, *i.e.*, those arising from, from deletions or insertions in one of the sequences are counted as mismatches.

- The comparison of sequences and determination of percent homology between two sequences can be accomplished using a mathematical algorithm. Preferably, the alignment can be performed using the Clustal Method. Multiple alignment parameters
- 20 include GAP Penalty =10, Gap Length Penalty = 10. For DNA alignments, the pairwise alignment parameters can be Htuple=2, Gap penalty=5, Window=4, and Diagonal saved=4. For protein alignments, the pairwise alignment parameters can be Ktuple=1, Gap penalty=3, Window=5, and Diagonals Saved=5.

- In a preferred embodiment, the percent identity between two amino acid
- 25 sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available online), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide
- 30 sequences is determined using the GAP program in the GCG software package (available online), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70,

or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (*CABIOS*, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0) (available online), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

An isolated nucleic acid molecule encoding a PGC-1 $\alpha$  protein homologous to the protein of SEQ ID NO:2 or SEQ ID NO:5 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4 or a homologous nucleotide sequence such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into SEQ ID NO:1 or SEQ ID NO:4 or the homologous nucleotide sequence by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*i.e.*, lysine, arginine, histidine), acidic side chains (*i.e.*, aspartic acid, glutamic acid), uncharged polar side chains (*i.e.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*i.e.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*i.e.*, threonine, valine, isoleucine) and aromatic side chains (*i.e.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in PGC-1 $\alpha$  is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a PGC-1 $\alpha$  coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for a PGC-1 $\alpha$  activity described herein to identify mutants that retain PGC-1 $\alpha$  activity. Following mutagenesis of SEQ ID NO:1 or SEQ ID NO:4, the encoded protein can be expressed recombinantly (as described herein) and the activity of the protein can be determined using, for example, assays described herein.

In addition to the nucleic acid molecules encoding PGC-1 $\alpha$  proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, *i.e.*,  
5 complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire PGC-1 $\alpha$  coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the  
10 coding strand of a nucleotide sequence encoding PGC-1 $\alpha$ . The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (*i.e.*, the entire coding region of SEQ ID NO:4 comprises nucleotides 92 to 2482, the entire coding region of SEQ ID NO:1 comprises nucleotides 89 to 2482). In another embodiment, the antisense nucleic acid molecule is antisense to  
15 a "noncoding region" of the coding strand of a nucleotide sequence encoding PGC-1 $\alpha$ . The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding PGC-1 $\alpha$  disclosed herein (*i.e.*, SEQ  
20 ID NO:1 and SEQ ID NO:4), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of PGC-1 $\alpha$  mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of PGC-1 $\alpha$  mRNA. For example, the antisense oligonucleotide can be  
25 complementary to the region surrounding the translation start site of PGC-1 $\alpha$  mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*i.e.*, an antisense  
30 oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the

molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *i.e.*, phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-  
5 (carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-  
10 methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-  
15 2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a PGC-1 $\alpha$  protein to thereby inhibit expression of the protein, *i.e.*, by inhibiting transcription and/or translation. The hybridization can be by  
25 conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of an antisense nucleic acid molecule of the invention includes direct injection at a tissue site. Alternatively, an antisense nucleic acid molecule can be  
30 modified to target selected cells and then administered systemically. For example, for systemic administration, an antisense molecule can be modified such that it specifically

binds to a receptor or an antigen expressed on a selected cell surface, *i.e.*, by linking the antisense nucleic acid molecule to a peptide or an antibody which binds to a cell surface receptor or antigen. The antisense nucleic acid molecule can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an  $\alpha$ -anomeric nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-*o*-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330).

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*i.e.*, hammerhead ribozymes (described in Haseloff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave PGC-1 $\alpha$  mRNA transcripts to thereby inhibit translation of PGC-1 $\alpha$  mRNA. A ribozyme having specificity for a PGC-1 $\alpha$ -encoding nucleic acid can be designed based upon the nucleotide sequence of a PGC-1 $\alpha$  cDNA disclosed herein (*i.e.*, SEQ ID NO:1 or SEQ ID NO:4). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a PGC-1 $\alpha$ -encoding mRNA. See, *i.e.*, Cech *et al.* U.S. Patent No. 4,987,071 and Cech *et al.* U.S. Patent No. 5,116,742. Alternatively, PGC-1 $\alpha$  mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *i.e.*, Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418.

Alternatively, PGC-1 $\alpha$  gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the PGC-1 $\alpha$  (*i.e.*, the PGC-1 $\alpha$  promoter and/or enhancers) to form triple helical structures that prevent transcription of the PGC-1 $\alpha$  gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6(6):569-84; Helene, C. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14(12):807-15.

## II. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to the use of vectors, preferably expression vectors, containing a nucleic acid encoding PGC-1 $\alpha$  (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*i.e.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*i.e.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*i.e.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory

sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (*i.e.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*i.e.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (*i.e.*, tissue-specific regulatory sequences). In a preferred embodiment, a muscle specific promoter is used to direct expression of the nucleotide sequence in muscle (*e.g.*, in a type I muscle cell or in a type II muscle cell). Muscle specific promoters include, without limitation, the muscle creatine kinase promoter, the dystrophin promoter, the myostatin promoter, the GDF-8 promoter, the UCP-3 promoter, the MyoD promoter, the MEF2 promoter, the myosin heavy chain promoter, the myosin light chain promoter, and a troponin promoter. It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (*i.e.*, PGC-1 $\alpha$  proteins, mutant forms of PGC-1 $\alpha$ , fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of PGC-1 $\alpha$  in prokaryotic or eukaryotic cells. For example, PGC-1 $\alpha$  can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be

transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. In one embodiment, the coding sequence of the PGC-1 $\alpha$  is cloned into a pGEX expression vector to create a vector encoding a fusion protein comprising, from the N-terminus to the C-terminus, GST-thrombin cleavage site- PGC-1 $\alpha$ . The fusion protein can be purified by affinity chromatography using glutathione-agarose resin. Recombinant PGC-1 $\alpha$  unfused to GST can be recovered by cleavage of the fusion protein with thrombin.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident  $\lambda$



prophage harboring a T7 *gn1* gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.* (1992) *Nucleic Acids Res.* 20:2111-2118).  
10 Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the PGC-1 $\alpha$  expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, (1987) *EMBO J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA).  
15

Alternatively, PGC-1 $\alpha$  can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (*i.e.*, Sf 9 cells) include the pAc series (Smith *et al.* (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).  
20

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements.  
25 For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed.*, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY,  
30 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*i.e.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the muscle specific casein kinase promoter, the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (*i.e.*, the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (*i.e.*, milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the  $\alpha$ -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to PGC-1 $\alpha$  mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene

expression using antisense genes see Weintraub, H. *et al.*, Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and  
5 "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used  
10 herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, PGC-1 $\alpha$  protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as muscle cells, Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

15 Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*i.e.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated  
20 transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual*, 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the  
25 expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*i.e.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418,  
30 hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding PGC-1 $\alpha$  or can be

introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*i.e.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

5 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) PGC-1 $\alpha$  protein. Accordingly, the invention further provides methods for producing PGC-1 $\alpha$  protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding PGC-1 $\alpha$  has been introduced) in a suitable medium until PGC-1 $\alpha$  is produced. In another embodiment, the  
10 method further comprises isolating PGC-1 $\alpha$  from the medium or the host cell.

### III. Transgenic Animals

The host cells of the invention can also be used to produce nonhuman transgenic animals. The nonhuman transgenic animals (*i.e.*, mice, rats, monkeys, horses, dogs,  
15 turkeys, fish, cows, pigs, sheep, goats, frogs, or chickens) can be used, for example, in screening assays designed to identify agents or compounds, *i.e.*, drugs, pharmaceuticals, etc., which are involved with type I muscle formation and/or capable of ameliorating detrimental symptoms of type I muscle associated disorders.

For example, in one embodiment, a host cell of the invention is a fertilized  
20 oocyte or an embryonic stem cell into which PGC-1 $\alpha$ -coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous PGC-1 $\alpha$  sequences have been introduced into their genome or homologous recombinant animals in which endogenous PGC-1 $\alpha$  sequences have been altered. Such animals are useful for studying the function and/or activity of PGC-1 $\alpha$  and  
25 for identifying and/or evaluating modulators of PGC-1 $\alpha$  activity. As used herein, a "transgenic animal" is a nonhuman animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include nonhuman primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is  
30 integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an

encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a nonhuman animal, preferably a mammal, more preferably a mouse, in which an endogenous PGC-1 $\alpha$  gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *i.e.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing PGC-1 $\alpha$  - encoding nucleic acid into the male pronuclei of a fertilized oocyte, *i.e.*, by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The human PGC-1 $\alpha$  cDNA sequence can be introduced as a transgene into the genome of a nonhuman animal. Alternatively, a nonhuman homologue of the human PGC-1 $\alpha$  gene (SEQ ID NO:1), such as a mouse PGC-1 $\alpha$  gene (SEQ ID NO:4), can be used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the PGC-1 $\alpha$  transgene to direct expression of PGC-1 $\alpha$  protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the PGC-1 $\alpha$  transgene in its genome and/or expression of PGC-1 $\alpha$  mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding PGC-1 $\alpha$  can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a PGC-1 $\alpha$  gene into which a deletion, addition or substitution has been introduced to thereby alter, *i.e.*, functionally disrupt, the PGC-1 $\alpha$  gene. The PGC-1 $\alpha$  gene can be a human gene (*i.e.*, from a human genomic clone isolated from a human

genomic library screened with the cDNA of SEQ ID NO:1), but more preferably, is a nonhuman homologue of a human PGC-1 $\alpha$  gene. For example, a mouse PGC-1 $\alpha$  gene can be used to construct a homologous recombination vector suitable for altering an endogenous PGC-1 $\alpha$  gene in the mouse genome. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous PGC-1 $\alpha$  gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a “knock out” vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous PGC-1 $\alpha$  gene is mutated or otherwise altered but still encodes functional protein (*i.e.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous PGC-1 $\alpha$  protein). In the homologous recombination vector, the altered portion of the PGC-1 $\alpha$  gene is flanked at its 5' and 3' ends by additional nucleic acid of the PGC-1 $\alpha$  gene to allow for homologous recombination to occur between the exogenous PGC-1 $\alpha$  gene carried by the vector and an endogenous PGC-1 $\alpha$  gene in an embryonic stem cell. The additional flanking PGC-1 $\alpha$  nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see *i.e.*, Thomas, K.R. and Capecchi, M. R. (1987) *Cell* 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (*i.e.*, by electroporation) and cells in which the introduced PGC-1 $\alpha$  gene has homologously recombined with the endogenous PGC-1 $\alpha$  gene are selected (see *i.e.*, Li, E. *et al.* (1992) *Cell* 69:915). The selected cells are then injected into a blastocyst of an animal (*i.e.*, a mouse) to form aggregation chimeras (see *i.e.*, Bradley, A. in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. (1991) *Current Opinion in Biotechnology* 2:823-829 and in PCT International

Publication Nos.: WO 90/11354 by Le Mouellec *et al.*; WO 91/01140 by Smithies *et al.*; WO 92/0968 by Zijlstra *et al.*; and WO 93/04169 by Berns *et al.*

In one embodiment of the invention, transgenic animals are created using a vector containing a muscle specific promoter operatively linked to a PGC-1 $\alpha$  nucleic acid molecule. Non-limiting examples of muscle specific promoters include muscle  
5 creatine kinase, dystrophin, myostatin (Gonzalez-Cadavid, N.F. et al. (1998) *Proc. Natl. Acad. Sci. USA* 95(25):14938-43), GDF-8 (PCT International Publication No. WO 00/04051), UCP-3, MyoD, MEF2, myosin heavy chain, myosin light chain, and various forms of troponin.

10 In another preferred embodiment of the invention, transgenic mouse strains were generated which express PGC-1 $\alpha$  from the muscle creatine kinase promoter. The PGC-1 $\alpha$  cDNA sequence was placed under the control of a muscle-specific promoter (muscle creatine kinase (MCK) promoter). Transgenic mice were generated using DNA microinjection and screened by PCR. Four independent founder lines were obtained  
15 (line #29, line #23, line #26, and line #31) and mated with wild type mice to obtain progeny for use in experiments.

Lines #23 and #31 show strong PGC-1 $\alpha$  mRNA expression, line #26 shows low PGC-1 $\alpha$  expression, while line #29 shows little PGC-1 $\alpha$  expression. These mice show a PGC-1 $\alpha$  dose-dependant increase in the expression of type I specific marker gene  
20 expression in the muscle, a dose-dependant decrease in the expression of type II specific marker gene expression in the muscle, and an increase in type I muscle fiber content, as determined by metachromatic and anti-myosin histological analysis. The transgenic mice have a greatly increased amount of dark-colored (type I) muscle throughout their entire bodies, including the hind-limb muscles. More specifically, the gastrocnemius  
25 muscle (normally a type II muscle) is the same dark color in the transgenic mice as the soleus (type I) muscle. The muscle fibers isolated from the transgenic mice also are more resistant to exercise-induced fatigue, a hallmark for slow-twitch muscle fibers and muscles following endurance training.

In another embodiment, transgenic nonhuman animals can be produced which  
30 contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For

a description of the *cre/loxP* recombinase system, see, *i.e.*, Lakso *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman *et al.* (1991) *Science* 251:1351-1355. If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, *i.e.*, by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the nonhuman transgenic animals described herein can also be produced according to the methods described in Wilmut, I. *et al.* (1997) *Nature* 385:810-813 and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, *i.e.*, a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G<sub>0</sub> phase. The quiescent cell can then be fused, *i.e.*, through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell, *i.e.*, the somatic cell, is isolated.

#### IV. Isolated PGC-1 $\alpha$ Proteins and Anti- PGC-1 $\alpha$ Antibodies

Another aspect of the invention pertains to the use of isolated PGC-1 $\alpha$  proteins, and biologically active portions thereof, as well as peptide fragments suitable for use as immunogens to raise anti- PGC-1 $\alpha$  antibodies. An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of PGC-1 $\alpha$  protein in which the protein is separated from cellular components of the cells in which it is naturally or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of PGC-1 $\alpha$  protein having less than about 30% (by dry weight) of non- PGC-1 $\alpha$  protein



(also referred to herein as a "contaminating protein"), more preferably less than about 20% of non- PGC-1 $\alpha$  protein, still more preferably less than about 10% of non- PGC-1 $\alpha$  protein, and most preferably less than about 5% non- PGC-1 $\alpha$  protein. When the PGC-1 $\alpha$  protein or biologically active portion thereof is recombinantly produced, it is also  
5 preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation. The language "substantially free of chemical precursors or other chemicals" includes preparations of PGC-1 $\alpha$  protein in which the protein is separated from chemical precursors or other chemicals which are  
10 involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of PGC-1 $\alpha$  protein having less than about 30% (by dry weight) of chemical precursors or non- PGC-1 $\alpha$  chemicals, more preferably less than about 20% chemical precursors or non- PGC-1 $\alpha$  chemicals, still more preferably less than about 10% chemical precursors or non- PGC-1 $\alpha$  chemicals, and most preferably less than about 5% chemical precursors or non- PGC-1 $\alpha$  chemicals. In preferred embodiments, isolated proteins or biologically active portions thereof lack contaminating proteins from the same animal from which the PGC-1 $\alpha$  protein is derived. Typically, such proteins are produced by recombinant expression of, for example, a human PGC-1 $\alpha$  protein in a nonhuman cell.

20 An isolated PGC-1 $\alpha$  protein or a portion thereof of the invention has one or more of the following biological activities: 1) modulation of the expression of myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, and/or cytochrome c; 2) modulate coactivation of MEF2 transcription factors; 3) modulation of type I muscle formation; 4) modulation of the conversion of type II muscle fibers into type I muscle  
25 fibers; 5) modulation of the response of muscle fibers to exercise induced fatigue; and/or 6) treatment of diseases or disorders characterized by aberrant PGC-1 $\alpha$  expression or activity, *i.e.*, heart failure, disuse atrophy, mitochondrial myopathy, and/or systemic metabolic disease. In preferred embodiments, the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid  
30 sequence of SEQ ID NO:2 or SEQ ID NO:5 such that the protein or portion thereof maintains the ability to modulate gluconeogenesis. The portion of the protein is

preferably a biologically active portion as described herein. In another preferred embodiment, the PGC-1 $\alpha$  protein (*i.e.*, amino acid residues 1-797 or amino acid residues 1-798) has an amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:5, respectively, or an amino acid sequence which is at least about 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:5. In yet another preferred embodiment, the PGC-1 $\alpha$  protein has an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, *i.e.*, hybridizes under stringent conditions, to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4 or a nucleotide sequence which is at least about 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:4. The preferred PGC-1 $\alpha$  proteins of the present invention also preferably possess at least one of the PGC-1 $\alpha$  biological activities described herein. For example, a preferred PGC-1 $\alpha$  protein of the present invention includes an amino acid sequence encoded by a nucleotide sequence which hybridizes, *i.e.*, hybridizes under stringent conditions, to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4 and which can modulate gluconeogenesis.

In other embodiments, the PGC-1 $\alpha$  protein is substantially homologous to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5 and retains the functional activity of the protein of SEQ ID NO:2 or SEQ ID NO:5 yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the PGC-1 $\alpha$  protein is a protein which comprises an amino acid sequence which is at least about 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more homologous to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5.

30

Biologically active portions of the PGC-1 $\alpha$  protein include peptides comprising amino acid sequences derived from the amino acid sequence of the PGC-1 $\alpha$  protein, *i.e.*, the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:5 or the amino acid sequence of a protein homologous to the PGC-1 $\alpha$  protein, which include fewer amino acids than the full length PGC-1 $\alpha$  protein or the full length protein which is homologous to the PGC-1 $\alpha$  protein, and exhibit at least one activity of the PGC-1 $\alpha$  protein.

Typically, biologically active portions (peptides, *i.e.*, peptides which are, for example, 5, 10, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) comprise a domain or motif, *i.e.*, a tyrosine phosphorylation site, a cAMP phosphorylation site, a serine-arginine (SR) rich domain, and/or an RNA binding motif, with at least one activity of the PGC-1 $\alpha$  protein. In a preferred embodiment, the biologically active portion of the protein which includes one or more the domains/motifs described herein can modulate type I muscle formation, mitochondrial biogenesis, as well as differentiation of adipocytes and/or thermogenesis in brown adipocytes, and/or gluconeogenesis. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the activities described herein. Preferably, the biologically active portions of the PGC-1 $\alpha$  protein include one or more selected domains/motifs or portions thereof having biological activity.

PGC-1 $\alpha$  proteins are preferably produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the PGC-1 $\alpha$  protein is expressed in the host cell. The PGC-1 $\alpha$  protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Alternative to recombinant expression, a PGC-1 $\alpha$  protein, polypeptide, or peptide can be synthesized chemically using standard peptide synthesis techniques. Moreover, native PGC-1 $\alpha$  protein can be isolated from cells (*i.e.*, brown adipocytes), for example using an anti- PGC-1 $\alpha$  antibody (described further below).

The invention also provides PGC-1 $\alpha$  chimeric or fusion proteins. As used herein, a PGC-1 $\alpha$  "chimeric protein" or "fusion protein" comprises a PGC-1 $\alpha$  polypeptide operatively linked to a non- PGC-1 $\alpha$  polypeptide. A "PGC-1 $\alpha$  polypeptide" refers to a polypeptide having an amino acid sequence corresponding to PGC-1 $\alpha$ ,  
5 whereas a "non- PGC-1 $\alpha$  polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the PGC-1 $\alpha$  protein, *i.e.*, a protein which is different from the PGC-1 $\alpha$  protein and which is derived from the same or a different organism. Within the fusion protein, the term "operatively linked" is intended to indicate that the PGC-1 $\alpha$  polypeptide and the non-  
10 PGC-1 $\alpha$  polypeptide are fused in-frame to each other. The non- PGC-1 $\alpha$  polypeptide can be fused to the N-terminus or C-terminus of the PGC-1 $\alpha$  polypeptide. For example, in one embodiment the fusion protein is a GST- PGC-1 $\alpha$  fusion protein in which the PGC-1 $\alpha$  sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant PGC-1 $\alpha$ . In another embodiment,  
15 the fusion protein is a PGC-1 $\alpha$  protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*i.e.*, mammalian host cells), expression and/or secretion of PGC-1 $\alpha$  can be increased through use of a heterologous signal sequence.

Preferably, a PGC-1 $\alpha$  chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the  
20 different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can  
25 be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel  
30 *et al.* John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*i.e.*, a GST polypeptide). A PGC-1 $\alpha$  -

encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the PGC-1 $\alpha$  protein.

The present invention also pertains to homologues of the PGC-1 $\alpha$  proteins which function as either a PGC-1 $\alpha$  agonist (mimetic) or a PGC-1 $\alpha$  antagonist. In a preferred embodiment, the PGC-1 $\alpha$  agonists and antagonists stimulate or inhibit, respectively, a subset of the biological activities of the naturally occurring form of the PGC-1 $\alpha$  protein. Thus, specific biological effects can be elicited by treatment with a homologue of limited function. In one embodiment, treatment of a subject with a homologue having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the PGC-1 $\alpha$  protein.

Homologues of the PGC-1 $\alpha$  protein can be generated by mutagenesis, *i.e.*, discrete point mutation or truncation of the PGC-1 $\alpha$  protein. As used herein, the term "homologue" refers to a variant form of the PGC-1 $\alpha$  protein which acts as an agonist or antagonist of the activity of the PGC-1 $\alpha$  protein. An agonist of the PGC-1 $\alpha$  protein can retain substantially the same, or a subset, of the biological activities of the PGC-1 $\alpha$  protein. An antagonist of the PGC-1 $\alpha$  protein can inhibit one or more of the activities of the naturally occurring form of the PGC-1 $\alpha$  protein, by, for example, competitively binding to a downstream or upstream member of the PGC-1 $\alpha$  cascade which includes the PGC-1 $\alpha$  protein. Thus, the mammalian PGC-1 $\alpha$  protein and homologues thereof of the present invention can be, for example, either positive or negative regulators of adipocyte differentiation and/or thermogenesis in brown adipocytes.

In an alternative embodiment, homologues of the PGC-1 $\alpha$  protein can be identified by screening combinatorial libraries of mutants, *i.e.*, truncation mutants, of the PGC-1 $\alpha$  protein for PGC-1 $\alpha$  protein agonist or antagonist activity. In one embodiment, a variegated library of PGC-1 $\alpha$  variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of PGC-1 $\alpha$  variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential PGC-1 $\alpha$  sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*i.e.*, for phage display) containing the set of PGC-1 $\alpha$  sequences

- therein. There are a variety of methods which can be used to produce libraries of potential PGC-1 $\alpha$  homologues from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector.
- 5 Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential PGC-1 $\alpha$  sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, *i.e.*, Narang, S.A. (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu. Rev. Biochem.* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucleic Acid Res.* 11:477.
- 10 In addition, libraries of fragments of the PGC-1 $\alpha$  protein coding can be used to generate a variegated population of PGC-1 $\alpha$  fragments for screening and subsequent selection of homologues of a PGC-1 $\alpha$  protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a PGC-1 $\alpha$  coding sequence with a nuclease under conditions wherein nicking occurs only
- 15 about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-
- 20 terminal and internal fragments of various sizes of the PGC-1 $\alpha$  protein.
- Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of
- 25 PGC-1 $\alpha$  homologues. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene
- 30 whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in

combination with the screening assays to identify PGC-1 $\alpha$  homologues (Arkin and Youvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delagrave *et al.* (1993) *Protein Eng.* 6(3):327-331).

5 An isolated PGC-1 $\alpha$  protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind PGC-1 $\alpha$  using standard techniques for polyclonal and monoclonal antibody preparation. The full-length PGC-1 $\alpha$  protein can be used or, alternatively, the invention provides antigenic peptide fragments of PGC-1 $\alpha$  for use as immunogens. The antigenic peptide of PGC-1 $\alpha$  comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:5 or a  
10 homologous amino acid sequence as described herein and encompasses an epitope of PGC-1 $\alpha$  such that an antibody raised against the peptide forms a specific immune complex with PGC-1 $\alpha$ . Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.  
15 Preferred epitopes encompassed by the antigenic peptide are regions of PGC-1 $\alpha$  that are located on the surface of the protein, *i.e.*, hydrophilic regions.

A PGC-1 $\alpha$  immunogen typically is used to prepare antibodies by immunizing a suitable subject, (*i.e.*, rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed  
20 PGC-1 $\alpha$  protein or a chemically synthesized PGC-1 $\alpha$  peptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic PGC-1 $\alpha$  preparation induces a polyclonal anti- PGC-1 $\alpha$  antibody response.

25 Accordingly, another aspect of the invention pertains to anti- PGC-1 $\alpha$  antibodies. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as PGC-1 $\alpha$ . Examples of immunologically active portions of immunoglobulin  
30 molecules include F(ab) and F(ab')<sub>2</sub> fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and

monoclonal antibodies that bind PGC-1 $\alpha$ . The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of PGC-1 $\alpha$ . A monoclonal antibody composition thus typically displays a single binding affinity for a particular PGC-1 $\alpha$  protein with which it immunoreacts.

Polyclonal anti- PGC-1 $\alpha$  antibodies can be prepared as described above by immunizing a suitable subject with a PGC-1 $\alpha$  immunogen. The anti- PGC-1 $\alpha$  antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized PGC-1 $\alpha$ . If desired, the antibody molecules directed against PGC-1 $\alpha$  can be isolated from the mammal (*i.e.*, from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, *i.e.*, when the anti- PGC-1 $\alpha$  antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497) (see also, Brown *et al.* (1981) *J. Immunol.* 127:539-46; Brown *et al.* (1980) *J. Biol. Chem.* 255:4980-83; Yeh *et al.* (1976) *Proc. Natl. Acad. Sci. USA* 76:2927-31; and Yeh *et al.* (1982) *Int. J. Cancer* 29:269-75), the more recent human B cell hybridoma technique (Kozbor *et al.* (1983) *Immunol. Today* 4:72), the EBV-hybridoma technique (Cole *et al.* (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) *Yale J. Biol. Med.*, 54:387-402; M. L. Gefter *et al.* (1977) *Somatic Cell Genet.* 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a PGC-1 $\alpha$  immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds PGC-1 $\alpha$ .



Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti- PGC-1 $\alpha$  monoclonal antibody (see, *i.e.*, G. Galfre *et al.* (1977) *Nature* 266:55052; Gefter *et al. Somatic Cell Genet.*, cited *supra*; Lerner, *Yale J. Biol. Med.*, cited *supra*; Kenneth, 5 *Monoclonal Antibodies*, cited *supra*). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (*i.e.*, a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of 10 the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, *i.e.*, the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma 15 lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the 20 invention are detected by screening the hybridoma culture supernatants for antibodies that bind PGC-1 $\alpha$ , *i.e.*, using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti- PGC-1 $\alpha$  antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (*i.e.*, an antibody phage display 25 library) with PGC-1 $\alpha$  to thereby isolate immunoglobulin library members that bind PGC-1 $\alpha$ . Kits for generating and screening phage display libraries are commercially available (*i.e.*, the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™ Phage Display Kit*, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in 30 generating and screening antibody display library can be found in, for example, Ladner *et al.* U.S. Patent No. 5,223,409; Kang *et al.* PCT International Publication No. WO

- 92/18619; Dower *et al.* PCT International Publication No. WO 91/17271; Winter *et al.* PCT International Publication WO 92/20791; Markland *et al.* PCT International Publication No. WO 92/15679; Breitling *et al.* PCT International Publication WO 93/01288; McCafferty *et al.* PCT International Publication No. WO 92/01047; Garrard *et al.* PCT International Publication No. WO 92/09690; Ladner *et al.* PCT International Publication No. WO 90/02809; Fuchs *et al.* (1991) *Bio/Technology* 9:1369-1372; Hay *et al.* (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275-1281; Griffiths *et al.* (1993) *EMBO J.* 12:725-734; Hawkins *et al.* (1992) *J. Mol. Biol.* 226:889-896; Clackson *et al.* (1991) *Nature* 352:624-628; Gram *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:3576-3580; Garrard *et al.* (1991) *Bio/Technology* 9:1373-1377; Hoogenboom *et al.* (1991) *Nucleic Acids Res.* 19:4133-4137; Barbas *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:7978-7982; and McCafferty *et al.* *Nature* (1990) 348:552-554.

- Additionally, recombinant anti- PGC-1 $\alpha$  antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson *et al.* International Application No. PCT/US86/02269; Akira, *et al.* European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison *et al.* European Patent Application 173,494; Neuberger *et al.* PCT International Publication No. WO 86/01533; Cabilly *et al.* U.S. Patent No. 4,816,567; Cabilly *et al.* European Patent Application 125,023; Better *et al.* (1988) *Science* 240:1041-1043; Liu *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu *et al.* (1987) *J. Immunol.* 139:3521-3526; Sun *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura *et al.* (1987) *Canc. Res.* 47:999-1005; Wood *et al.* (1985) *Nature* 314:446-449; and Shaw *et al.* (1988) *J. Natl. Cancer Inst.* 80:1553-1559; Morrison, S. L. (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *BioTechniques* 4:214; Winter U.S. Patent 5,225,539; Jones *et al.* (1986) *Nature* 321:552-525; Verhoeven *et al.* (1988) *Science* 239:1534; and Beidler *et al.* (1988) *J. Immunol.* 141:4053-4060.

An anti- PGC-1 $\alpha$  antibody (*i.e.*, monoclonal antibody) can be used to isolate PGC-1 $\alpha$  by standard techniques, such as affinity chromatography or immunoprecipitation. An anti- PGC-1 $\alpha$  antibody can facilitate the purification of natural PGC-1 $\alpha$  from cells and of recombinantly produced PGC-1 $\alpha$  expressed in host cells.

5 Moreover, an anti- PGC-1 $\alpha$  antibody can be used to detect PGC-1 $\alpha$  protein (*i.e.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the PGC-1 $\alpha$  protein. Anti- PGC-1 $\alpha$  antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *i.e.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be

10 facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable prosthetic

15 group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive

20 material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

#### V. Pharmaceutical Compositions

The PGC-1 $\alpha$  nucleic acid molecules, PGC-1 $\alpha$  proteins, PGC-1 $\alpha$  modulators, and anti- PGC-1 $\alpha$  antibodies (also referred to herein as “active compounds”) of the invention

25 can be incorporated into pharmaceutical compositions suitable for administration to a subject, *i.e.*, a human. Such compositions typically comprise the nucleic acid molecule, protein, modulator, or antibody and a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and

30 absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known

in the art. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the invention.

Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible  
5 with its intended route of administration. Examples of routes of administration include parenteral, *i.e.*, intravenous, intradermal, subcutaneous, oral (*i.e.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils,  
10 polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases,  
15 such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the  
20 extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage  
25 and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the  
30 maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various

antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (*i.e.*, a PGC-1 $\alpha$  protein or anti- PGC-1 $\alpha$  antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *i.e.*, a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For  
5 transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active  
10 compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (*i.e.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

15 In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.  
20 Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled  
25 in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound  
30 calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are

dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

## 5 VI. Gene Therapy

In a preferred embodiment, the nucleic acid molecules used in the methods of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent No. 5,328,470) or by stereotactic injection (see *i.e.*, Chen  
10 *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *i.e.* retroviral vectors, the pharmaceutical preparation can include one  
15 or more cells which produce the gene delivery system.

Viral vectors include, for example, recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1. Retrovirus vectors and adeno-associated virus vectors are generally understood to be the recombinant gene delivery system of choice for the transfer of exogenous genes *in vivo*, particularly into humans. Adenovirus  
20 preferentially targets the liver when administered systemically (greater than 90+%; (Antinozzi *et al.* (1999) *Annu. Rev. Nutr.* 19:511-544) for reasons that may have to do with the expression of viral receptors or the lack of vascular barriers in the liver. Alternatively they can be used for introducing exogenous genes *ex vivo* into liver cells in culture. These vectors provide efficient delivery of genes into liver cells, and the  
25 transferred nucleic acids are stably integrated into the chromosomal DNA of the host cell.

A major prerequisite for the use of viruses is to ensure the safety of their use, particularly with regard to the possibility of the spread of wild-type virus in the cell population. The development of specialized cell lines (termed "packaging cells") which  
30 produce only replication-defective retroviruses has increased the utility of retroviruses for gene therapy, and defective retroviruses are well characterized for use in gene

transfer for gene therapy purposes (for a review see Miller, A.D. (1990) *Blood* 76:271). Thus, recombinant retrovirus can be constructed in which part of the retroviral coding sequence (*gag*, *pol*, *env*) is replaced by a gene of interest rendering the retrovirus replication defective. The replication defective retrovirus is then packaged into virions  
5 which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F.M. *et al.* (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses  
10 include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include  $\psi$ Crip,  $\psi$ Cre,  $\psi$ 2 and  $\psi$ Am.

15 Furthermore, it has been shown that it is possible to limit the infection spectrum of retroviruses and consequently of retroviral-based vectors, by modifying the viral packaging proteins on the surface of the viral particle (see, for example PCT publications WO93/25234 and WO94/06920). For instance, strategies for the modification of the infection spectrum of retroviral vectors include: coupling antibodies  
20 specific for cell surface antigens to the viral *env* protein (Roux *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:9079-9083; Julan *et al.* (1992) *J. Gen. Virol.* 73:3251-3255; and Goud *et al.* (1983) *Virology* 163:251-254); or coupling cell surface receptor ligands to the viral *env* proteins (Neda *et al.* (1991) *J. Biol. Chem.* 266:14143-14146). Coupling can be in the form of the chemical cross-linking with a protein or other variety (*i.e.*  
25 lactose to convert the *env* protein to an asialoglycoprotein), as well as by generating fusion proteins (*i.e.* single-chain antibody/*env* fusion proteins). Thus, in a specific embodiment of the invention, viral particles containing a nucleic acid molecule containing a gene of interest operably linked to appropriate regulatory elements, are modified for example according to the methods described above, such that they can  
30 specifically target subsets of liver cells. For example, the viral particle can be coated with antibodies to surface molecule that are specific to certain types of liver cells. This



method is particularly useful when only specific subsets of liver cells are desired to be transfected.

Another viral gene delivery system useful in the present invention utilizes adenovirus-derived vectors. The genome of an adenovirus can be manipulated such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See for example Berkner *et al.* (1988) *Biotechniques* 6:616; Rosenfeld *et al.* (1991) *Science* 252:431-434; and Rosenfeld *et al.* (1992) *Cell* 68:143-155. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (*i.e.*, Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art. Recombinant adenoviruses can be advantageous in certain circumstances in that they are not capable of infecting nondividing cells. Furthermore, the virus particle is relatively stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity. Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis *in situations* where introduced DNA becomes integrated into the host genome (*i.e.*, retroviral DNA). Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner *et al.* cited *supra*; Haj-Ahmand and Graham (1986) *J. Virol.* 57:267). Most replication-defective adenoviral vectors currently in use and therefore favored by the present invention are deleted for all or parts of the viral E1 and E3 genes but retain as much as 80 % of the adenoviral genetic material (see, *i.e.*, Jones *et al.* (1979) *Cell* 16:683; Berkner *et al.*, *supra*; and Graham *et al.* in Methods in Molecular Biology, E.J. Murray, Ed. (Humana, Clifton, NJ, 1991) vol. 7. pp. 109-127). Expression of the gene of interest comprised in the nucleic acid molecule can be under control of, for example, the E1A promoter, the major late promoter (MLP) and associated leader sequences, the E3 promoter, or exogenously added promoter sequences.

Yet another viral vector system useful for delivery of a nucleic acid molecule comprising a gene of interest is the adeno-associated virus (AAV). Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an

adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review see Muzyczka *et al.* *Curr. Topics Microbiol. Immunol.* (1992) 158:97-129). Adeno-associated viruses exhibit a high frequency of stable integration (see for example Flotte *et al.* (1992) *Am. J. Respir. Cell. Mol. Biol.* 7:349-356; Samulski *et al.* (1989) *J. Virol.* 63:3822-3828; and McLaughlin *et al.* (1989) *J. Virol.* 62:1963-1973). Vectors containing as few as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb. An AAV vector such as that described in Tratschin *et al.* (1985) *Mol. Cell. Biol.* 5:3251-3260 can be used to introduce DNA into T cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat *et al.* (1984) *Proc. Natl. Acad. Sci. USA* 81:6466-6470; Tratschin *et al.* (1985) *Mol. Cell. Biol.* 4:2072-2081; Wondisford *et al.* (1988) *Mol. Endocrinol.* 2:32-39; Tratschin *et al.* (1984) *J. Virol.* 51:611-619; and Flotte *et al.* (1993) *J. Biol. Chem.* 268:3781-3790). Other viral vector systems that may have application in gene therapy have been derived from herpes virus, vaccinia virus, and several RNA viruses.

Still another viral vector system useful for delivery of a nucleic acid molecule comprising a gene of interest include the Herpes simplex virus type 1 (HSV-1) amplicon vectors for transfer of a gene into muscle (Wang, Y. *et al.* (2002) *Hum. Gene Ther.* 13(2):261-273);

Other methods relating to the use of viral vectors in gene therapy can be found in, *i.e.*, Kay, M.A. (1997) *Chest* 111(6 Supp.):138S-142S; Ferry, N. and Heard, J. M. (1998) *Hum. Gene Ther.* 9:1975-81; Shiratory, Y. *et al.* (1999) *Liver* 19:265-74; Oka, K. *et al.* (2000) *Curr. Opin. Lipidol.* 11:179-86; Thule, P.M. and Liu, J.M. (2000) *Gene Ther.* 7:1744-52; Yang, N.S. (1992) *Crit. Rev. Biotechnol.* 12:335-56; Alt, M. (1995) *J. Hepatol.* 23:746-58; Brody, S. L. and Crystal, R. G. (1994) *Ann. N.Y. Acad. Sci.* 716:90-101; Strayer, D. S. (1999) *Expert Opin. Investig. Drugs* 8:2159-2172; Smith-Arica, J. R. and Bartlett, J. S. (2001) *Curr. Cardiol. Rep.* 3:43-49; and Lee, H. C. *et al.* (2000) *Nature* 408:483-8.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

## VII. Uses and Methods of the Invention

5           The nucleic acid molecules, polypeptides, polypeptide homologues, modulators, and antibodies described herein can be used in methods of treatment as well as drug screening assays. A PGC-1 $\alpha$  protein of the invention has one or more of the activities described herein and can thus be used to, for example, modulate mitochondrial biogenesis and/or type I muscle formation. The isolated nucleic acid molecules of the  
10          invention can be used to express PGC-1 $\alpha$  protein (*i.e.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect PGC-1 $\alpha$  mRNA (*i.e.*, in a biological sample) or a genetic lesion in a PGC-1 $\alpha$  gene, and to modulate PGC-1 $\alpha$  activity, as described further below. In addition, the PGC-1 $\alpha$  proteins can be used to screen drugs or compounds which modulate PGC-1 $\alpha$  protein activity as well as to treat  
15          disorders characterized by insufficient excessive production of PGC-1 $\alpha$  protein or production of PGC-1 $\alpha$  protein forms which have increased or decreased activity compared to wild type PGC-1 $\alpha$ . Moreover, the anti- PGC-1 $\alpha$  antibodies of the invention can be used to detect and isolate PGC-1 $\alpha$  protein and modulate PGC-1 $\alpha$  protein activity.

          The invention provides a method (also referred to herein as a "screening assay")  
20          for identifying modulators, *i.e.*, candidate or test compounds or agents (*i.e.*, peptides, peptidomimetics, small molecules or other drugs) which bind to PGC-1 $\alpha$  proteins, have a stimulatory or inhibitory effect on, for example, PGC-1 $\alpha$  expression or PGC-1 $\alpha$  activity, or have a stimulatory or inhibitory effect on, for example, the expression or activity of a PGC-1 $\alpha$  target molecule.

25           In one embodiment, the invention provides assays for screening candidate or test compounds which are target molecules of a PGC-1 $\alpha$  protein or polypeptide or biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a PGC-1 $\alpha$  protein or polypeptide or biologically active portion thereof. The test  
30          compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological

libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are  
5 applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K. S. (1997) *Anticancer Drug Des.* 12:45).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example, in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994) *J. Med. Chem.*  
10 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and Gallop *et al.* (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (*i.e.*, Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner USP 5,223,409), spores (Ladner USP  
15 '409), plasmids (Cull *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:1865-1869) or on phage (Scott and Smith (1990) *Science* 249:386-390); (Devlin (1990) *Science* 249:404-406); (Cwirla *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:6378-6382); (Felici (1991) *J. Mol. Biol.* 222:301-310); (Ladner *supra.*).

20 In one embodiment, an assay is a cell-based assay in which a cell which expresses a PGC-1 $\alpha$  protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate PGC-1 $\alpha$  activity is determined. Determining the ability of the test compound to modulate PGC-1 $\alpha$  activity can be accomplished by monitoring, for example, PEPCK, glucose-6-phosphatase,  
25 and/or fructose-1,6-bisphosphatase expression; and/or glucose release into the culture medium in a cell which expresses PGC-1 $\alpha$ . The cell, for example, can be of mammalian origin, *i.e.*, an Fao hepatoma cell.

The ability of the test compound to modulate PGC-1 $\alpha$  binding to a target molecule can also be determined. Determining the ability of the test compound to  
30 modulate PGC-1 $\alpha$  binding to a target molecule can be accomplished, for example, by coupling the PGC-1 $\alpha$  target molecule with a radioisotope or enzymatic label such that

binding of the PGC-1 $\alpha$  target molecule to PGC-1 $\alpha$  can be determined by detecting the labeled PGC-1 $\alpha$  target molecule in a complex. Alternatively, PGC-1 $\alpha$  could be coupled with a radioisotope or enzymatic label to monitor the ability of a test compound to modulate PGC-1 $\alpha$  binding to a PGC-1 $\alpha$  target molecule in a complex. Determining the ability of the test compound to bind PGC-1 $\alpha$  can be accomplished, for example, by coupling the compound with a radioisotope or enzymatic label such that binding of the compound to PGC-1 $\alpha$  can be determined by detecting the labeled PGC-1 $\alpha$  compound in a complex. For example, compounds (*i.e.*, PGC-1 $\alpha$  target molecules) can be labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

It is also within the scope of this invention to determine the ability of a compound or target molecule to interact with PGC-1 $\alpha$  without the labeling of any of the interactants. For example, a microphysiometer can be used to detect the interaction of a compound with PGC-1 $\alpha$  without the labeling of either the compound or the PGC-1 $\alpha$ . McConnell, H. M. *et al.* (1992) *Science* 257:1906-1912. As used herein, a "microphysiometer" (*i.e.*, Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a compound and PGC-1 $\alpha$ .

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a PGC-1 $\alpha$  target molecule with a test compound and determining the ability of the test compound to modulate (*i.e.* stimulate or inhibit) the activity of the PGC-1 $\alpha$  target molecule. Determining the ability of the test compound to modulate the activity of a PGC-1 $\alpha$  target molecule can be accomplished, for example, by determining the ability of a PGC-1 $\alpha$  protein to bind to or interact with the PGC-1 $\alpha$  target molecule, or by determining the ability of a PGC-1 $\alpha$  protein to induce expression from a reporter construct.

Determining the ability of the PGC-1 $\alpha$  protein, or a biologically active fragment thereof, to bind to or interact with a PGC-1 $\alpha$  target molecule can be accomplished by one of the methods described above for determining direct binding. In a preferred embodiment, determining the ability of the PGC-1 $\alpha$  protein to bind to or interact with a PGC-1 $\alpha$  target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular response (*i.e.*, expression of type I muscle specific genes or mitochondrial specific genes), detecting catalytic/enzymatic activity of the target molecule upon an appropriate substrate, detecting the induction of a reporter gene (comprising a target-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *i.e.*, luciferase), or detecting a target-regulated cellular response (*i.e.*, differentiation into type I muscle or resistance to response to induced fatigue).

In yet another embodiment, an assay of the present invention is a cell-free assay in which a PGC-1 $\alpha$  protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to bind to the PGC-1 $\alpha$  protein or biologically active portion thereof is determined. Preferred biologically active portions of the PGC-1 $\alpha$  proteins to be used in assays of the present invention include fragments which participate in interactions with target molecules. Binding of the test compound to the PGC-1 $\alpha$  protein can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the PGC-1 $\alpha$  protein or biologically active portion thereof with a known compound which binds PGC-1 $\alpha$  to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a PGC-1 $\alpha$  protein, wherein determining the ability of the test compound to interact with a PGC-1 $\alpha$  protein comprises determining the ability of the test compound to preferentially bind to PGC-1 $\alpha$  or biologically active portion thereof as compared to the known compound.

In another embodiment, the assay is a cell-free assay in which a PGC-1 $\alpha$  protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate (*i.e.*, stimulate or inhibit) the activity of the PGC-1 $\alpha$  protein or biologically active portion thereof is determined. Determining the ability of

the test compound to modulate the activity of a PGC-1 $\alpha$  protein can be accomplished, for example, by determining the ability of the PGC-1 $\alpha$  protein to bind to a PGC-1 $\alpha$  target molecule by one of the methods described above for determining direct binding. Determining the ability of the PGC-1 $\alpha$  protein to bind to a PGC-1 $\alpha$  target molecule can also be accomplished using a technology such as real-time Biomolecular Interaction Analysis (BIA). Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo *et al.* (1995) *Curr. Opin. Struct. Biol.* 5:699-705. As used herein, "BIA" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (*i.e.*, BIAcore). Changes in the optical phenomenon of surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In an alternative embodiment, determining the ability of the test compound to modulate the activity of a PGC-1 $\alpha$  protein can be accomplished by determining the ability of the PGC-1 $\alpha$  protein to further modulate the activity of a downstream effector of a PGC-1 $\alpha$  target molecule. For example, the activity of the effector molecule on an appropriate target can be determined or the binding of the effector to an appropriate target can be determined as previously described.

In yet another embodiment, the cell-free assay involves contacting a PGC-1 $\alpha$  protein or biologically active portion thereof with a known compound which binds the PGC-1 $\alpha$  protein (*i.e.*, PPAR $\gamma$ , HNF-4 $\alpha$ , FKHR, or the PEPCK promoter) to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the PGC-1 $\alpha$  protein, wherein determining the ability of the test compound to interact with the PGC-1 $\alpha$  protein comprises determining the ability of the PGC-1 $\alpha$  protein to preferentially bind to or modulate the activity of a PGC-1 $\alpha$  target molecule.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either PGC-1 $\alpha$  or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to a PGC-1 $\alpha$  protein, or interaction of a PGC-1 $\alpha$  protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in

any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/ PGC-1 $\alpha$  fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized micrometer plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or PGC-1 $\alpha$  protein, and the mixture incubated under conditions conducive to complex formation (*i.e.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of PGC-1 $\alpha$  binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either a PGC-1 $\alpha$  protein or a PGC-1 $\alpha$  target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated PGC-1 $\alpha$  protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (*i.e.*, biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with PGC-1 $\alpha$  protein or target molecules but which do not interfere with binding of the PGC-1 $\alpha$  protein to its target molecule can be derivatized to the wells of the plate, and unbound target or PGC-1 $\alpha$  protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the PGC-1 $\alpha$  protein or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the PGC-1 $\alpha$  protein or target molecule.

In another embodiment, modulators of PGC-1 $\alpha$  expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of PGC-1 $\alpha$  mRNA or protein in the cell is determined. The level of expression of PGC-1 $\alpha$



mRNA or protein in the presence of the candidate compound is compared to the level of expression of PGC-1 $\alpha$  mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of PGC-1 $\alpha$  expression based on this comparison. For example, when expression of PGC-1 $\alpha$  mRNA or protein is  
5 greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of PGC-1 $\alpha$  mRNA or protein expression. Alternatively, when expression of PGC-1 $\alpha$  mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of PGC-1 $\alpha$   
10 mRNA or protein expression. The level of PGC-1 $\alpha$  mRNA or protein expression in the cells can be determined by methods described herein for detecting PGC-1 $\alpha$  mRNA or protein.

In yet another aspect of the invention, the PGC-1 $\alpha$  proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, *i.e.*, U.S. Patent No.  
15 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300) to identify other proteins which bind to or interact with PGC-1 $\alpha$  ("PGC-1 $\alpha$  -binding proteins" or "PGC-1 $\alpha$  -bp") and are involved in PGC-1 $\alpha$  activity. Such PGC-1 $\alpha$  -binding proteins are also likely to  
20 be involved in the propagation of signals by the PGC-1 $\alpha$  proteins or PGC-1 $\alpha$  targets as, for example, downstream elements of a PGC-1 $\alpha$  -mediated signaling pathway. Alternatively, such PGC-1 $\alpha$  -binding proteins may be PGC-1 $\alpha$  inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the  
25 assay utilizes two different DNA constructs. In one construct, the gene that codes for a PGC-1 $\alpha$  protein is fused to a gene encoding the DNA binding domain of a known transcription factor (*i.e.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If  
30 the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a PGC-1 $\alpha$  -dependent complex, the DNA-binding and activation domains of the transcription factor

are brought into close proximity. This proximity allows transcription of a reporter gene (*i.e.*, LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the  
5 cloned gene which encodes the protein which interacts with the PGC-1 $\alpha$  protein.

In another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-based or a cell-free assay, and the ability of the agent to modulate the activity of a PGC-1 $\alpha$  protein can be confirmed *in vivo*, *i.e.*, in an animal such as a mouse transgenic for  
10 PGC-1 $\alpha$ , particularly wherein the PGC-1 $\alpha$  is expressed in the muscle. Compounds can also be tested in wild-type mice for the ability to increase type I muscle fiber formation. Other animals useful in the methods of the invention include those with heart failure, disuse atrophy, mitochondrial myopathies, and/or systemic metabolic diseases.

This invention further pertains to novel agents identified by the above-described  
15 screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (*i.e.*, a PGC-1 $\alpha$  modulating agent, an antisense PGC-1 $\alpha$  nucleic acid molecule, a PGC-1 $\alpha$ -specific antibody, or a PGC-1 $\alpha$  binding partner) can be used in an animal model to determine the efficacy, toxicity, or side effects of  
20 treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

In yet another embodiment, the invention provides a method for identifying a  
25 compound (*i.e.*, a screening assay) capable of use in the treatment of a disorder characterized by (or associated with) aberrant or abnormal PGC-1 $\alpha$  nucleic acid expression or PGC-1 $\alpha$  polypeptide activity. This method typically includes the step of assaying the ability of the compound or agent to modulate the expression of the PGC-1 $\alpha$  nucleic acid or the activity of the PGC-1 $\alpha$  protein thereby identifying a compound for  
30 treating a disorder characterized by aberrant or abnormal PGC-1 $\alpha$  nucleic acid expression or PGC-1 $\alpha$  polypeptide activity. Disorders characterized by aberrant or

abnormal PGC-1 $\alpha$  nucleic acid expression or PGC-1 $\alpha$  protein activity are described herein. Methods for assaying the ability of the compound or agent to modulate the expression of the PGC-1 $\alpha$  nucleic acid or activity of the PGC-1 $\alpha$  protein are typically cell-based assays. For example, cells which are sensitive to ligands which transduce  
5 signals via a pathway involving PGC-1 $\alpha$  can be induced to overexpress a PGC-1 $\alpha$  protein in the presence and absence of a candidate compound. Candidate compounds which produce a statistically significant change in PGC-1 $\alpha$  -dependent responses (either stimulation or inhibition) can be identified. In one embodiment, expression of the PGC-1 $\alpha$  nucleic acid or activity of a PGC-1 $\alpha$  protein is modulated in cells and the effects of  
10 candidate compounds on the readout of interest (such as rate of cell proliferation or differentiation) are measured. For example, the expression of genes which are up- or down-regulated in response to a PGC-1 $\alpha$  protein-dependent signal cascade (*i.e.*, myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, and/or cytochrome c) can be assayed. In preferred embodiments, the regulatory regions of such  
15 genes, *i.e.*, the 5' flanking promoter and enhancer regions, are operably linked to a detectable marker (such as luciferase) which encodes a gene product that can be readily detected. Phosphorylation of PGC-1 $\alpha$  or PGC-1 $\alpha$  target molecules can also be measured, for example, by immunoblotting.

Alternatively, modulators of PGC-1 $\alpha$  nucleic acid expression (*i.e.*, compounds  
20 which can be used to treat a disorder characterized by aberrant or abnormal PGC-1 $\alpha$  nucleic acid expression or PGC-1 $\alpha$  protein activity) can be identified in a method wherein a cell is contacted with a candidate compound and the expression of PGC-1 $\alpha$  mRNA or protein in the cell is determined. The level of expression of PGC-1 $\alpha$  mRNA or protein in the presence of the candidate compound is compared to the level of  
25 expression of PGC-1 $\alpha$  mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of PGC-1 $\alpha$  nucleic acid expression based on this comparison and be used to treat a disorder characterized by aberrant PGC-1 $\alpha$  nucleic acid expression. For example, when expression of PGC-1 $\alpha$  mRNA or polypeptide is greater (statistically significantly greater) in the presence of the  
30 candidate compound than in its absence, the candidate compound is identified as a stimulator of PGC-1 $\alpha$  nucleic acid expression. Alternatively, when PGC-1 $\alpha$  nucleic acid

expression is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of PGC-1 $\alpha$  nucleic acid expression. The level of PGC-1 $\alpha$  nucleic acid expression in the cells can be determined by methods described herein for detecting PGC-1 $\alpha$  mRNA or protein.

Modulators of PGC-1 $\alpha$  protein activity and/or PGC-1 $\alpha$  nucleic acid expression identified according to these drug screening assays can be used to treat, for example, type I muscle associated disorders such as heart failure, disuse atrophy, mitochondrial myopathies, and/or systemic metabolic diseases. Modulators of PGC-1 $\alpha$  protein activity and/or PGC-1 $\alpha$  nucleic acid expression may also be used to treat disorders related to other functions of PGC-1 $\alpha$  unrelated to type I muscle formation. These methods of treatment include the steps of administering the modulators of PGC-1 $\alpha$  protein activity and/or nucleic acid expression, *i.e.*, in a pharmaceutical composition as described in subsection IV above, to a subject in need of such treatment, *i.e.*, a subject with a disorder described herein.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patent applications, patents, and published patent applications, as well as the Figures and the Sequence Listing cited throughout this application are hereby incorporated by reference.

## EXAMPLES

### EXAMPLE 1: PGC-1 $\alpha$ IS PREFERENTIALLY EXPRESSED IN SLOW TWITCH MUSCLE FIBERS

This example describes the investigation of PGC-1 $\alpha$  expression levels in muscle. RNA was extracted from various types of mouse muscle using standard methods and subjected to a standard Northern blotting protocol using a PGC-1 $\alpha$  probe. High levels of PGC-1 $\alpha$  mRNA expression were seen in soleus (slow-twitch muscles). Extensor digitorum longus (EDL), quadriceps, gastrocnemius, and tibialis anterior (TA) muscles (all fast-twitch muscles) all showed low-level expression. PGC-1 $\alpha$  expression was also

examined in soleus, EDL, quadriceps, and TA muscles. Moderate expression was seen in all of these muscle types.

## **EXAMPLE 2: INDUCTION OF SLOW-TWITCH MUSCLE FIBER**

### **5 DIFFERENTIATION BY TRANSGENIC OVEREXPRESSION OF PGC-1 $\alpha$**

This example describes the results of overexpression of PGC-1 $\alpha$  in transgenic mice. The PGC-1 $\alpha$  cDNA sequence was placed under the control of a muscle-specific promoter (the muscle creatine kinase (MCK) promoter). The muscle creatine kinase promoter is expressed in both type I and type II muscle fibers, but is enriched in type II muscle. Transgenic mice were generated using DNA microinjection and screened by PCR. Four independent founder lines were obtained (#23, #26, #29, #31) and mated with wild type mice to obtain progeny for use in experiments. Transgenic lines #23 and #31 showed strong PGC-1 $\alpha$  mRNA expression. Line #26 showed low-level PGC-1 $\alpha$  mRNA expression. Line #29 showed little PGC-1 $\alpha$  mRNA expression. Western blotting showed that PGC-1 $\alpha$  protein expression levels were not increased in the soleus (type I) muscles of the high expressing transgenic mice. While no expression of PGC-1 $\alpha$  protein is normally seen in plantaris muscles in non-transgenic mice, PGC-1 $\alpha$  protein is expressed in the plantaris muscles of the high-expressing transgenic mice at the same level as in soleus muscle.

mRNA was extracted from the muscle fibers of the transgenic lines and subjected to Northern blotting. Transgenic PGC-1 $\alpha$  expression resulted in enhanced expression of markers indicative of mitochondrial biogenesis. These markers include medium chain Acyl CoA dehydrogenase (MCAD), cytochrome c oxidase II (COX II), cytochrome c oxidase IV (COX IV), and cytochrome c. Transgenic PGC-1 $\alpha$  expression also resulted in a dose-dependant decrease in the expression of a type II (fast-twitch) fiber specific marker (troponin I fast) and a dose-dependant increase in the expression of type I (slow-twitch) fiber specific markers (myoglobin, troponin I slow) in otherwise fast-twitch (type II) fibers, indicating a switch of differentiation program toward type I fibers in the presence of PGC-1 $\alpha$ . Western blotting also indicated a switch in the differentiation program toward type I fibers in the presence of PGC-1 $\alpha$ . The vastus muscle isolated

from the transgenic mice showed strong increases in the levels of myosin, troponin, and cytochrome c (a mitochondrial marker) protein.

Macroscopic examination of the skeletal muscles of the transgenic mice indicated a greatly increased amount of dark-colored (type I) muscle throughout the entire bodies of the mice, as compared to wild type. Specific examination of the hind-limb muscles further showed that the muscles were much darker than the same muscles in the wild type mice. Specific side-by-side examination of the soleus and gastrocnemius muscles showed that the gastrocnemius muscle (normally a type II muscle) was the same dark color in the transgenic mice as the soleus muscle.

Metachromatic and anti-myosin histological analysis of plantaris muscle confirmed that the number of type I fibers is significantly increased in the transgenic mice, as compared to their wild type littermate controls.

The muscles from the transgenic mice were also tested for type I specific functional properties. EDL muscles were isolated and subjected to electrostimulation, and the force generated by the muscles was measured. Fatigue was defined as the time point when the force generated dropped to 30% of the initial force generated. This assay mimics the effects of exercise on the muscles. Using this assay, the EDL muscles isolated from the transgenic mice are significantly more resistant to exercise-induced fatigue ( $P < 0.05$ ), a hallmark for slow-twitch muscle fibers and muscles following endurance training.

### **EXAMPLE 3: AUTOREGULATORY LOOP CONTROLS PGC-1 $\alpha$** **EXPRESSION IN SKELETAL MUSCLE**

Skeletal muscle contains muscle fibers that differ greatly in their oxidative capacity. Prolonged electrical stimulation or exercise training can lead to a muscle fiber type conversion of type II (fast-twitch) to type I (slow-twitch) fibers (Booth, F. W., and Thomason, D. B. (1991) *Physiol Rev* 71, 541-585). Conversely, physical inactivity or denervation can cause a switch to type II fibers (Booth, F. W., and Thomason, D. B. (1991) *Physiol Rev* 71, 541-585). The conversion to type I fibers is characterized by a dramatic change in expression of a large number of genes that increase the oxidative capacity and number of mitochondria, as well as synthesis of distinct contractile proteins

characteristic of this muscle fiber type (Berchtold, M. W., *et al.* (2000) *Physiol Rev* 80, 1215-1265). Exercise training is accompanied by an increase in motor nerve activity that subsequently elevates intracellular calcium levels in the muscle (Olson, E. N., and Williams, R. S. (2000) *Bioassays* 22, 510-519; Hood, D. A. (2001) *J Appl Physiol* 90, 1137-1157). Calcium and the calcium-binding protein calmodulin activate both the calcium/calmodulin-dependent protein kinase IV (CaMKIV) and the protein phosphatase calcineurin A (CnA) as well as many other factors (Hood, D. A. (2001) *J Appl Physiol* 90, 1137-1157). Activated CaMKIV catalyzes protein phosphorylation events that result in release of the myocyte enhancer factor 2 (MEF2) transcription factors from a complex including the histone deacetylases HDAC1/2 and HDAC4/5, the repressor Cabin-1 and the adaptor mSin3 (Corcoran, E. E., and Means, A. R. (2001) *J Biol Chem* 276, 2975-2978). Upon phosphorylation by CaMKIV, these factors are bound to 14-3-3 proteins and exported from the nucleus; as a consequence, the MEF2s are now transcriptionally active and can bind co-activator proteins including CBP/p300 or PGC-1 $\alpha$  (McKinsey, T. A., *et al.* (2001) *Curr Opin Genet Dev* 11, 497-504; McKinsey, T. A., *et al.* (2002) *Trends Biochem Sci* 27, 40-47; Michael, L. F., *et al.* (2001) *Proc Natl Acad Sci U S A* 98, 3820-3825).

In another arm of the calcium signaling pathway, activated CnA dephosphorylates members of the nuclear factor of activated T-cells (NFAT) family, thereby stimulating a cytoplasmic-nuclear translocation of these proteins (Olson, E. N., and Williams, R. S. (2000) *Cell* 101, 689-692). The combined action of MEF2s and NFATs in the nucleus increases the transcription of prototypical muscle fiber type I genes, and thus promotes muscle fiber type switching from type II to type I (Chin, E. R., *et al.* (1998) *Genes Dev* 12, 2499-2509). Activated CnA provides a further boost to this process by dephosphorylating MEF and enhancing its transcriptional activity (Wu, H., *et al.* (2001) *EMBO J* 20, 6414-6423).

Proof of concept of this general model came from transgenic mice that express either constitutively active CnA or CaMKIV, respectively (Naya, F. J., *et al.* (2000) *J Biol Chem* 275, 4545-4548; Wu, H., *et al.* (2002) *Science* 296, 349-352). In these mice, the relative amount of type I muscle fibers is greatly increased in comparison to wildtype animals, supporting a crucial role for CnA and CaMKIV in muscle fiber type

determination. They are furthermore characterized by enhanced mitochondrial biogenesis, upregulation of enzymes involved in oxidative metabolism and greater resistance to fatigue (Wu, H. *et al.* (2002) *Science* 296, 349-352). Interestingly, the main effect of CaMKIV and CnA was observed in an increase of type I muscle fiber number, but not skeletal muscle hypertrophy. Although CnA has been implicated in the molecular mechanism that stimulates hypertrophy, these animal models demonstrate that slow fiber type determination and muscular hypertrophy can be separated and depend on the cellular stimuli and context (Naya, F. J., *et al.* (2000) *J Biol Chem* 275, 4545-4548; Musaro, A., *et al.* (1999) *Nature* 400, 581-585).

PGC-1 $\alpha$  was originally cloned from brown adipose tissue and has been shown to coactivate a variety of nuclear receptors and other transcription factors (described in U.S. Patent No. 6,166,192, incorporated herein in its entirety by reference). Moreover, PGC-1 $\alpha$  is a potent stimulator of mitochondrial biogenesis and oxidative metabolism in several tissues including skeletal muscle (Michael, L. F., *et al.* (2001) *Proc Natl Acad Sci USA* 98, 3820-3825; Wu, Z., *et al.* (1999) *Cell* 98, 115-124). These aspects of energy metabolism are crucial in muscle fiber type differentiation, and thus, as set forth herein, transgenic expression of PGC-1 $\alpha$  driven by a muscle-specific promoter results in a dramatic increase of type I muscle fibers. Increased expression of fiber type I proteins, higher oxidative capacity and greater resistance to fatigue can be observed in the mice that ectopically express PGC-1 $\alpha$ . It has also been found that PGC-1 $\alpha$  may regulate its own transcription and with this autoregulatory loop helps to maintain expression of fiber type I-specific genes.

## METHODS AND MATERIALS

### Plasmids and reagents.

The 5'-flanking sequence of mouse PGC-1 $\alpha$  was obtained from the CELERA™ Mouse Genome database. Various fragments of this promoter were subsequently amplified by PCR and subcloned into the pGL3basic reporter gene vector (PROMEGA™). Thus, the constructs containing the regions between +78 and -2533 or -6483 in respect to the transcriptional start site were denominated 2 kb and 6 kb, respectively. All constructs were verified by sequencing. Expression plasmids for



MEF2C, MEF2D, NFATc3, CaMKIV and constitutively active CnA were gifts from Dr. Eric N. Olson, University of Texas Southwestern Medical Center, Dallas, TX. The dominant negative cyclic AMP response element binding protein (CREB) called ACREB was provided by Dr. Charles Vinson, National Cancer Institute, National  
5 Institutes of Health, Bethesda, MD. All reagents were obtained from SIGMA™.

#### Site-directed mutagenesis.

Site-directed mutagenesis was performed as described previously (Handschin, C., and Meyer, U. A. (2000) *J Biol Chem* 275, 13362-13369). Briefly, PCR amplifications  
10 were performed by using overlapping primers at the target sites, the resulting PCR product was digested with *DpnI* to remove residual template and subsequently transformed into bacteria. Clones containing the mutation were digested with *KpnI* and *BglII* and the insert subcloned into a new reporter gene vector. The cAMP-responsive element (CRE) and the MEF-binding site were mutated into a *BglII* and a *SacII* site and  
15 termed ΔCRE and ΔMEF2, respectively. Constructs were verified by both restriction digestion and sequencing.

#### Cell culture, transfection and reporter gene assays.

C2C12 cells were maintained in DMEM supplemented with 10% fetal calf serum  
20 and 1 μM Na-pyruvate in subconfluent cultures. Cells were subsequently transfected using Lipofectamine transfection reagent (INVITROGEN™) and reporter gene levels were determined 48 hours after transfection. Cells were lysed and analyzed for luciferase expression using the Enhanced Luciferase Assay Kit (BD PHARMINGEN™) according to the supplier's manual. Reporter gene expressions were subsequently normalized  
25 against β-galactosidase levels driven by the cotransfected pSV-β-galactosidase expression vector (PROMEGA™). Finally, these relative expression were normalized against empty reporter gene vector expression.

**Analysis of PGC-1 $\alpha$  gene expression in wildtype and transgenic PGC-1 $\alpha$  mice.**

Wildtype and transgenic mice from strain #31 (described above in Example 2) that highly express PGC-1 $\alpha$  in muscle were sacrificed, skeletal muscle was collected, total RNA isolated using the Trizol reagent following the manufacturer's instructions and subsequently reverse transcribed. Primers for the ABI Prism 7700 sequence detector (APPLIED BIOSYSTEMS™) were designed with the Primer Express™ software targeting either PGC-1 $\alpha$  exon 2, PGC-1 $\alpha$  3' untranslated region, mouse cytochrome c, uncoupling protein 3, myoglobin, glyceraldehyde 3-phosphate dehydrogenase and 18S rRNA. Using the SYBR green PCR master mix, expression levels of total PGC-1 $\alpha$  (primers for exon 2) and endogenous PGC-1 $\alpha$  (primers for the 3' untranslated region) as well as of the other genes were determined from at least three wildtype and transgenic mice and subsequently normalized against 18S rRNA levels.

**RESULTS**

PGC-1 $\alpha$  has been shown to be elevated in the skeletal muscles of mice that contain CaMKIV expressed transgenically in this tissue (Wu, H., *et al.* (2002) *Science* 296, 349-352). Furthermore, CaMKIV was found to activate the human PGC-1 $\alpha$  promoter but the mechanistic basis to this has not been investigated (Wu, H., *et al.* (2002) *Science* 296, 349-352). As depicted in Figure 1A, proximal promoter fragments that are 2 kb or 6 kb in size are both activated when co-transfected with a vector expressing a constitutively active CaMKIV. Coexpression of a constitutively active CnA has only a minimal effect on reporter gene levels corroborating the results obtained in the transgenic CaMKIV and CnA models, respectively (Wu, H., *et al.* (2002) *Science* 296, 349-352). The combination of CaMKIV and CnA has at least an additive effect in increasing transcription controlled by the PGC-1 $\alpha$  promoter. In this experiment, C2C12 cells were cotransfected with expression plasmids for CnA, CaMKIV and ACREB together with reporter gene plasmids containing different fragments of the mouse PGC-1 $\alpha$  promoter. After 48 hours, cells were harvested and reporter gene levels determined.

CaMKIV has been shown to phosphorylate and activate many proteins including CREB. Since CREB has been shown to be an important component of PGC-1 $\alpha$  expression in the fasted liver (Herzig, S., *et al.* (2001) *Nature* 413, 179-183), dominant

negative ACREB protein was utilized to examine a potential role for CREB in the CaMKIV-mediated control of the PGC-1 $\alpha$  promoter. While ACREB had no effect on the PGC-1 $\alpha$  promoter when expressed alone, this protein is able to severely reduce the activation of the PGC-1 $\alpha$  promoter by CaMKIV alone or CaMKIV in combination with  
5 CnA (Figure 1A).

The human PGC-1 $\alpha$  promoter contains a CRE at -133/-116 that is crucial for PGC-1 $\alpha$  induction by cAMP in the liver (Herzig, S., *et al.* (2001) *Nature* 413, 179-183). Similarly, a very conserved putative CRE can be identified in the mouse PGC-1 $\alpha$  promoter at approximately the same distance from the transcriptional start site (Figure  
10 1B). The functional role of this mouse CRE was tested by site-directed mutagenesis followed by stimulation of the mutated promoter with 100  $\mu$ M forskolin, a reagent which stimulates formation of cAMP, for 10 hours. As shown in Figure 1C, mutagenesis of the CRE site abolished induction of 2 kb of the mouse PGC-1 $\alpha$  promoter by forskolin. The same results were obtained when treating the cells with 8-bromo-cAMP whereas the  
15 inactive analog 1,9-dideoxyforskolin had no effect on the PGC-1  $\alpha$  promoter (data not shown). Importantly, the CRE PGC-1 $\alpha$  promoter showed dramatically impaired response to CaMKIV alone or the combination of CaMKIV and CnA in these assays, indicating a key role for CREB in the induction of PGC-1 $\alpha$  expression by these mediators of calcium signaling (Figure 1C). Similar observations were made when  
20 using larger fragments of the mouse PGC-1 $\alpha$  promoter. In this experiment, C2C12 cells were cotransfected with expression plasmids for CnA, CaMKIV and ACREB together with reporter gene plasmids containing 2 kb of wildtype or PGC-1 $\alpha$  promoter with a mutation in the CRE site ( $\Delta$ CRE), respectively. Cells were subsequently treated with either vehicle (0.1% DMSO) or 100  $\mu$ M forskolin for 10 hours and harvested 48 hours  
25 after transfection before reporter gene levels were determined.

While CREB appears to be an important factor in the induction of PGC-1 $\alpha$ , the increased effect of CaMKIV in combination with CnA indicates that factors in addition to CREB are likely to be involved in the transcription of the PGC-1 $\alpha$  gene in muscle. Since MEF2 and NFAT transcription factors are known targets of CaMKIV and CnA in  
30 muscle fiber type determination, the role of these factors in control of the PGC-1 $\alpha$  promoter was tested. As depicted in Figure 2A, MEF2C, MEF2D or NFATc3 alone did

not have a significant effect on the 6 kb PGC-1  $\alpha$  promoter construct. However, since MEF2 proteins are known to be coactivated by PGC-1 $\alpha$  (Michael, L. F., *et al.* (2001) *Proc Natl Acad Sci U S A* 98, 3820-3825), these factors were cotransfected and the experiments revealed coactivation of both MEF2C and MEF2D but not NFAT by PGC-1 $\alpha$  (Figure 2A). These data indicate that PGC-1 $\alpha$  participates in the activation of its own promoter, and the MEF2 proteins may be upstream as well as downstream of PGC-1 $\alpha$  expression. In this experiment, C2C12 cells were cotransfected with expression plasmids for MEF2C, MEF2D, NFAT and PGC-1 $\alpha$  together with reporter gene plasmids containing 6 kb of the mouse PGC-1 $\alpha$  promoter. After 48 hours, cells were harvested and reporter gene levels determined.

The transcriptional capacities of both MEF2 and NFAT are known to be increased by CaMKIV- and CnA-mediated changes in phosphorylation status. CnA is able to substantially increase the activity of MEF2C and MEF2D (Figure 2B). The strongest effect on the PGC-1 $\alpha$  promoter was observed when cotransfecting MEF2C or MEF2D together with CnA and PGC-1 $\alpha$  (Figure 2B). No effect was found by the coexpression of any of these proteins with NFAT. In contrast to the effects of CnA, the effect of CaMKIV on this reporter gene construct was neither changed by addition of MEF2s nor PGC-1 $\alpha$ . This indicates that a major effect of CaMKIV may be in activating PGC-1 $\alpha$  expression via CREB independent on PGC-1 $\alpha$  coactivation whereas CnA apparently is able to further increase the potency of MEF2s to stimulate transcription of PGC-1 $\alpha$ . Similarly, in this experiment, C2C12 cells were cotransfected with expression plasmids for MEF2C, MEF2D, NFAT, CnA and PGC-1 $\alpha$  together with reporter gene plasmids containing 6 kb of the mouse PGC-1 $\alpha$  promoter. After 48 hours, cells were harvested and reporter gene levels determined.

As depicted in Figure 3A, computer-aided sequence analysis of the mouse PGC-1 $\alpha$  5'-flanking region revealed a high-scoring MEF2 binding site at -1464/-1447 (TRANSFAC matrix V\$AMEF2.01) and a NFAT binding site at -1547/-1536 (TRANSFAC matrix V\$NFAT.01) (Quandt, K., *et al.* (1995) *Nucleic Acids Res* 23, 4878-4884). Similar configurations of adjacent MEF2 and NFAT binding sites have previously been described in several muscle fiber type I specific promoters (Chin, E. R., *et al.* (1998) *Genes Dev* 12, 2499-2509). Thus, whether site-directed mutagenesis of this site affects

MEF2 activity on the reporter gene construct was tested. The mutated 2 kb fragment (referred to as  $\Delta$ MEF2) is no longer able to mediate MEF2C or MEF2D induction either when activated by CnA or when coactivated with PGC-1 $\alpha$ , indicating that this site is responsible for the MEF2 action (Figure 3B). In this experiment, C2C12 cells were  
5 cotransfected with expression plasmids for MEF2C, MEF2D, CnA and PGC-1 $\alpha$  together with reporter gene plasmids containing 2 kb of wildtype or 2 kb of mouse PGC-1 $\alpha$  promoter with a mutation in the MEF2-binding site ( $\Delta$ MEF2). After 48 hours, cells were harvested and reporter gene levels determined.

The ability of PGC-1 $\alpha$  to stimulate the PGC-1 $\alpha$  promoter via coactivation of the  
10 MEF2 proteins indicates a potential autoregulatory loop (Figure 4A). Exercise and subsequently elevated intracellular calcium levels result in an activation of both CaMKIV and CnA in skeletal muscle. Activated CaMKIV can phosphorylate CREB which then increases transcription of PGC-1 $\alpha$  via a conserved CREB-binding site in the proximal promoter. Moreover, CaMKIV and CnA activate the transcriptional activity of  
15 MEF2s in part by promoting the dissociation of inhibitory HDACs and Cabin1. MEF2s, potentially in combination with NFAT, bind to at least one MEF2-binding site in the PGC-1 $\alpha$  flanking region and increase transcriptional activity. Newly synthesized PGC-1 $\alpha$  protein can coactivate MEF2s and thus positively regulate its own transcription. PGC-1 $\alpha$  may also compete with the inhibitory HDACs and Cabin 1 for binding to  
20 MEF2s and thus ensure a stable transcription leading to muscle fiber type I determination.

Thus, increased levels of PGC-1 $\alpha$  protein should lead to a stable expression of PGC-1 $\alpha$  by coactivation of MEF2s on its own promoter. In order to critically test this hypothesis, real-time PCR primers for the PGC-1 $\alpha$  3' untranslated region were designed  
25 that should allow distinct determination of the levels of ectopically expressed and endogenous PGC-1 $\alpha$ . Total RNA from wildtype and transgenic skeletal muscle were analyzed for the expression levels of total and endogenous PGC-1 $\alpha$  mRNA using real-time PCR primers targeted for exon 2 (Figure 4B) and the 3' untranslated region (Figure 4C), respectively. The same RNA was analyzed for the expression of cytochrome c (Cyt  
30 c), uncoupling protein-3 (UCP-3), myoglobin and glyceraldehyde 3-phosphate

dehydrogenase (GAPDH) (Figure 4D). Relative mRNA expression levels were normalized against 18S rRNA levels.

As shown in Figure 4B, primers designed to target PGC-1 $\alpha$  exon 2 reveal a more than 80-fold increase in total PGC-1 $\alpha$  levels in the muscle of transgenic mice in comparison to wildtype animals. These findings are similar to the results observed in Northern blots for the high-expressing transgenic line #31 (Lin, J., *et al.* (2002) *Nature* 418, 797-801). When exclusively measuring endogenous PGC-1 $\alpha$  with primers designed for the 3' untranslated region that is missing in the transgenic constructs, an approximately 7-fold elevation of endogenous PGC-1 $\alpha$  was observed in the transgenic animals as compared to wildtype mice (Figure 4C). A robust increase in the transcript levels of cytochrome c (Cyt c), uncoupling protein-3 (UCP-3) and myoglobin in the RNA isolated from skeletal muscle of the transgenic mice was also shown whereas glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels remained unchanged (Figure 4D).

These results strongly indicate a regulation of PGC-1 $\alpha$  transcription by PGC-1 $\alpha$  protein in an autoregulatory loop. Moreover, PGC-1 $\alpha$  gene expression in muscle is reminiscent of other prototypical fiber type I genes such as myoglobin. Thus, gene expression analysis of transgenic PGC-1 $\alpha$  animals further underscores the importance of PGC-1 $\alpha$  in its own regulation.

Accordingly, based on these results, it appears that CaMKIV stimulates PGC-1 $\alpha$  expression, namely by phosphorylating and thus activating CREB, a transcription factor implicated in PGC-1 $\alpha$  transcription in many different tissues (Puigserver, P. *et al.* (1998) *Cell* 92, 829-839; Herzig, S., *et al.* (2001) *Nature* 413, 179-183).

These data indicate an initial activation of PGC-1 $\alpha$  transcription by CaMKIV via CREB (Figure 4A). As soon as PGC-1 $\alpha$  is expressed, it can act as cofactor for de-repressed MEF2 on fiber type I target genes as well as its own promoter, thus ensuring stable, high expression levels. Moreover, PGC-1 $\alpha$  binding to MEF2 may prevent binding of the MEF2-repressing HDACs and Cabin1 proteins. Although CnA and NFAT did not affect the PGC-1 $\alpha$  promoter on their own, an increase in CaMKIV- and MEF2-mediated induction was observed when CnA and NFAT were cotransfected. This may be explained by CnA-triggered activation of MEFs and other factors or by

stabilization of MEF2-binding to the promoter due to NFAT. Recent reports using *in vivo* models support the methods described herein, such as the data showing rapid increase of PGC-1 $\alpha$  mRNA and protein levels after exercise in rats and man (Goto, M., *et al.* (2000) *Biochem Biophys Res Commun* 274, 350-354; Terada, S., *et al.* (2002) *Biochem Biophys Res Commun* 296, 350-354; Baar, K., *et al.* (2002) *FASEB J* 16, 1879-1886).

### Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

What is claimed:

1. A method for modulating type I muscle formation comprising contacting a cell with an agent that modulates PGC-1 $\alpha$  expression or activity, such that type I muscle formation is modulated.
2. The method of claim 1, wherein PGC-1 $\alpha$  expression or activity is increased.
3. The method of claim 1, wherein PGC-1 $\alpha$  expression or activity is decreased.
4. The method of claim 1, wherein type I muscle formation is increased.
5. The method of claim 1, wherein the agent is a PGC-1 $\alpha$  nucleic acid molecule.
6. The method of claim 5, wherein the PGC-1 $\alpha$  nucleic acid molecule is derived from a human.
7. The method of claim 6, wherein the PGC-1 $\alpha$  nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO:1.
8. The method of claim 5, wherein the PGC-1 $\alpha$  nucleic acid molecule is contained within a vector.
9. The method of claim 8, wherein the vector is an adenoviral or an adeno-associated vector.
10. The method of claim 1, wherein the agent is a PGC-1 $\alpha$  polypeptide.



11. The method of claim 10, wherein the PGC-1 $\alpha$  polypeptide is derived from a human.
12. The method of claim 11, wherein the PGC-1 $\alpha$  polypeptide comprises the amino acid sequence of SEQ ID NO:2.
13. The method of claim 1, wherein the agent is a small molecule.
14. The method of claim 1, wherein the cell is a muscle cell.
15. The method of claim 14, wherein the muscle cell is a skeletal muscle cell.
16. The method of claim 15, wherein the skeletal muscle cell is selected from the group consisting of a type I muscle cell and a type II muscle cell.
17. The method of claim 1, wherein the method is performed *in vitro*.
18. The method of claim 1, wherein the method is performed *in vivo*.
19. The method of claim 18, wherein the method is performed in a mouse.
20. The method of claim 18, wherein the method is performed in a human.
21. A method for identifying a compound capable of modulating type I muscle formation comprising:
- a) contacting a cell with a compound; and
  - b) determining whether PGC-1 $\alpha$  expression or activity is modulated.
22. The method of claim 21, wherein PGC-1 $\alpha$  expression or activity is increased.

23. The method of claim 21, wherein PGC-1 $\alpha$  expression is measured by Northern blotting.

24. The method of claim 21, wherein determining whether PGC-1 $\alpha$  expression or activity is modulated comprises determining whether expression of at least one of myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, or cytochrome c is modulated.

25. The method of claim 24, wherein expression is measured by Northern blotting,

26. The method of claim 21, wherein the cell is a muscle cell.

27. The method of claim 21, wherein the muscle cell is a skeletal muscle cell.

28. The method of claim 27, wherein the skeletal muscle cell is selected from the group consisting of: a type I muscle cell and a type II muscle cell.

29. A compound identified by the method of claim 21.

30. A method for identifying a compound capable of treating a disorder characterized by aberrant type I muscle formation comprising assaying the ability of the compound to modulate the expression or activity of PGC-1 $\alpha$  to thereby identify a compound capable of treating a disorder characterized by aberrant type I muscle formation.

31. The method of claim 30, wherein PGC-1 $\alpha$  expression or activity is increased.

32. The method of claim 30, wherein PGC-1 $\alpha$  expression is measured by Northern blotting.

33. The method of claim 30, wherein determining whether PGC-1 $\alpha$  expression or activity is modulated comprises determining whether expression of at least one of myoglobin, troponin I slow, troponin I fast, MCAD, COX II, COX IV, or cytochrome c is modulated.
34. The method of claim 33, wherein expression is measured by Northern blotting.
35. The method of claim 30, wherein the cell is a muscle cell.
36. The method of claim 35, wherein the muscle cell is a skeletal muscle cell.
37. The method of claim 36, wherein the skeletal muscle cell is selected from the group consisting of: a type I muscle cell and a type II muscle cell.
38. A compound identified by the method of claim 30.
39. A method for treating a subject having a disorder characterized by aberrant type I muscle formation comprising administering to the subject an agent capable of modulating PGC-1 $\alpha$  expression or activity, such that the disorder is treated.
40. The method of claim 39, wherein the disorder is selected from the group consisting of heart failure, disuse atrophy, a mitochondrial myopathy, and a systemic metabolic disorder.
41. The method of claim 39, wherein PGC-1 $\alpha$  expression or activity is increased.
42. The method of claim 41, wherein type I muscle formation is increased.

43. The method of claim 39, wherein the agent is a PGC-1 $\alpha$  nucleic acid molecule.

44. The method of claim 43, wherein the PGC-1 $\alpha$  nucleic acid molecule is  
5 derived from a human.

45. The method of claim 44, wherein the PGC-1 $\alpha$  nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO:1.

10 46. The method of claim 43, wherein the PGC-1 $\alpha$  nucleic acid molecule is contained within a vector.

47. The method of claim 46, wherein the vector is an adenoviral or an adeno-associated vector.

15

48. The method of claim 39, wherein the agent is a small molecule.

49. A method for increasing type I muscle formation in a subject comprising administering to the subject an agent capable of increasing PGC-1 $\alpha$  expression or  
20 activity, such that type I muscle formation is increased.

50. The method of claim 49, wherein the agent is a PGC-1 $\alpha$  nucleic acid molecule.

25 51. The method of claim 50, wherein the PGC-1 $\alpha$  nucleic acid molecule is derived from a human.

52. The method of claim 51, wherein the PGC-1 $\alpha$  nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO:1.

30

53. The method of claim 50, wherein the PGC-1 $\alpha$  nucleic acid molecule is contained within a vector.

54. The method of claim 53, wherein the vector is an adenoviral or an adeno-  
5 associated vector.

55. The method of claim 49, wherein the agent is a small molecule.

56. A nonhuman transgenic animal comprising an exogenous PGC-1 $\alpha$   
10 nucleic acid molecule, wherein the exogenous PGC-1 $\alpha$  nucleic acid molecule is expressed in the skeletal muscle of the animal.

57. The transgenic animal of claim 56, wherein the exogenous PGC-1 $\alpha$  nucleic acid molecule is operatively linked to a muscle specific promoter.

15

58. The transgenic animal of claim 57, wherein the muscle specific promoter is selected from the group consisting of: the muscle creatine kinase promoter, the dystrophin promoter, the myostatin promoter, the GDF-8 promoter, the UCP-3 promoter, the MyoD promoter, the MEF2 the promoter, the myosin heavy chain promoter, the  
20 myosin light chain promoter, and a troponin promoter.


59. The transgenic animal of claim 57, wherein the expression of at least one of myoglobin, troponin I slow, MCAD, COX II, COX IV, or cytochrome c is upregulated in the muscle cells of the animal.

25

60. The transgenic animal of claim 56, wherein the animal is a mouse.

*Fig. 1*

1/4




**B**

CRE

HumanPGC-1 $\alpha$  - 133 AGTGACGTCA GGAGTTTG - 116


MousePGC-1 $\alpha$  - 146 AGTGACGTCA GGAGTTTG - 129

$\Delta$ CRE - 146 AGTAGATCTA GGAGTTTG - 129



SUBSTITUTE SHEET (RULE 26)

2/4

*Fig. 2*


SUBSTITUTE SHEET (RULE 26)

3/4

*Fig. 3*

**A**


TRANSFACMatrix V\$AMEF2.01	NKGN <b>Y</b> TAAAAATANCYNN
HumanPGC-1 $\alpha$	-1293 TTACCTAAATATAATTTG -1308
MousePGC-1 $\alpha$	-1549 GCATCTAAATATAATTTA -1564
$\Delta$ MEF2	-1549 GCATCTCCGCGGAATTTA -1564



SUBSTITUTE SHEET (RULE 26)



4/4

*Fig. 4*

SUBSTITUTE SHEET (RULE 26)

## SEQUENCE LISTING

<110> Dana Farber Cancer Institute, et al.

<120> Methods and Compositions For Modulating Type I Muscle  
Formation Using PGC-1alpha

<130> DFN-041PC

<140>

<141>

<150> 60/357,069

<151> 2002-02-13

<160> 20

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 3023

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (89)..(2482)

<400> 1

```

cagggtggctg gttgcctgca tgagtgtgtg ctctgtgtca ctgtggattg gagttgaaaa 60
agcttgactg gcgtcattca ggagctgg atg gcg tgg gac atg tgc aac cag      112
                               Met Ala Trp Asp Met Cys Asn Gln
                               1           5

gac tct gag tct gta tgg agt gac atc gag tgt gct gct ctg gtt ggt      160
Asp Ser Glu Ser Val Trp Ser Asp Ile Glu Cys Ala Ala Leu Val Gly
   10           15           20

gaa gac cag cct ctt tgc cca gat ctt cct gaa ctt gat ctt tct gaa      208
Glu Asp Gln Pro Leu Cys Pro Asp Leu Pro Glu Leu Asp Leu Ser Glu
   25           30           35           40

cta gat gtg aac gac ttg gat aca gac agc ttt ctg ggt gga ctc aag      256
Leu Asp Val Asn Asp Leu Asp Thr Asp Ser Phe Leu Gly Gly Leu Lys
           45           50           55

tgg tgc agt gac caa tca gaa ata ata tcc aat cag tac aac aat gag      304
Trp Cys Ser Asp Gln Ser Glu Ile Ile Ser Asn Gln Tyr Asn Asn Glu
           60           65           70

cct tca aac ata ttt gag aag ata gat gaa gag aat gag gca aac ttg      352
Pro Ser Asn Ile Phe Glu Lys Ile Asp Glu Glu Asn Glu Ala Asn Leu
           75           80           85

cta gca gtc ctc aca gag aca cta gac agt ctc cct gtg gat gaa gac      400
Leu Ala Val Leu Thr Glu Thr Leu Asp Ser Leu Pro Val Asp Glu Asp
           90           95          100

gga ttg ccc tca ttt gat gcg ctg aca gat gga gac gtg acc act gac      448
Gly Leu Pro Ser Phe Asp Ala Leu Thr Asp Gly Asp Val Thr Thr Asp

```

105	110	115	120	
aat gag gct agt cct tcc tcc atg cct gac ggc acc cct cca ccc cag	Asn Glu Ala Ser Pro Ser Ser Met Pro Asp Gly Thr Pro Pro Pro Gln	496		
125	130	135		
gag gca gaa gag ccg tct cta ctt aag aag ctc tta ctg gca cca gcc	Glu Ala Glu Glu Pro Ser Leu Leu Lys Lys Leu Leu Leu Ala Pro Ala	544		
140	145	150		
aac act cag cta agt tat aat gaa tgc agt ggt ctc agt acc cag aac	Asn Thr Gln Leu Ser Tyr Asn Glu Cys Ser Gly Leu Ser Thr Gln Asn	592		
155	160	165		
cat gca aat cac aat cac agg atc aga aca aac cct gca att gtt aag	His Ala Asn His Asn His Arg Ile Arg Thr Asn Pro Ala Ile Val Lys	640		
170	175	180		
act gag aat tca tgg agc aat aaa gcg aag agt att tgt caa cag caa	Thr Glu Asn Ser Trp Ser Asn Lys Ala Lys Ser Ile Cys Gln Gln Gln	688		
185	190	195	200	
aag cca caa aga cgt ccc tgc tcg gag ctt ctc aaa tat ctg acc aca	Lys Pro Gln Arg Arg Pro Cys Ser Glu Leu Leu Lys Tyr Leu Thr Thr	736		
205	210	215		
aac gat gac cct cct cac acc aaa ccc aca gag aac aga aac agc agc	Asn Asp Asp Pro Pro His Thr Lys Pro Thr Glu Asn Arg Asn Ser Ser	784		
220	225	230		
aga gac aaa tgc acc tcc aaa aag aag tcc cac aca cag tcg cag tca	Arg Asp Lys Cys Thr Ser Lys Lys Lys Ser His Thr Gln Ser Gln Ser	832		
235	240	245		
caa cac tta caa gcc aaa cca aca act tta tct ctt cct ctg acc cca	Gln His Leu Gln Ala Lys Pro Thr Thr Leu Ser Leu Pro Leu Thr Pro	880		
250	255	260		
gag tca cca aat gac ccc aag ggt tcc cca ttt gag aac aag act att	Glu Ser Pro Asn Asp Pro Lys Gly Ser Pro Phe Glu Asn Lys Thr Ile	928		
265	270	275	280	
gaa cgc acc tta agt gtg gaa ctc tct gga act gca ggc cta act cca	Glu Arg Thr Leu Ser Val Glu Leu Ser Gly Thr Ala Gly Leu Thr Pro	976		
285	290	295		
ccc acc act cct cct cat aaa gcc aac caa gat aac cct ttt agg gct	Pro Thr Thr Pro Pro His Lys Ala Asn Gln Asp Asn Pro Phe Arg Ala	1024		
300	305	310		
tct cca aag ctg aag tcc tct tgc aag act gtg gtg cca cca cca tca	Ser Pro Lys Leu Lys Ser Ser Cys Lys Thr Val Val Pro Pro Pro Ser	1072		
315	320	325		
aag aag ccc agg tac agt gag tct tct ggt aca caa ggc aat aac tcc	Lys Lys Pro Arg Tyr Ser Glu Ser Ser Gly Thr Gln Gly Asn Asn Ser	1120		
330	335	340		
acc aag aaa ggg ccg gag caa tcc gag ttg tat gca caa ctc agc aag	Thr Lys Lys Gly Pro Glu Gln Ser Glu Leu Tyr Ala Gln Leu Ser Lys	1168		
345	350	355	360	

tcc tca gtc ctc act ggt gga cac gag gaa agg aag acc aag cgg ccc	1216
Ser Ser Val Leu Thr Gly Gly His Glu Glu Arg Lys Thr Lys Arg Pro	
365 370 375	
agt ctg cgg ctg ttt ggt gac cat gac tat tgc cag tca att aat tcc	1264
Ser Leu Arg Leu Phe Gly Asp His Asp Tyr Cys Gln Ser Ile Asn Ser	
380 385 390	
aaa acg gaa ata ctc att aat ata tca cag gag ctc caa gac tct aga	1312
Lys Thr Glu Ile Leu Ile Asn Ile Ser Gln Glu Leu Gln Asp Ser Arg	
395 400 405	
caa cta gaa aat aaa gat gtc tcc tct gat tgg cag ggg cag att tgt	1360
Gln Leu Glu Asn Lys Asp Val Ser Ser Asp Trp Gln Gly Gln Ile Cys	
410 415 420	
tct tcc aca gat tca gac cag tgc tac ctg aga gag act ttg gag gca	1408
Ser Ser Thr Asp Ser Asp Gln Cys Tyr Leu Arg Glu Thr Leu Glu Ala	
425 430 435 440	
agc aag cag gtc tct cct tgc agc aca aga aaa cag ctc caa gac cag	1456
Ser Lys Gln Val Ser Pro Cys Ser Thr Arg Lys Gln Leu Gln Asp Gln	
445 450 455	
gaa atc cga gcc gag ctg aac aag cac ttc ggt cat ccc agt caa gct	1504
Glu Ile Arg Ala Glu Leu Asn Lys His Phe Gly His Pro Ser Gln Ala	
460 465 470	
gtt ttt gac gac gaa gca gac aag acc ggt gaa ctg agg gac agt gat	1552
Val Phe Asp Asp Glu Ala Asp Lys Thr Gly Glu Leu Arg Asp Ser Asp	
475 480 485	
ttc agt aat gaa caa ttc tcc aaa cta cct atg ttt ata aat tca gga	1600
Phe Ser Asn Glu Gln Phe Ser Lys Leu Pro Met Phe Ile Asn Ser Gly	
490 495 500	
cta gcc atg gat ggc ctg ttt gat gac agc gaa gat aaa agt gat aaa	1648
Leu Ala Met Asp Gly Leu Phe Asp Asp Ser Glu Asp Lys Ser Asp Lys	
505 510 515 520	
ctg agc tac cct tgg gat ggc acg caa tcc tat tca ttg ttc aat gtg	1696
Leu Ser Tyr Pro Trp Asp Gly Thr Gln Ser Tyr Ser Leu Phe Asn Val	
525 530 535	
tct cct tct tgt tct tct ttt aac tct cca tgt aga gat tct gtg tca	1744
Ser Pro Ser Cys Ser Ser Phe Asn Ser Pro Cys Arg Asp Ser Val Ser	
540 545 550	
cca ccc aaa tcc tta ttt tct caa aga ccc caa agg atg cgc tct cgt	1792
Pro Pro Lys Ser Leu Phe Ser Gln Arg Pro Gln Arg Met Arg Ser Arg	
555 560 565	
tca agg tcc ttt tct cga cac agg tcg tgt tcc cga tca cca tat tcc	1840
Ser Arg Ser Phe Ser Arg His Arg Ser Cys Ser Arg Ser Pro Tyr Ser	
570 575 580	
agg tca aga tca agg tct cca ggc agt aga tcc tct tca aga tcc tgc	1888
Arg Ser Arg Ser Arg Ser Pro Gly Ser Arg Ser Ser Ser Arg Ser Cys	
585 590 595 600	

tat tac tat gag tca agc cac tac aga cac cgc acg cac cga aat tct	1936
Tyr Tyr Tyr Glu Ser Ser His Tyr Arg His Arg Thr His Arg Asn Ser	
605 610 615	
ccc ttg tat gtg aga tca cgt tca aga tcg ccc tac agc cgt cgg ccc	1984
Pro Leu Tyr Val Arg Ser Arg Ser Arg Ser Pro Tyr Ser Arg Arg Pro	
620 625 630	
agg tat gac agc tac gag gaa tat cag cac gag agg ctg aag agg gaa	2032
Arg Tyr Asp Ser Tyr Glu Glu Tyr Gln His Glu Arg Leu Lys Arg Glu	
635 640 645	
gaa tat cgc aga gag tat gag aag cga gag tct gag agg gcc aag caa	2080
Glu Tyr Arg Arg Glu Tyr Glu Lys Arg Glu Ser Glu Arg Ala Lys Gln	
650 655 660	
agg gag agg cag agg cag aag gca att gaa gag cgc cgt gtg att tat	2128
Arg Glu Arg Gln Arg Gln Lys Ala Ile Glu Glu Arg Arg Val Ile Tyr	
665 670 675 680	
gtc ggt aaa atc aga cct gac aca aca cgg aca gaa ctg agg gac cgt	2176
Val Gly Lys Ile Arg Pro Asp Thr Thr Arg Thr Glu Leu Arg Asp Arg	
685 690 695	
ttt gaa gtt ttt ggt gaa att gag gag tgc aca gta aat ctg cgg gat	2224
Phe Glu Val Phe Gly Glu Ile Glu Glu Cys Thr Val Asn Leu Arg Asp	
700 705 710	
gat gga gac agc tat ggt ttc att acc tac cgt tat acc tgt gat gct	2272
Asp Gly Asp Ser Tyr Gly Phe Ile Thr Tyr Arg Tyr Thr Cys Asp Ala	
715 720 725	
ttt gct gct ctt gaa aat gga tac act ttg cgc agg tca aac gaa act	2320
Phe Ala Ala Leu Glu Asn Gly Tyr Thr Leu Arg Arg Ser Asn Glu Thr	
730 735 740	
gac ttt gag ctg tac ttt tgt gga cgc aag caa ttt ttc aag tct aac	2368
Asp Phe Glu Leu Tyr Phe Cys Gly Arg Lys Gln Phe Phe Lys Ser Asn	
745 750 755 760	
tat gca gac cta gat tca aac tca gat gac ttt gac cct gct tcc acc	2416
Tyr Ala Asp Leu Asp Ser Asn Ser Asp Asp Phe Asp Pro Ala Ser Thr	
765 770 775	
aag agc aag tat gac tct ctg gat ttt gat agt tta ctg aaa gaa gct	2464
Lys Ser Lys Tyr Asp Ser Leu Asp Phe Asp Ser Leu Leu Lys Glu Ala	
780 785 790	
cag aga agc ttg cgc agg taacatgttc cctagctgag gatgacagag	2512
Gln Arg Ser Leu Arg Arg	
795	
ggatggcgaa tacctcatgg gacagcgcgt ccttccttaa agactattgc aagtcatact	2572
taggaatttc tcctacttta cactctctgt acaaaaacaa aacaaaacaa caacaatata	2632
acaagaacaa caacaacaat aacaacaatg gtttacatga acacagctgc tgaagaggca	2692
agagacagaa tgatatccag taagcacatg tttattcatg ggtgtcagct ttgcttttcc	2752
tggagtctct tggatgagga gtgtgcgtgt gtgcatgtat gtgtgtgtgt atgtatgtgt	2812

gtggtgtgtg tgcttggttt aggggaagta tgtgtgggta catgtgagga ctgggggcac 2872  
 ctgaccagaa tgcgcaaggg caaaccattt caaatggcag cagttccatg aagacacact 2932  
 taaaacctag aacttcaaaa tgttcgtatt ctattcaaaa ggaaaaatat atatatatat 2992  
 atatatatat aaattaaaaa aaaaaaaaaa a 3023

<210> 2

<211> 798

<212> PRT

<213> Homo sapiens

<400> 2

Met	Ala	Trp	Asp	Met	Cys	Asn	Gln	Asp	Ser	Glu	Ser	Val	Trp	Ser	Asp
1				5					10					15	
Ile	Glu	Cys	Ala	Ala	Leu	Val	Gly	Glu	Asp	Gln	Pro	Leu	Cys	Pro	Asp
			20					25					30		
Leu	Pro	Glu	Leu	Asp	Leu	Ser	Glu	Leu	Asp	Val	Asn	Asp	Leu	Asp	Thr
		35					40					45			
Asp	Ser	Phe	Leu	Gly	Gly	Leu	Lys	Trp	Cys	Ser	Asp	Gln	Ser	Glu	Ile
	50					55					60				
Ile	Ser	Asn	Gln	Tyr	Asn	Asn	Glu	Pro	Ser	Asn	Ile	Phe	Glu	Lys	Ile
65					70					75					80
Asp	Glu	Glu	Asn	Glu	Ala	Asn	Leu	Leu	Ala	Val	Leu	Thr	Glu	Thr	Leu
			85						90					95	
Asp	Ser	Leu	Pro	Val	Asp	Glu	Asp	Gly	Leu	Pro	Ser	Phe	Asp	Ala	Leu
			100					105					110		
Thr	Asp	Gly	Asp	Val	Thr	Thr	Asp	Asn	Glu	Ala	Ser	Pro	Ser	Ser	Met
		115					120					125			
Pro	Asp	Gly	Thr	Pro	Pro	Pro	Gln	Glu	Ala	Glu	Glu	Pro	Ser	Leu	Leu
	130						135				140				
Lys	Lys	Leu	Leu	Leu	Ala	Pro	Ala	Asn	Thr	Gln	Leu	Ser	Tyr	Asn	Glu
145					150					155					160
Cys	Ser	Gly	Leu	Ser	Thr	Gln	Asn	His	Ala	Asn	His	Asn	His	Arg	Ile
			165						170					175	
Arg	Thr	Asn	Pro	Ala	Ile	Val	Lys	Thr	Glu	Asn	Ser	Trp	Ser	Asn	Lys
			180					185					190		
Ala	Lys	Ser	Ile	Cys	Gln	Gln	Gln	Lys	Pro	Gln	Arg	Arg	Pro	Cys	Ser
		195					200					205			
Glu	Leu	Leu	Lys	Tyr	Leu	Thr	Thr	Asn	Asp	Asp	Pro	Pro	His	Thr	Lys
	210					215					220				
Pro	Thr	Glu	Asn	Arg	Asn	Ser	Ser	Arg	Asp	Lys	Cys	Thr	Ser	Lys	Lys
225					230					235					240

Lys Ser His Thr Gln Ser Gln Ser Gln His Leu Gln Ala Lys Pro Thr  
 245 250 255  
 Thr Leu Ser Leu Pro Leu Thr Pro Glu Ser Pro Asn Asp Pro Lys Gly  
 260 265 270  
 Ser Pro Phe Glu Asn Lys Thr Ile Glu Arg Thr Leu Ser Val Glu Leu  
 275 280 285  
 Ser Gly Thr Ala Gly Leu Thr Pro Pro Thr Thr Pro Pro His Lys Ala  
 290 295 300  
 Asn Gln Asp Asn Pro Phe Arg Ala Ser Pro Lys Leu Lys Ser Ser Cys  
 305 310 315 320  
 Lys Thr Val Val Pro Pro Pro Ser Lys Lys Pro Arg Tyr Ser Glu Ser  
 325 330 335  
 Ser Gly Thr Gln Gly Asn Asn Ser Thr Lys Lys Gly Pro Glu Gln Ser  
 340 345 350  
 Glu Leu Tyr Ala Gln Leu Ser Lys Ser Ser Val Leu Thr Gly Gly His  
 355 360 365  
 Glu Glu Arg Lys Thr Lys Arg Pro Ser Leu Arg Leu Phe Gly Asp His  
 370 375 380  
 Asp Tyr Cys Gln Ser Ile Asn Ser Lys Thr Glu Ile Leu Ile Asn Ile  
 385 390 395 400  
 Ser Gln Glu Leu Gln Asp Ser Arg Gln Leu Glu Asn Lys Asp Val Ser  
 405 410 415  
 Ser Asp Trp Gln Gly Gln Ile Cys Ser Ser Thr Asp Ser Asp Gln Cys  
 420 425 430  
 Tyr Leu Arg Glu Thr Leu Glu Ala Ser Lys Gln Val Ser Pro Cys Ser  
 435 440 445  
 Thr Arg Lys Gln Leu Gln Asp Gln Glu Ile Arg Ala Glu Leu Asn Lys  
 450 455 460  
 His Phe Gly His Pro Ser Gln Ala Val Phe Asp Asp Glu Ala Asp Lys  
 465 470 475 480  
 Thr Gly Glu Leu Arg Asp Ser Asp Phe Ser Asn Glu Gln Phe Ser Lys  
 485 490 495  
 Leu Pro Met Phe Ile Asn Ser Gly Leu Ala Met Asp Gly Leu Phe Asp  
 500 505 510  
 Asp Ser Glu Asp Lys Ser Asp Lys Leu Ser Tyr Pro Trp Asp Gly Thr  
 515 520 525  
 Gln Ser Tyr Ser Leu Phe Asn Val Ser Pro Ser Cys Ser Ser Phe Asn  
 530 535 540  
 Ser Pro Cys Arg Asp Ser Val Ser Pro Pro Lys Ser Leu Phe Ser Gln  
 545 550 555 560  
 Arg Pro Gln Arg Met Arg Ser Arg Ser Arg Ser Phe Ser Arg His Arg

7

565	570	575
Ser Cys Ser Arg Ser Pro Tyr Ser Arg Ser Arg Ser Arg Ser Pro Gly		
580	585	590
Ser Arg Ser Ser Ser Arg Ser Cys Tyr Tyr Tyr Glu Ser Ser His Tyr		
595	600	605
Arg His Arg Thr His Arg Asn Ser Pro Leu Tyr Val Arg Ser Arg Ser		
610	615	620
Arg Ser Pro Tyr Ser Arg Arg Pro Arg Tyr Asp Ser Tyr Glu Glu Tyr		
625	630	635
Gln His Glu Arg Leu Lys Arg Glu Glu Tyr Arg Arg Glu Tyr Glu Lys		
645	650	655
Arg Glu Ser Glu Arg Ala Lys Gln Arg Glu Arg Gln Arg Gln Lys Ala		
660	665	670
Ile Glu Glu Arg Arg Val Ile Tyr Val Gly Lys Ile Arg Pro Asp Thr		
675	680	685
Thr Arg Thr Glu Leu Arg Asp Arg Phe Glu Val Phe Gly Glu Ile Glu		
690	695	700
Glu Cys Thr Val Asn Leu Arg Asp Asp Gly Asp Ser Tyr Gly Phe Ile		
705	710	715
Thr Tyr Arg Tyr Thr Cys Asp Ala Phe Ala Ala Leu Glu Asn Gly Tyr		
725	730	735
Thr Leu Arg Arg Ser Asn Glu Thr Asp Phe Glu Leu Tyr Phe Cys Gly		
740	745	750
Arg Lys Gln Phe Phe Lys Ser Asn Tyr Ala Asp Leu Asp Ser Asn Ser		
755	760	765
Asp Asp Phe Asp Pro Ala Ser Thr Lys Ser Lys Tyr Asp Ser Leu Asp		
770	775	780
Phe Asp Ser Leu Leu Lys Glu Ala Gln Arg Ser Leu Arg Arg		
785	790	795

&lt;210&gt; 3

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; VARIANT

&lt;222&gt; 2, 3

&lt;223&gt; Xaa = Any Amino Acid

&lt;400&gt; 3

Leu Xaa Xaa Leu Leu

1

5

&lt;210&gt; 4



8.

&lt;211&gt; 3066

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (92)..(2482)

&lt;400&gt; 4

```

aattcggcac gaggttgccct gcatgagtgt gtgctgtgtg tcagagtgga ttggagttga 60
aaaagcttga ctggcgctcat tcgggagctg g atg gct tgg gac atg tgc agc      112
                               Met Ala Trp Asp Met Cys Ser
                               1           5

caa gac tct gta tgg agt gac ata gag tgt gct gct ctg gtt ggt gag      160
Gln Asp Ser Val Trp Ser Asp Ile Glu Cys Ala Ala Leu Val Gly Glu
          10           15           20

gac cag cct ctt tgc cca gat ctt cct gaa ctt gac ctt tct gaa ctt      208
Asp Gln Pro Leu Cys Pro Asp Leu Pro Glu Leu Asp Leu Ser Glu Leu
          25           30           35

gat gtg aat gac ttg gat aca gac agc ttt ctg ggt gga ttg aag tgg      256
Asp Val Asn Asp Leu Asp Thr Asp Ser Phe Leu Gly Gly Leu Lys Trp
          40           45           50           55

tgt agc gac caa tcg gaa atc ata tcc aac cag tac aac aat gag cct      304
Cys Ser Asp Gln Ser Glu Ile Ile Ser Asn Gln Tyr Asn Asn Glu Pro
          60           65           70

gcg aac ata ttt gag aag ata gat gaa gag aat gag gca aac ttg cta      352
Ala Asn Ile Phe Glu Lys Ile Asp Glu Glu Asn Glu Ala Asn Leu Leu
          75           80           85

gcg gtc ctc aca gag aca ctg gac agt ctc ccc gtg gat gaa gac gga      400
Ala Val Leu Thr Glu Thr Leu Asp Ser Leu Pro Val Asp Glu Asp Gly
          90           95           100

ttg ccc tca ttt gat gca ctg aca gat gga gcc gtg acc act gac aac      448
Leu Pro Ser Phe Asp Ala Leu Thr Asp Gly Ala Val Thr Thr Asp Asn
          105           110           115

gag gcc agt cct tcc tcc atg cct gac ggc acc cct ccc cct cag gag      496
Glu Ala Ser Pro Ser Ser Met Pro Asp Gly Thr Pro Pro Pro Gln Glu
          120           125           130           135

gca gaa gag ccg tct cta ctt aag aag ctc tta ctg gca cca gcc aac      544
Ala Glu Glu Pro Ser Leu Leu Lys Lys Leu Leu Leu Ala Pro Ala Asn
          140           145           150

act cag ctc agc tac aat gaa tgc agc ggt ctt agc act cag aac cat      592
Thr Gln Leu Ser Tyr Asn Glu Cys Ser Gly Leu Ser Thr Gln Asn His
          155           160           165

gca gca aac cac acc cac agg atc aga aca aac cct gcc att gtt aag      640
Ala Ala Asn His Thr His Arg Ile Arg Thr Asn Pro Ala Ile Val Lys
          170           175           180

acc gag aat tca tgg agc aat aaa gcg aag agc att tgt caa cag caa      688
Thr Glu Asn Ser Trp Ser Asn Lys Ala Lys Ser Ile Cys Gln Gln Gln

```

185	190	195	
aag cca caa aga cgt ccc tgc tca gag ctt ctc aag tat ctg acc aca Lys Pro Gln Arg Arg Pro Cys Ser Glu Leu Leu Lys Tyr Leu Thr Thr 200 205 210 215			736
aac gat gac cct cct cac acc aaa ccc aca gaa aac agg aac agc agc Asn Asp Asp Pro Pro His Thr Lys Pro Thr Glu Asn Arg Asn Ser Ser 220 225 230			784
aga gac aaa tgt gct tcc aaa aag aag tcc cat aca caa ccg cag tcg Arg Asp Lys Cys Ala Ser Lys Lys Lys Ser His Thr Gln Pro Gln Ser 235 240 245			832
caa cat gct caa gcc aaa cca aca act tta tct ctt cct ctg acc cca Gln His Ala Gln Ala Lys Pro Thr Leu Ser Leu Pro Leu Thr Pro 250 255 260			880
gag tca cca aat gac ccc aag ggt tcc cca ttt gag aac aag act att Glu Ser Pro Asn Asp Pro Lys Gly Ser Pro Phe Glu Asn Lys Thr Ile 265 270 275			928
gag cga acc tta agt gtg gaa ctc tct gga act gca ggc cta act cct Glu Arg Thr Leu Ser Val Glu Leu Ser Gly Thr Ala Gly Leu Thr Pro 280 285 290 295			976
ccc aca act cct cct cat aaa gcc aac caa gat aac cct ttc aag gct Pro Thr Thr Pro Pro His Lys Ala Asn Gln Asp Asn Pro Phe Lys Ala 300 305 310			1024
tcg cca aag ctg aag ccc tct tgc aag acc gtg gtg cca ccg cca acc Ser Pro Lys Leu Lys Pro Ser Cys Lys Thr Val Val Pro Pro Pro Thr 315 320 325			1072
aag agg gcc cgg tac agt gag tgt tct ggt acc caa ggc agc cac tcc Lys Arg Ala Arg Tyr Ser Glu Cys Ser Gly Thr Gln Gly Ser His Ser 330 335 340			1120
acc aag aaa ggg ccc gag caa tct gag ttg tac gca caa ctc agc aag Thr Lys Lys Gly Pro Glu Gln Ser Glu Leu Tyr Ala Gln Leu Ser Lys 345 350 355			1168
tcc tca ggg ctc agc cga gga cac gag gaa agg aag act aaa cgg ccc Ser Ser Gly Leu Ser Arg Gly His Glu Glu Arg Lys Thr Lys Arg Pro 360 365 370 375			1216
agt ctc cgg ctg ttt ggt gac cat gac tac tgt cag tca ctc aat tcc Ser Leu Arg Leu Phe Gly Asp His Asp Tyr Cys Gln Ser Leu Asn Ser 380 385 390			1264
aaa acg gat ata ctc att aac ata tca cag gag ctc caa gac tct aga Lys Thr Asp Ile Leu Ile Asn Ile Ser Gln Glu Leu Gln Asp Ser Arg 395 400 405			1312
caa cta gac ttc aaa gat gcc tcc tgt gac tgg cag ggg cac atc tgt Gln Leu Asp Phe Lys Asp Ala Ser Cys Asp Trp Gln Gly His Ile Cys 410 415 420			1360
tct tcc aca gat tca ggc cag tgc tac ctg aga gag act ttg gag gcc Ser Ser Thr Asp Ser Gly Gln Cys Tyr Leu Arg Glu Thr Leu Glu Ala 425 430 435			1408

agc aag cag gtc tct cct tgc agc acc aga aaa cag ctc caa gac cag	1456
Ser Lys Gln Val Ser Pro Cys Ser Thr Arg Lys Gln Leu Gln Asp Gln	
440 445 450 455	
gaa atc cga gcg gag ctg aac aag cac ttc ggt cat ccc tgt caa gct	1504
Glu Ile Arg Ala Glu Leu Asn Lys His Phe Gly His Pro Cys Gln Ala	
460 465 470	
gtg ttt gac gac aaa tca gac aag acc agt gaa cta agg gat ggc gac	1552
Val Phe Asp Asp Lys Ser Asp Lys Thr Ser Glu Leu Arg Asp Gly Asp	
475 480 485	
ttc agt aat gaa caa ttc tcc aaa cta cct gtg ttt ata aat tca gga	1600
Phe Ser Asn Glu Gln Phe Ser Lys Leu Pro Val Phe Ile Asn Ser Gly	
490 495 500	
cta gcc atg gat ggc cta ttt gat gac agt gaa gat gaa agt gat aaa	1648
Leu Ala Met Asp Gly Leu Phe Asp Asp Ser Glu Asp Glu Ser Asp Lys	
505 510 515	
ctg agc tac cct tgg gat ggc acg cag ccc tat tca ttg ttc gat gtg	1696
Leu Ser Tyr Pro Trp Asp Gly Thr Gln Pro Tyr Ser Leu Phe Asp Val	
520 525 530 535	
tgc cct tct tgc tct tcc ttt aac tct ccg tgt cga gac tca gtg tca	1744
Ser Pro Ser Cys Ser Ser Phe Asn Ser Pro Cys Arg Asp Ser Val Ser	
540 545 550	
cca ccg aaa tcc tta ttt tct caa aga ccc caa agg atg cgc tct cgt	1792
Pro Pro Lys Ser Leu Phe Ser Gln Arg Pro Gln Arg Met Arg Ser Arg	
555 560 565	
tca aga tcc ttt tct cga cac agg tcg tgt tcc cga tca cca tat tcc	1840
Ser Arg Ser Phe Ser Arg His Arg Ser Cys Ser Arg Ser Pro Tyr Ser	
570 575 580	
agg tca aga tca agg tcc cca ggc agt aga tcc tct tca aga tcc tgt	1888
Arg Ser Arg Ser Arg Ser Pro Gly Ser Arg Ser Ser Ser Arg Ser Cys	
585 590 595	
tac tac tat gaa tca agc cac tac aga cac cgc aca cac cgc aat tct	1936
Tyr Tyr Tyr Glu Ser Ser His Tyr Arg His Arg Thr His Arg Asn Ser	
600 605 610 615	
ccc ttg tat gtg aga tca cgt tca agg tca ccc tac agc cgt agg ccc	1984
Pro Leu Tyr Val Arg Ser Arg Ser Arg Ser Pro Tyr Ser Arg Arg Pro	
620 625 630	
agg tac gac agc tat gaa gcc tat gag cac gaa agg ctc aag agg gat	2032
Arg Tyr Asp Ser Tyr Glu Ala Tyr Glu His Glu Arg Leu Lys Arg Asp	
635 640 645	
gaa tac cgc aaa gag cac gag aag cgg gag tct gaa agg gcc aaa cag	2080
Glu Tyr Arg Lys Glu His Glu Lys Arg Glu Ser Glu Arg Ala Lys Gln	
650 655 660	
aga gag agg cag aag cag aaa gca att gaa gag cgc cgt gtg att tac	2128
Arg Glu Arg Gln Lys Gln Lys Ala Ile Glu Glu Arg Arg Val Ile Tyr	
665 670 675	

11

gtt ggt aaa atc aga cct gac aca acg cgg aca gaa ttg aga gac cgc 2176  
 Val Gly Lys Ile Arg Pro Asp Thr Thr Arg Thr Glu Leu Arg Asp Arg  
 680 685 690 695

ttt gaa gtt ttt ggt gaa att gag gaa tgc acc gta aat ctg cgg gat 2224  
 Phe Glu Val Phe Gly Glu Ile Glu Glu Cys Thr Val Asn Leu Arg Asp  
 700 705 710

gat gga gac agc tat ggt ttc atc acc tac cgt tac acc tgt gac gct 2272  
 Asp Gly Asp Ser Tyr Gly Phe Ile Thr Tyr Arg Tyr Thr Cys Asp Ala  
 715 720 725

ttc gct gct ctt gag aat gga tat act tta cgc agg tcg aac gaa act 2320  
 Phe Ala Ala Leu Glu Asn Gly Tyr Thr Leu Arg Arg Ser Asn Glu Thr  
 730 735 740

gac ttc gag ctg tac ttt tgt gga cgg aag caa ttt ttc aag tct aac 2368  
 Asp Phe Glu Leu Tyr Phe Cys Gly Arg Lys Gln Phe Phe Lys Ser Asn  
 745 750 755

tat gca gac cta gat acc aac tca gac gat ttt gac cct gct tcc acc 2416  
 Tyr Ala Asp Leu Asp Thr Asn Ser Asp Asp Phe Asp Pro Ala Ser Thr  
 760 765 770 775

aag agc aag tat gac tct ctg gat ttt gat agt tta ctg aag gaa gct 2464  
 Lys Ser Lys Tyr Asp Ser Leu Asp Phe Asp Ser Leu Leu Lys Glu Ala  
 780 785 790

cag aga agc ttg cgc agg taacgtgttc ccaggctgag gaatgacaga 2512  
 Gln Arg Ser Leu Arg Arg  
 795

gagatggtca atacctcatg ggacagcgtg tcctttccca agactcttgc aagtcatact 2572

taggaatttc tcctacttta cactctctgt acaaaaaataa aacaaaacaa aacaacaata 2632

acaacaacaa caacaacaat aacaacaaca accataccag aacaagaaca acggtttaca 2692

tgaacacagc tgctgaagag gcaagagaca gaatgataat ccagtaagca cacgtttatt 2752

cacgggtgtc agctttgctt tccttgaggg ctcttggtga cagtgtgtgt gcgtgtgtgt 2812

gtgtgggtgt gcgtgtgtgt atgtgtgtgt gtgtacttgt ttggaaagta catatgtaca 2872

catgtgagga cttgggggca cctgaacaga acgaacaagg gcgaccctt caaatggcag 2932

catttccatg aagacacact taaaacctac aacttcaaaa tgttcgtatt ctatacaaaa 2992

ggaaaataaaa taaatataaa aaaaaaaaaa aaaaaactcg agagatctat gaatcgtaga 3052

tactgaaaaa cccc 3066

<210> 5  
 <211> 797  
 <212> PRT  
 <213> Mus musculus

<400> 5  
 Met Ala Trp Asp Met Cys Ser Gln Asp Ser Val Trp Ser Asp Ile Glu  
 1 5 10 15

Cys Ala Ala Leu Val Gly Glu Asp Gln Pro Leu Cys Pro Asp Leu Pro  
 20 25 30  
 Glu Leu Asp Leu Ser Glu Leu Asp Val Asn Asp Leu Asp Thr Asp Ser  
 35 40 45  
 Phe Leu Gly Gly Leu Lys Trp Cys Ser Asp Gln Ser Glu Ile Ile Ser  
 50 55 60  
 Asn Gln Tyr Asn Asn Glu Pro Ala Asn Ile Phe Glu Lys Ile Asp Glu  
 65 70 75 80  
 Glu Asn Glu Ala Asn Leu Leu Ala Val Leu Thr Glu Thr Leu Asp Ser  
 85 90 95  
 Leu Pro Val Asp Glu Asp Gly Leu Pro Ser Phe Asp Ala Leu Thr Asp  
 100 105 110  
 Gly Ala Val Thr Thr Asp Asn Glu Ala Ser Pro Ser Ser Met Pro Asp  
 115 120 125  
 Gly Thr Pro Pro Pro Gln Glu Ala Glu Glu Pro Ser Leu Leu Lys Lys  
 130 135 140  
 Leu Leu Leu Ala Pro Ala Asn Thr Gln Leu Ser Tyr Asn Glu Cys Ser  
 145 150 155 160  
 Gly Leu Ser Thr Gln Asn His Ala Ala Asn His Thr His Arg Ile Arg  
 165 170 175  
 Thr Asn Pro Ala Ile Val Lys Thr Glu Asn Ser Trp Ser Asn Lys Ala  
 180 185 190  
 Lys Ser Ile Cys Gln Gln Gln Lys Pro Gln Arg Arg Pro Cys Ser Glu  
 195 200 205  
 Leu Leu Lys Tyr Leu Thr Thr Asn Asp Asp Pro Pro His Thr Lys Pro  
 210 215 220  
 Thr Glu Asn Arg Asn Ser Ser Arg Asp Lys Cys Ala Ser Lys Lys Lys  
 225 230 235 240  
 Ser His Thr Gln Pro Gln Ser Gln His Ala Gln Ala Lys Pro Thr Thr  
 245 250 255  
 Leu Ser Leu Pro Leu Thr Pro Glu Ser Pro Asn Asp Pro Lys Gly Ser  
 260 265 270  
 Pro Phe Glu Asn Lys Thr Ile Glu Arg Thr Leu Ser Val Glu Leu Ser  
 275 280 285  
 Gly Thr Ala Gly Leu Thr Pro Pro Thr Thr Pro Pro His Lys Ala Asn  
 290 295 300  
 Gln Asp Asn Pro Phe Lys Ala Ser Pro Lys Leu Lys Pro Ser Cys Lys  
 305 310 315 320  
 Thr Val Val Pro Pro Pro Thr Lys Arg Ala Arg Tyr Ser Glu Cys Ser  
 325 330 335

13

Gly Thr Gln Gly Ser His Ser Thr Lys Lys Gly Pro Glu Gln Ser Glu  
 340 345 350  
 Leu Tyr Ala Gln Leu Ser Lys Ser Ser Gly Leu Ser Arg Gly His Glu  
 355 360 365  
 Glu Arg Lys Thr Lys Arg Pro Ser Leu Arg Leu Phe Gly Asp His Asp  
 370 375 380  
 Tyr Cys Gln Ser Leu Asn Ser Lys Thr Asp Ile Leu Ile Asn Ile Ser  
 385 390 395 400  
 Gln Glu Leu Gln Asp Ser Arg Gln Leu Asp Phe Lys Asp Ala Ser Cys  
 405 410 415  
 Asp Trp Gln Gly His Ile Cys Ser Ser Thr Asp Ser Gly Gln Cys Tyr  
 420 425 430  
 Leu Arg Glu Thr Leu Glu Ala Ser Lys Gln Val Ser Pro Cys Ser Thr  
 435 440 445  
 Arg Lys Gln Leu Gln Asp Gln Glu Ile Arg Ala Glu Leu Asn Lys His  
 450 455 460  
 Phe Gly His Pro Cys Gln Ala Val Phe Asp Asp Lys Ser Asp Lys Thr  
 465 470 475 480  
 Ser Glu Leu Arg Asp Gly Asp Phe Ser Asn Glu Gln Phe Ser Lys Leu  
 485 490 495  
 Pro Val Phe Ile Asn Ser Gly Leu Ala Met Asp Gly Leu Phe Asp Asp  
 500 505 510  
 Ser Glu Asp Glu Ser Asp Lys Leu Ser Tyr Pro Trp Asp Gly Thr Gln  
 515 520 525  
 Pro Tyr Ser Leu Phe Asp Val Ser Pro Ser Cys Ser Ser Phe Asn Ser  
 530 535 540  
 Pro Cys Arg Asp Ser Val Ser Pro Pro Lys Ser Leu Phe Ser Gln Arg  
 545 550 555 560  
 Pro Gln Arg Met Arg Ser Arg Ser Arg Ser Phe Ser Arg His Arg Ser  
 565 570 575  
 Cys Ser Arg Ser Pro Tyr Ser Arg Ser Arg Ser Arg Ser Pro Gly Ser  
 580 585 590  
 Arg Ser Ser Ser Arg Ser Cys Tyr Tyr Tyr Glu Ser Ser His Tyr Arg  
 595 600 605  
 His Arg Thr His Arg Asn Ser Pro Leu Tyr Val Arg Ser Arg Ser Arg  
 610 615 620  
 Ser Pro Tyr Ser Arg Arg Pro Arg Tyr Asp Ser Tyr Glu Ala Tyr Glu  
 625 630 635 640  
 His Glu Arg Leu Lys Arg Asp Glu Tyr Arg Lys Glu His Glu Lys Arg  
 645 650 655  
 Glu Ser Glu Arg Ala Lys Gln Arg Glu Arg Gln Lys Gln Lys Ala Ile

660	665	670
Glu Glu Arg Arg Val Ile Tyr Val Gly Lys Ile Arg Pro Asp Thr Thr		
675	680	685
Arg Thr Glu Leu Arg Asp Arg Phe Glu Val Phe Gly Glu Ile Glu Glu		
690	695	700
Cys Thr Val Asn Leu Arg Asp Asp Gly Asp Ser Tyr Gly Phe Ile Thr		
705	710	715
Tyr Arg Tyr Thr Cys Asp Ala Phe Ala Ala Leu Glu Asn Gly Tyr Thr		
725	730	735
Leu Arg Arg Ser Asn Glu Thr Asp Phe Glu Leu Tyr Phe Cys Gly Arg		
740	745	750
Lys Gln Phe Phe Lys Ser Asn Tyr Ala Asp Leu Asp Thr Asn Ser Asp		
755	760	765
Asp Phe Asp Pro Ala Ser Thr Lys Ser Lys Tyr Asp Ser Leu Asp Phe		
770	775	780
Asp Ser Leu Leu Lys Glu Ala Gln Arg Ser Leu Arg Arg		
785	790	795

&lt;210&gt; 6

&lt;211&gt; 1893

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 6

```

gaattcggca cgaggcctgc atgagtgtgt gctgtgtgtc agagtggatt ggagttgaaa 60
aagcttgact ggcgtcattc gggagctgga tggcttgagg catgtgcagc caagactctg 120
tatggagtga catagagtgt gctgctctgg ttggtgagga ccagcctctt tgcccagatc 180
ttcctgaact tgacctttct gaacttgatg tgaatgactt ggatacagac agctttcttg 240
gtggattgaa gtggtgtagc gaccaatcgg aaatcatatc caaccagtac aacaatgagc 300
ctgcgaacat atttgagaag atagatgaag agaatgaggc gaacttgcta gcggtcctca 360
cagagacact ggacagtctc ccogtggatg aagacggatt gccctcattt gatgcactga 420
cagatggagc cgtgaccact gacaacgagg ccagtccttc ctccatgcct gacggcacc 480
ctccccctca ggaggcagaa gagccgtctc tacttaagaa gctcttactg gcaccagcca 540
aactcagct cagctacaat gaatgcagcg gtcttagcac tcagaaccat gcagcaaac 600
acaccacag gatcagaaca aacctgcca ttgttaagac cgagaattca tggagcaata 660
aagcgaagag ctttgtcaa cagcaaaagc caciaagacg tccctgctca gagcttctca 720
agtatctgac caciaacgat gacctcctc acaccaaacc cacagaaaac aggaacagca 780
gcagagacaa atgtgcttcc aaaaagaagt ccatacaca accgcagtcg caacatgctc 840
aagccaaacc aacaacttta tctcttctc tgacccaga gtcaccaa at gaccccaagg 900
gttccccatt tgagaacaag actattgagc gaaccttaag tgtggaactc tctggaactg 960
cagctccact agtgccaagg gagcatccat gcatcattac atccaggtcg atattgaatg 1020
tcttcatgca aagatgtctt tctaatttat aaatatgaac acatcacaca acttggtgtc 1080
attctattaa aggtgtaaaa actaatttga tttcaaaata gctgttggtta gtaaagcaag 1140
atgagagaaa ggagaatggt cttgtggcag aaggcattta aatctattgc atattggagat 1200
tttttttcag aactaccaa caggatttta tgtctgaaat ggaaatggaa aggcaatgtc 1260
agcctaacaa ggtgatggct tgaaacacaa gcatgaagg aactttgtta gggacaaaa 1320
taactggtcc ccaattttat gtatatacat acatgttttg gctatcacta taaacatggt 1380
gaaagcaatg gagctgtttt ataactgata aaaagatgaa tagaacaaaa taaccagctg 1440
tctttttact ctcgaccac tgggttctgc ccatatttcc ttccattcac atatctttgg 1500
ttacctgtt tgaaatgggg tagacatgcg gtttaatttg tttgttatta tattatttgt 1560
ttgaggattt cataataag tgcaatatat ttgcatcatt tccaccccaa cacctcccaa 1620
aaccacccat ctcaaattca ttactcttt ttctataatt gtttttgtca tatattacac 1680
acacacaaag gcgcatacac acacacgcac acacaggcac acacacacac acacacacac 1740

```

15

acacacacac acacacacac tgagagttgc cctaatttag ggttgaccac ttagggttca 1800  
 ggtctcatcc ctgaaaaatg aagaagaaga agaagaagaa gaagaagaag aagaagaaga 1860  
 agaagaagaa gaagaagaaa aaaaaaaaaa aaa 1893

&lt;210&gt; 7

&lt;211&gt; 320

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 7

Met	Ala	Trp	Asp	Met	Cys	Ser	Gln	Asp	Ser	Val	Trp	Ser	Asp	Ile	Glu
1				5					10					15	
Cys	Ala	Ala	Leu	Val	Gly	Glu	Asp	Gln	Pro	Leu	Cys	Pro	Asp	Leu	Pro
			20					25					30		
Glu	Leu	Asp	Leu	Ser	Glu	Leu	Asp	Val	Asn	Asp	Leu	Asp	Thr	Asp	Ser
		35					40					45			
Phe	Leu	Gly	Gly	Leu	Lys	Trp	Cys	Ser	Asp	Gln	Ser	Glu	Ile	Ile	Ser
	50				55						60				
Asn	Gln	Tyr	Asn	Asn	Glu	Pro	Ala	Asn	Ile	Phe	Glu	Lys	Ile	Asp	Glu
65					70				75					80	
Glu	Asn	Glu	Ala	Asn	Leu	Leu	Ala	Val	Leu	Thr	Glu	Thr	Leu	Asp	Ser
				85					90					95	
Leu	Pro	Val	Asp	Glu	Asp	Gly	Leu	Pro	Ser	Phe	Asp	Ala	Leu	Thr	Asp
			100					105						110	
Gly	Ala	Val	Thr	Thr	Asp	Asn	Glu	Ala	Ser	Pro	Ser	Ser	Met	Pro	Asp
		115					120					125			
Gly	Thr	Pro	Pro	Pro	Gln	Glu	Ala	Glu	Glu	Pro	Ser	Leu	Leu	Lys	Lys
		130				135						140			
Leu	Leu	Leu	Ala	Pro	Ala	Asn	Thr	Gln	Leu	Ser	Tyr	Asn	Glu	Cys	Ser
145					150					155				160	
Gly	Leu	Ser	Thr	Gln	Asn	His	Ala	Ala	Asn	His	Thr	His	Arg	Ile	Arg
				165					170					175	
Thr	Asn	Pro	Ala	Ile	Val	Lys	Thr	Glu	Asn	Ser	Trp	Ser	Asn	Lys	Ala
			180					185					190		
Lys	Ser	Ile	Cys	Gln	Gln	Gln	Lys	Pro	Gln	Arg	Arg	Pro	Cys	Ser	Glu
		195					200					205			
Leu	Leu	Lys	Tyr	Leu	Thr	Thr	Asn	Asp	Asp	Pro	Pro	His	Thr	Lys	Pro
	210				215						220				
Thr	Glu	Asn	Arg	Asn	Ser	Ser	Arg	Asp	Lys	Cys	Ala	Ser	Lys	Lys	Lys
225					230					235				240	
Ser	His	Thr	Gln	Pro	Gln	Ser	Gln	His	Ala	Gln	Ala	Lys	Pro	Thr	Thr
				245					250					255	
Leu	Ser	Leu	Pro	Leu	Thr	Pro	Glu	Ser	Pro	Asn	Asp	Pro	Lys	Gly	Ser
			260					265					270		
Pro	Phe	Glu	Asn	Lys	Thr	Ile	Glu	Arg	Thr	Leu	Ser	Val	Glu	Leu	Ser
		275					280					285			
Gly	Thr	Ala	Ala	Pro	Leu	Val	Pro	Arg	Glu	His	Pro	Cys	Ile	Ile	Thr
		290				295					300				
Ser	Arg	Ser	Ile	Leu	Asn	Val	Phe	Met	Gln	Arg	Cys	Leu	Ser	Asn	Leu
305					310					315				320	

&lt;210&gt; 8

&lt;211&gt; 1744

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; 1543

&lt;223&gt; n = A,T,C or G



&lt;400&gt; 8

```

gaattcggca cgaggtcaga gtggattgga gttgaaaaag cttgactggc gtcattcggg 60
agctggatgg cttgggacat gtgcagccaa gactctgtat ggagtgacat agagtgtgct 120
gctctggttg gtgaggacca gcctctttgc ccagatcttc ctgaacttga cctttctgaa 180
cttgatgtga atgacttgga tacagacagc tttctgggtg gattgaagtg gtgtagcgac 240
caatcggaaa tcatatccaa ccagtacaac aatgagcctg cgaacatatt tgagaagata 300
gatgaagaga atgaggcaaa cttgctagcg gtcctcacag agacactgga cagtctcccc 360
gtggatgaag acggattgcc ctcatattgat gcactgacag atggagccgt gaccactgac 420
aacgaggcca gtccttcctc catgcctgac ggcacccctc cccctcagga ggcagaagag 480
ccgtctctac ttaagaagct cttactggca ccagccaaca ctcagctcag ctacaatgaa 540
tgcagcggtc ttagcactca gaaccatgca gcaaaccaca cccacaggat cagaacaaac 600
cctgccattg ttaagaccga gaattcatgg agcaataaag cgaagagcat ttgtcaacag 660
caaaagccac aaagacgtcc ctgctcagag cttctcaagt atctgaccac aaacgatgac 720
cctcctcaca ccaaacccac agaaaacagg aacagcagca gagacaaatg tgcttccaaa 780
aagaagtccc atacacaacc gcagtcgcaa catgctcaag ccaaaccaac aactttatct 840
cttcctctga cccagagtc accaaatgac cccaagggtt cccatttga gaacaagact 900
attgagcgaa ccttaagtgt ggaactctct ggaactgcag gtgtaaaaac taatttgatt 960
tcaaaatagc tgttgttagt taagcaagat gagagaaaag agaattgttct tgtggcagaa 1020
ggcatttaaa tctattgcat atggagattt tttttcagac actaccaaca ggattttatg 1080
tctgaaatgg aaatgaaaag gcaatgtcag cctaacaagg tgatggcttg aaacacaaga 1140
catgaaggaa ctttgttagg gaccaaataa actggtcccc aattttatgt atatacatac 1200
atgttttggc tatcactata aacatggtga aagcaatgga gctgttttat aactgataaa 1260
aagatgaata gaacaaaata accagctgtc tttttactct cggaccactg ggttctgccc 1320
atatttcctt ccattcacat atctttggtt accttgttg aaatggggtg gacatgcggt 1380
taatttggtt tgttattata ttatttggtt gaggatttca taaataagtg caatatattt 1440
gcatcatttc caccacaaca cctcccaaaa ccacccatct caaattcatt tactcttttt 1500
ctataattgt tttgtcata tattacacac acacaaaggc acntacacac acacgcacac 1560
acaggcacac acacacacac acacacacac acacacactg agaattgccc 1620
taatttaggg ttgaccactt agggttcagt ttttttcctt ggaaaatggg ggggggggaa 1680
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1740
aaaaa

```

&lt;210&gt; 9

&lt;211&gt; 300

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 9

```

Met Ala Trp Asp Met Cys Ser Gln Asp Ser Val Trp Ser Asp Ile Glu
1      5      10      15
Cys Ala Ala Leu Val Gly Glu Asp Gln Pro Leu Cys Pro Asp Leu Pro
20     25     30
Glu Leu Asp Leu Ser Glu Leu Asp Val Asn Asp Leu Asp Thr Asp Ser
35     40     45
Phe Leu Gly Gly Leu Lys Trp Cys Ser Asp Gln Ser Glu Ile Ile Ser
50     55     60
Asn Gln Tyr Asn Asn Glu Pro Ala Asn Ile Phe Glu Lys Ile Asp Glu
65     70     75     80
Glu Asn Glu Ala Asn Leu Leu Ala Val Leu Thr Glu Thr Leu Asp Ser
85     90     95
Leu Pro Val Asp Glu Asp Gly Leu Pro Ser Phe Asp Ala Leu Thr Asp
100    105    110
Gly Ala Val Thr Thr Asp Asn Glu Ala Ser Pro Ser Ser Met Pro Asp
115    120    125
Gly Thr Pro Pro Pro Gln Glu Ala Glu Glu Pro Ser Leu Leu Lys Lys
130    135    140
Leu Leu Leu Ala Pro Ala Asn Thr Gln Leu Ser Tyr Asn Glu Cys Ser
145    150    155    160
Gly Leu Ser Thr Gln Asn His Ala Ala Asn His Thr His Arg Ile Arg
165    170    175

```

17

Thr	Asn	Pro	Ala	Ile	Val	Lys	Thr	Glu	Asn	Ser	Trp	Ser	Asn	Lys	Ala
			180					185					190		
Lys	Ser	Ile	Cys	Gln	Gln	Gln	Lys	Pro	Gln	Arg	Arg	Pro	Cys	Ser	Glu
		195					200					205			
Leu	Leu	Lys	Tyr	Leu	Thr	Thr	Asn	Asp	Asp	Pro	Pro	His	Thr	Lys	Pro
	210					215					220				
Thr	Glu	Asn	Arg	Asn	Ser	Ser	Arg	Asp	Lys	Cys	Ala	Ser	Lys	Lys	Lys
225					230					235				240	
Ser	His	Thr	Gln	Pro	Gln	Ser	Gln	His	Ala	Gln	Ala	Lys	Pro	Thr	Thr
			245					250						255	
Leu	Ser	Leu	Pro	Leu	Thr	Pro	Glu	Ser	Pro	Asn	Asp	Pro	Lys	Gly	Ser
		260					265						270		
Pro	Phe	Glu	Asn	Lys	Thr	Ile	Glu	Arg	Thr	Leu	Ser	Val	Glu	Leu	Ser
	275						280					285			
Gly	Thr	Ala	Gly	Val	Lys	Thr	Asn	Leu	Ile	Ser	Lys				
	290					295					300				

&lt;210&gt; 10

&lt;211&gt; 3030

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

```

atgcctcctg tgtatgcctc tgagtatgtc ttgccactcc aggggtggagg gtcgggggag 60
gagcaactct atgtgactt tccagaactc gacctctccc agctggatgc cagcgacttt 120
gactcggcca cctgctttgg ggagctgcag tgggtgcccg agaactcaga gactgaaccc 180
aaccagtaca gccccgatga ctccgagctc ttccagattg acagtgagaa tgaggccctc 240
ctggcagagc tcaccaagac cctggatgac atccctgaag atgacgtggg tctgggtgcc 300
ttcccagccc tggatggtgg agacgctcta tcatgcacct cagcttcgcc tgccccctca 360
tctgcacccc ccagccctgc cccggagaag cctcggccc cagcccctga ggtggacgag 420
ctctcactgc tgcagaagct cctcctggcc acatcctacc caacatcaag ctctgacacc 480
cagaaggaag ggaccgcctg gcgccaggca ggctcagat ctaaaagtca acggccttgt 540
gttaaggcgg acagcaccca agacaagaag gctcccatga tgcagtctca gagccgaagt 600
tgtacagaac tacataagca cctcacctcg gcacagtgtc gcctgcagga tcgggggtctg 660
cagccaccat gcctccagag tccccggctc cctgccaaag aggacaagga gccgggtgag 720
gactgcccga gccccagcc agctccagcc tctccccggg actccctagc tctgggcagg 780
gcagaccocg gtgccccggt ttcccaggaa gacatgcagg cgatggtgca actcatacgc 840
tacatgcaca cctactgcct ccccagagg aagctgcccc cacagacccc tgagccactc 900
cccaaggcct gcagcaaccc ctcccagcag gtcagatccc ggccctggtc ccggcaccac 960
tccaaagcct cctgggctga gttctccatt ctgagggaac ttctggctca agacgtgtct 1020
tgtgatgtca gcaaacccta cgtctggcc acgctgttt atgcctccct cacacctcgg 1080
tcaaggccca ggccccccaa agacagtcag gcctcccctg gtcgcccac ctcgggtggag 1140
gaggtaaagg tgcagcttc acccaagagc accgggccc gaccaagcct gcgcccactg 1200
cggctggagg tgaaaaggga ggtccgccc cctgccagac tgcagcagca ggaggaggaa 1260
gacgaggaa gaggaggga ggaagaggaa gaagaaaaag aggaggagga ggagtggggc 1320
aggaaaaggc caggccgagg cctgccatgg acgaagctgg ggaggaaagt ggagagctct 1380
gtgtgccccg tcgggcgttc tcggagactg aacctgagc tgggcccctg gctgacattt 1440
gcagatgagc cgctggtccc ctccgagccc caaggtgtc tgcctcact gtgcctggct 1500
cccaaggcct acgacgtaga gcgggagctg ggcagcccca cggacgagga cagtggccaa 1560
gaccagcagc tctacgggg accccagatc cctgccctgg agagcccctg tgagagtggc 1620
gaccaaactt ttggcaagaa gagctttgag cagaccttga cagtggagct ctgtggcaca 1680
gcaggtgagc caggggctt ccaactggcag gtgccttcag gaaaacaccc gtgcactctc 1740
gagtttttca tcatgcatgg gcaaggactc accccacca ccacaccacc gtacaagccc 1800
acagaggagg atcccttcaa accagacatc aagcatagtc taggcaaaga aatagctctc 1860
agcctcccct cccctgaggg cctctcactc aaggccacc caggggctgc ccacaagctg 1920
ccaaagaagc acccagagcg aagtgagctc ctgtccacc tgcgacatgc cacagcccag 1980
ccagcctccc aggttgcca gaagcgtccc ttctcctgtt cctttggaga ccatgactac 2040
tgccaggtgc tccgaccaga aggcgtcctg caaaggaagg tgcagaggtc ctgggagccc 2100
tctggggttc acctgagga ctggccccc caggggtgcc cttgggctga ggcacaggcc 2160
cctggcaggg aggaagacag aagctgtgat gctggcgccc cacccaagga cagcacgtg 2220

```

```

ctgagagacc atgagatccg tgccagcctc accaaacact ttgggctgct ggagaccgcc 2280
ctggaggagg aagacctggc ctcctgcaag agccctgagt atgacactgt ctttgaagac 2340
agcagcagca gcagcggcga gagcagcttc ctcccagagg aggaagagga agaaggggag 2400
gaggaggagg aggacgatga agaagaggac tcaggggtca gcccacttg ctctgaccac 2460
tgccctacc agagcccacc aagcaaggcc aaccggcagc tctgttcccg cagccgctca 2520
agctctggct cttaccctg ccactcctgg tcaccagcca ctccaaggaa cttcagatgt 2580
gagagcagag ggccgtgttc agacagaacg ccaagcatcc ggcacgccag gaagcggcgg 2640
gaaaaggcca ttggggaagg ccgcgtggtg tacattcaaa atctctccag cgacatgagc 2700
tcccgagagc tgaagaggcg ctttgaagtg tttggtgaga ttgaggagtg cgagggtgtg 2760
acaagaaata ggagaggcga gaagtacggc ttcataccct accggtgttc tgagcacgcg 2820
gccctctctt tgacaaaggg cgctgccctg aggaagcgca acgagccctc cttccagctg 2880
agctacggag ggctccggca cttctgctgg cccagataca ctgactacga ttccaattca 2940
gaagaggccc ttctgcgtc agggaaaagc aagtatgaag ccatggattt tgacagctta 3000
ctgaaaggagg cccagcagag cctgcattga 3030

```

&lt;210&gt; 11

&lt;211&gt; 1009

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

```

Met Pro Pro Val Tyr Ala Ser Glu Tyr Val Leu Pro Leu Gln Gly Gly
 1          5          10          15
Gly Ser Gly Glu Gln Leu Tyr Ala Asp Phe Pro Glu Leu Asp Leu
 20          25          30
Ser Gln Leu Asp Ala Ser Asp Phe Asp Ser Ala Thr Cys Phe Gly Glu
 35          40          45
Leu Gln Trp Cys Pro Glu Asn Ser Glu Thr Glu Pro Asn Gln Tyr Ser
 50          55          60
Pro Asp Asp Ser Glu Leu Phe Gln Ile Asp Ser Glu Asn Glu Ala Leu
 65          70          75          80
Leu Ala Glu Leu Thr Lys Thr Leu Asp Asp Ile Pro Glu Asp Asp Val
 85          90          95
Gly Leu Ala Ala Phe Pro Ala Leu Asp Gly Gly Asp Ala Leu Ser Cys
100          105          110
Thr Ser Ala Ser Pro Ala Pro Ser Ser Ala Pro Pro Ser Pro Ala Pro
115          120          125
Glu Lys Pro Ser Ala Pro Ala Pro Glu Val Asp Glu Leu Ser Leu Leu
130          135          140
Gln Lys Leu Leu Leu Ala Thr Ser Tyr Pro Thr Ser Ser Ser Asp Thr
145          150          155          160
Gln Lys Glu Gly Thr Ala Trp Arg Gln Ala Gly Leu Arg Ser Lys Ser
165          170          175
Gln Arg Pro Cys Val Lys Ala Asp Ser Thr Gln Asp Lys Lys Ala Pro
180          185          190
Met Met Gln Ser Gln Ser Arg Ser Cys Thr Glu Leu His Lys His Leu
195          200          205
Thr Ser Ala Gln Cys Cys Leu Gln Asp Arg Gly Leu Gln Pro Pro Cys
210          215          220
Leu Gln Ser Pro Arg Leu Pro Ala Lys Glu Asp Lys Glu Pro Gly Glu
225          230          235          240
Asp Cys Pro Ser Pro Gln Pro Ala Pro Ala Ser Pro Arg Asp Ser Leu
245          250          255
Ala Leu Gly Arg Ala Asp Pro Gly Ala Pro Val Ser Gln Glu Asp Met
260          265          270
Gln Ala Met Val Gln Leu Ile Arg Tyr Met His Thr Tyr Cys Leu Pro
275          280          285
Gln Arg Lys Leu Pro Pro Gln Thr Pro Glu Pro Leu Pro Lys Ala Cys
290          295          300
Ser Asn Pro Ser Gln Gln Val Arg Ser Arg Pro Trp Ser Arg His His
305          310          315          320

```

Ser Lys Ala Ser Trp Ala Glu Phe Ser Ile Leu Arg Glu Leu Leu Ala  
 325 330 335  
 Gln Asp Val Leu Cys Asp Val Ser Lys Pro Tyr Arg Leu Ala Thr Pro  
 340 345 350  
 Val Tyr Ala Ser Leu Thr Pro Arg Ser Arg Pro Arg Pro Pro Lys Asp  
 355 360 365  
 Ser Gln Ala Ser Pro Gly Arg Pro Ser Ser Val Glu Glu Val Arg Ile  
 370 375 380  
 Ala Ala Ser Pro Lys Ser Thr Gly Pro Arg Pro Ser Leu Arg Pro Leu  
 385 390 395 400  
 Arg Leu Glu Val Lys Arg Glu Val Arg Arg Pro Ala Arg Leu Gln Gln  
 405 410 415  
 Gln Glu Glu Glu Asp Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu  
 420 425 430  
 Lys Glu Glu Glu Glu Glu Trp Gly Arg Lys Arg Pro Gly Arg Gly Leu  
 435 440 445  
 Pro Trp Thr Lys Leu Gly Arg Lys Leu Glu Ser Ser Val Cys Pro Val  
 450 455 460  
 Arg Arg Ser Arg Arg Leu Asn Pro Glu Leu Gly Pro Trp Leu Thr Phe  
 465 470 475 480  
 Ala Asp Glu Pro Leu Val Pro Ser Glu Pro Gln Gly Ala Leu Pro Ser  
 485 490 495  
 Leu Cys Leu Ala Pro Lys Ala Tyr Asp Val Glu Arg Glu Leu Gly Ser  
 500 505 510  
 Pro Thr Asp Glu Asp Ser Gly Gln Asp Gln Gln Leu Leu Arg Gly Pro  
 515 520 525  
 Gln Ile Pro Ala Leu Glu Ser Pro Cys Glu Ser Gly Asp Pro Thr Phe  
 530 535 540  
 Gly Lys Lys Ser Phe Glu Gln Thr Leu Thr Val Glu Leu Cys Gly Thr  
 545 550 555 560  
 Ala Gly Glu Pro Gly Phe His Trp Gln Val Pro Ser Gly Lys His  
 565 570 575  
 Pro Cys Ile Ser Glu Phe Phe Ile Met His Gly Gln Gly Leu Thr Pro  
 580 585 590  
 Pro Thr Thr Pro Pro Tyr Lys Pro Thr Glu Glu Asp Pro Phe Lys Pro  
 595 600 605  
 Asp Ile Lys His Ser Leu Gly Lys Glu Ile Ala Leu Ser Leu Pro Ser  
 610 615 620  
 Pro Glu Gly Leu Ser Leu Lys Ala Thr Pro Gly Ala Ala His Lys Leu  
 625 630 635 640  
 Pro Lys Lys His Pro Glu Arg Ser Glu Leu Leu Ser His Leu Arg His  
 645 650 655  
 Ala Thr Ala Gln Pro Ala Ser Gln Ala Gly Gln Lys Arg Pro Phe Ser  
 660 665 670  
 Cys Ser Phe Gly Asp His Asp Tyr Cys Gln Val Leu Arg Pro Glu Gly  
 675 680 685  
 Val Leu Gln Arg Lys Val Leu Arg Ser Trp Glu Pro Ser Gly Val His  
 690 695 700  
 Leu Glu Asp Trp Pro Gln Gln Gly Ala Pro Trp Ala Glu Ala Gln Ala  
 705 710 715 720  
 Pro Gly Arg Glu Glu Asp Arg Ser Cys Asp Ala Gly Ala Pro Pro Lys  
 725 730 735  
 Asp Ser Thr Leu Leu Arg Asp His Glu Ile Arg Ala Ser Leu Thr Lys  
 740 745 750  
 His Phe Gly Leu Leu Glu Thr Ala Leu Glu Glu Glu Asp Leu Ala Ser  
 755 760 765  
 Cys Lys Ser Pro Glu Tyr Asp Thr Val Phe Glu Asp Ser Ser Ser Ser  
 770 775 780  
 Ser Gly Glu Ser Ser Phe Leu Pro Glu Glu Glu Glu Glu Gly Glu  
 785 790 795 800  
 Glu Glu Glu Glu Asp Asp Glu Glu Glu Asp Ser Gly Val Ser Pro Thr

20

			805					810					815		
Cys	Ser	Asp	His	Cys	Pro	Tyr	Gln	Ser	Pro	Pro	Ser	Lys	Ala	Asn	Arg
			820					825					830		
Gln	Leu	Cys	Ser	Arg	Ser	Arg	Ser	Ser	Ser	Gly	Ser	Ser	Pro	Cys	His
		835					840					845			
Ser	Trp	Ser	Pro	Ala	Thr	Arg	Arg	Asn	Phe	Arg	Cys	Glu	Ser	Arg	Gly
	850					855					860				
Pro	Cys	Ser	Asp	Arg	Thr	Pro	Ser	Ile	Arg	His	Ala	Arg	Lys	Arg	Arg
	865				870				875					880	
Glu	Lys	Ala	Ile	Gly	Glu	Gly	Arg	Val	Val	Tyr	Ile	Gln	Asn	Leu	Ser
			885					890						895	
Ser	Asp	Met	Ser	Ser	Arg	Glu	Leu	Lys	Arg	Arg	Phe	Glu	Val	Phe	Gly
		900					905					910			
Glu	Ile	Glu	Glu	Cys	Glu	Val	Leu	Thr	Arg	Asn	Arg	Arg	Gly	Glu	Lys
	915						920				925				
Tyr	Gly	Phe	Ile	Thr	Tyr	Arg	Cys	Ser	Glu	His	Ala	Ala	Leu	Ser	Leu
	930				935						940				
Thr	Lys	Gly	Ala	Ala	Leu	Arg	Lys	Arg	Asn	Glu	Pro	Ser	Phe	Gln	Leu
	945				950				955						960
Ser	Tyr	Gly	Gly	Leu	Arg	His	Phe	Cys	Trp	Pro	Arg	Tyr	Thr	Asp	Tyr
			965					970						975	
Asp	Ser	Asn	Ser	Glu	Glu	Ala	Leu	Pro	Ala	Ser	Gly	Lys	Ser	Lys	Tyr
		980					985					990			
Glu	Ala	Met	Asp	Phe	Asp	Ser	Leu	Leu	Lys	Glu	Ala	Gln	Gln	Ser	Leu
	995						1000					1005			

His

&lt;210&gt; 12

&lt;211&gt; 3664

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 12

```

ctcgtccct ccccgggcg ggctcggcgc tgactccgcc gcacgctgca gccgcggtg 60
gaagatggcg gggaaacgact gcggcgcgct gctggatgaa gagctctcgt ccttcttcct 120
caactatctc tctgacacgc aggggtggga ctctggagag gaacagctgt gtgctgactt 180
gccagagctt gacctctccc agctggacgc cagtgacttt gactcagcca cgtgctttgg 240
ggagctgcag tgggtcccgc agacctcaga gacagagccc agccagtaca gccccgatga 300
ctccgagctc ttccagattg acagtgagaa tgaagctctc ttggctgcgc ttacgaagac 360
cctggatgac atccccgaag acgatgtggg gctggctgcc ttcccagaac tggatgaagg 420
cgacacacca tcctgcaccc cagcctcacc tgccccctta tctgcacccc ccagccccac 480
cctggagagg cttctgtccc cagcgtctga cgtggacgag ctttactgc tacagaagct 540
cctcctggcc acatcctccc caacagcaag ctctgacgct ctgaaggacg gggccacctg 600
gtcccagacc agcctcagtt ccagaagtca gcggccttgt gtcaagggtg atggcaccca 660
ggataagaag acccccacac tgcgggctca gagccggcct tgtacggaac tgcataagca 720
cctcacttcg gtgctgccct gtcccagagt gaaagcctgc tccccaaactc cgcacccgag 780
ccctcggtc ctctccaaag aggaggagga ggaggtggg gaggattgcc caagcccttg 840
gccgactcca gcctcgcccc aagactccct agcacaggac acggccagcc ccgacagtgc 900
ccagcctccc gaggaggatg tgagggccat ggtacagctc attcgctaca tgcataccta 960
ctgctgcctc cagaggaagc tgcccacacg ggcccagag ccaatcccc aggcctgcag 1020
cagcctctcc aggcaggtc aacccgatc ccgcatccc ccaaagcct tctggactga 1080
gttctctatc ctaagggaac ttctggccca agatctctc tgtgatgtta gcaagcccta 1140
ccgcttgccc atacctgtct atgcttcctt cacacctcag tccaggccca ggcccccaa 1200
ggacagtcag gcctcccctg ccactctgc catggcagaa gaggtgagaa tctactgctt 1260
ccccagagc accgggccta gaccagcct gcgtcctctg aggttgagg tgaaacggga 1320
tgtaacaag cctacaagc aaaagcgga ggaagatgag gaggaggagg aggaagaaga 1380
agaagaggaa gaagaaaaa aagagggaag agaggagtgg ggcaggaaga gaccaggtcg 1440
tggcctgcc tggaccaaca tagggaggaa gatggacagc tccgtgtgcc ccgtgcggcg 1500
ctccaggaga ctgaatccag agctgggtcc ctggctgaca ttcactgatg agcccttagg 1560

```

```

tcctctgccc tcgatgtgcc tggatacaga gaccacaaac ctggaggaag acctgggcag 1620
cctcacagac agtagtcaag gccggcagct cccccaggga tccagatcc ccgccctgga 1680
aagcccctgt gagagtgggt gcggagacac agatgaagat ccaagctgcc cacagcccac 1740
ttccagagac tcctccaggt gcctcatgct ggcttgtca caaagcgact ctcttgcaa 1800
gaagagcttt gaggagtccc tgacggtgga gctttgcggc acggcaggac tcacgccacc 1860
caccacacct ccatacaagc caatggagga ggaccccttc aagccagaca ccaagctcag 1920
cccaggccaa gacacagctc ccagccttcc ctcccccgag gctcttcgc tcacagccac 1980
cccaggagct tcccacaagc tgcccaagag gcacccagag cgaagcgagc tcctgtccca 2040
tttgagcat gccacaaccc aaccagtctc acaggctggc cagaagcgcc ccttctctg 2100
ctcctttgga gaccacgact actgccaggt gctcaggcca gaggtgccc tgcaaggaa 2160
ggtgctgcgg tcctgggagc caatcggggt ccacctgaa gacttgccc agcagggtgc 2220
ccctctgcca acggaacaa aggcccttag gagggaggca aaccagaact gtgacctac 2280
ccacaaggac agcatgcagc taagagacca tgagatccgt gccagtctca caaagcactt 2340
tgggctgctg gagactgctc tgggaaggtga agacctggcg tcctgtaaaa gcccgagta 2400
tgacaccgta tttaggaca gcagcagcag cagtggcgag agtagcttcc tgcttgagga 2460
ggaggaggaa gaggaggag gaggggaaga ggacgatgaa ggagaggact cagggtcag 2520
ccctccctgc tctgatcact gccctacca gagccaccc agtaaggcca gtcggcagc 2580
ctgctcccga agccgctcca gttccggctc ctgctcctgc agctcctggt caccagccac 2640
ccggaagaac ttcagacgtg agagcagagg gccctgttca gatggaaccc caagcgtccg 2700
gcatgccagg aagcggcggg aaaaggccat cgggtgaaggc cgtgtggtat acattcgaaa 2760
tctctccagt gacatgagct ctcggaact aaagaagcgc tttgaggtgt tcggtgagat 2820
tgtagagtgc caggtgctga cgagaagtaa aagaggccag aagcacggtt ttatcagctt 2880
ccggtgttca gagcacgtg cctgtccgt gaggaacggc gccaccctga gaaagcgcaa 2940
tgagccctcc ttccacctga gctatggagg gctccggcac ttccgttggc ccagatacac 3000
tgactatgat cccacatctg aggagtcctt tccctcatct gggaaaagca agtacgaagc 3060
catggatttt gacagcttac tgaaagaggc ccagcagagc ctgcattgat atcagcctta 3120
accttcgagg aatacctcaa tacctcagac aaggcccttc caatatgttt acgttttcaa 3180
agaaaagagt atatgagaag gagagcgagc gagcgagcga gcgagcgagt gagcgtgaga 3240
gatcacacag gagagagaaa gacttgaatc tgctgtcgtt tcctttaaaa aaaaaaaac 3300
gaaaaacaaa aacaaatcaa tgtttacatt gaacaaagct gcttccgtcc gtctgtccgt 3360
ccgtccgtcc gtccgtgagt taccattctg atgatgttcc actgccagc tagcgtcgtc 3420
ctcgcttcca gcggatcgtc ctgggtgcgc ctccaagtgc tgtcagtcgt cctctgcccc 3480
tcccaccgga ctgacttcct tctgttagac ttgagctgtg ttcacataac atcttctgtc 3540
tgtagagtgt gatgatgaca ttgttacttg tgaatagaat caggagttag aaactcattt 3600
ttaattgaag aaaaaaaaaa tatatcctta aaaagaaaaa aaaaaaaca aatgtaaaaa 3660
aaaa

```

&lt;210&gt; 13

&lt;211&gt; 1014

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 13

```

Met Ala Gly Asn Asp Cys Gly Ala Leu Leu Asp Glu Glu Leu Ser Ser
1          5          10          15
Phe Phe Leu Asn Tyr Leu Ser Asp Thr Gln Gly Gly Asp Ser Gly Glu
20          25          30
Glu Gln Leu Cys Ala Asp Leu Pro Glu Leu Asp Leu Ser Gln Leu Asp
35          40          45
Ala Ser Asp Phe Asp Ser Ala Thr Cys Phe Gly Glu Leu Gln Trp Cys
50          55          60
Pro Glu Thr Ser Glu Thr Glu Pro Ser Gln Tyr Ser Pro Asp Asp Ser
65          70          75          80
Glu Leu Phe Gln Ile Asp Ser Glu Asn Glu Ala Leu Leu Ala Ala Leu
85          90          95
Thr Lys Thr Leu Asp Asp Ile Pro Glu Asp Asp Val Gly Leu Ala Ala
100          105          110
Phe Pro Glu Leu Asp Glu Gly Asp Thr Pro Ser Cys Thr Pro Ala Ser
115          120          125
Pro Ala Pro Leu Ser Ala Pro Pro Ser Pro Thr Leu Glu Arg Leu Leu
130          135          140

```

Ser Pro Ala Ser Asp Val Asp Glu Leu Ser Leu Leu Gln Lys Leu Leu  
 145 150 155 160  
 Leu Ala Thr Ser Ser Pro Thr Ala Ser Ser Asp Ala Leu Lys Asp Gly  
 165 170 175  
 Ala Thr Trp Ser Gln Thr Ser Leu Ser Ser Arg Ser Gln Arg Pro Cys  
 180 185 190  
 Val Lys Val Asp Gly Thr Gln Asp Lys Lys Thr Pro Thr Leu Arg Ala  
 195 200 205  
 Gln Ser Arg Pro Cys Thr Glu Leu His Lys His Leu Thr Ser Val Leu  
 210 215 220  
 Pro Cys Pro Arg Val Lys Ala Cys Ser Pro Thr Pro His Pro Ser Pro  
 225 230 235 240  
 Arg Leu Leu Ser Lys Glu Glu Glu Glu Glu Val Gly Glu Asp Cys Pro  
 245 250 255  
 Ser Pro Trp Pro Thr Pro Ala Ser Pro Gln Asp Ser Leu Ala Gln Asp  
 260 265 270  
 Thr Ala Ser Pro Asp Ser Ala Gln Pro Pro Glu Glu Asp Val Arg Ala  
 275 280 285  
 Met Val Gln Leu Ile Arg Tyr Met His Thr Tyr Cys Leu Pro Gln Arg  
 290 295 300  
 Lys Leu Pro Gln Arg Ala Pro Glu Pro Ile Pro Gln Ala Cys Ser Ser  
 305 310 315 320  
 Leu Ser Arg Gln Val Gln Pro Arg Ser Arg His Pro Pro Lys Ala Phe  
 325 330 335  
 Trp Thr Glu Phe Ser Ile Leu Arg Glu Leu Leu Ala Gln Asp Ile Leu  
 340 345 350  
 Cys Asp Val Ser Lys Pro Tyr Arg Leu Ala Ile Pro Val Tyr Ala Ser  
 355 360 365  
 Leu Thr Pro Gln Ser Arg Pro Arg Pro Pro Lys Asp Ser Gln Ala Ser  
 370 375 380  
 Pro Ala His Ser Ala Met Ala Glu Glu Val Arg Ile Thr Ala Ser Pro  
 385 390 395 400  
 Lys Ser Thr Gly Pro Arg Pro Ser Leu Arg Pro Leu Arg Leu Glu Val  
 405 410 415  
 Lys Arg Asp Val Asn Lys Pro Thr Arg Gln Lys Arg Glu Glu Asp Glu  
 420 425 430  
 Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Lys Glu Glu Glu  
 435 440 445  
 Glu Glu Glu Trp Gly Arg Lys Arg Pro Gly Arg Gly Leu Pro Trp Thr  
 450 455 460  
 Lys Leu Gly Arg Lys Met Asp Ser Ser Val Cys Pro Val Arg Arg Ser  
 465 470 475 480  
 Arg Arg Leu Asn Pro Glu Leu Gly Pro Trp Leu Thr Phe Thr Asp Glu  
 485 490 495  
 Pro Leu Gly Ala Leu Pro Ser Met Cys Leu Asp Thr Glu Thr His Asn  
 500 505 510  
 Leu Glu Glu Asp Leu Gly Ser Leu Thr Asp Ser Ser Gln Gly Arg Gln  
 515 520 525  
 Leu Pro Gln Gly Ser Gln Ile Pro Ala Leu Glu Ser Pro Cys Glu Ser  
 530 535 540  
 Gly Cys Gly Asp Thr Asp Glu Asp Pro Ser Cys Pro Gln Pro Thr Ser  
 545 550 555 560  
 Arg Asp Ser Ser Arg Cys Leu Met Leu Ala Leu Ser Gln Ser Asp Ser  
 565 570 575  
 Leu Gly Lys Lys Ser Phe Glu Glu Ser Leu Thr Val Glu Leu Cys Gly  
 580 585 590  
 Thr Ala Gly Leu Thr Pro Pro Thr Thr Pro Pro Tyr Lys Pro Met Glu  
 595 600 605  
 Glu Asp Pro Phe Lys Pro Asp Thr Lys Leu Ser Pro Gly Gln Asp Thr  
 610 615 620  
 Ala Pro Ser Leu Pro Ser Pro Glu Ala Leu Pro Leu Thr Ala Thr Pro

23

625	630										635					640				
Gly	Ala	Ser	His	Lys	Leu	Pro	Lys	Arg	His	Pro	Glu	Arg	Ser	Glu	Leu					
				645					650					655						
Leu	Ser	His	Leu	Gln	His	Ala	Thr	Thr	Gln	Pro	Val	Ser	Gln	Ala	Gly					
			660					665					670							
Gln	Lys	Arg	Pro	Phe	Ser	Cys	Ser	Phe	Gly	Asp	His	Asp	Tyr	Cys	Gln					
			675				680					685								
Val	Leu	Arg	Pro	Glu	Ala	Ala	Leu	Gln	Arg	Lys	Val	Leu	Arg	Ser	Trp					
						695					700									
Glu	Pro	Ile	Gly	Val	His	Leu	Glu	Asp	Leu	Ala	Gln	Gln	Gly	Ala	Pro					
705					710					715					720					
Leu	Pro	Thr	Glu	Thr	Lys	Ala	Pro	Arg	Arg	Glu	Ala	Asn	Gln	Asn	Cys					
				725					730					735						
Asp	Pro	Thr	His	Lys	Asp	Ser	Met	Gln	Leu	Arg	Asp	His	Glu	Ile	Arg					
			740					745					750							
Ala	Ser	Leu	Thr	Lys	His	Phe	Gly	Leu	Leu	Glu	Thr	Ala	Leu	Glu	Gly					
			755				760					765								
Glu	Asp	Leu	Ala	Ser	Cys	Lys	Ser	Pro	Glu	Tyr	Asp	Thr	Val	Phe	Glu					
	770					775					780									
Asp	Ser	Ser	Ser	Ser	Ser	Gly	Glu	Ser	Ser	Phe	Leu	Leu	Glu	Glu	Glu					
785					790					795					800					
Glu	Glu	Glu	Glu	Glu	Gly	Gly	Glu	Glu	Asp	Asp	Glu	Gly	Glu	Asp	Ser					
				805					810					815						
Gly	Val	Ser	Pro	Pro	Cys	Ser	Asp	His	Cys	Pro	Tyr	Gln	Ser	Pro	Pro					
			820					825					830							
Ser	Lys	Ala	Ser	Arg	Gln	Leu	Cys	Ser	Arg	Ser	Arg	Ser	Ser	Ser	Gly					
			835				840					845								
Ser	Ser	Ser	Cys	Ser	Ser	Trp	Ser	Pro	Ala	Thr	Arg	Lys	Asn	Phe	Arg					
	850					855					860									
Arg	Glu	Ser	Arg	Gly	Pro	Cys	Ser	Asp	Gly	Thr	Pro	Ser	Val	Arg	His					
865					870					875					880					
Ala	Arg	Lys	Arg	Arg	Glu	Lys	Ala	Ile	Gly	Glu	Gly	Arg	Val	Val	Tyr					
				885					890					895						
Ile	Arg	Asn	Leu	Ser	Ser	Asp	Met	Ser	Ser	Arg	Glu	Leu	Lys	Lys	Arg					
			900					905					910							
Phe	Glu	Val	Phe	Gly	Glu	Ile	Val	Glu	Cys	Gln	Val	Leu	Thr	Arg	Ser					
			915				920					925								
Lys	Arg	Gly	Gln	Lys	His	Gly	Phe	Ile	Thr	Phe	Arg	Cys	Ser	Glu	His					
	930					935					940									
Ala	Ala	Leu	Ser	Val	Arg	Asn	Gly	Ala	Thr	Leu	Arg	Lys	Arg	Asn	Glu					
945					950					955					960					
Pro	Ser	Phe	His	Leu	Ser	Tyr	Gly	Gly	Leu	Arg	His	Phe	Arg	Trp	Pro					
				965					970					975						
Arg	Tyr	Thr	Asp	Tyr	Asp	Pro	Thr	Ser	Glu	Glu	Ser	Leu	Pro	Ser						

```
<210> 14
<211> 18
<212> DNA
<213> Homo sapiens
```

<220>  
<223>. Domain

<400> 14  
agtgacgtca ggagtttg



<210> 15  
<211> 18  
<212> DNA  
<213> Mus musculus

<220>  
<223> Domain

<400> 15  
agtgacgtca ggagtttg 18

<210> 16  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Domain

<400> 16  
agtagatcta ggagtttg 18

<210> 17  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Domain

<400> 17  
Asn Lys Gly Asn Tyr Thr Ala Ala Ala Ala Thr Ala Asn Cys Tyr  
1 5 10 15  
Asn Asn

<210> 18  
<211> 18  
<212> DNA  
<213> Homo sapiens

<220>  
<223> Domain

<400> 18  
ttacctaaat ataatttg 18

<210> 19  
<211> 18  
<212> DNA  
<213> Mus musculus

<400> 19  
gcacataaat ataattta 18

<210> 20  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Domain

<400> 20

gcacctccgc ggaattta